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Abstract 
Improving functional outcomes of elderly, high risk, populations is of enormous public 
health importance with both high social and economic value. Lower limb ischaemia is a 
chronic and disabling condition with increasing prevalence among elderly populations and 
has been shown to be associated with impaired physical function and balance. The aim of 
this study was to investigate the impact of standard treatment, through angioplasty or 
exercise therapy, on clinical indicators of lower limb ischaemia, physical function, balance, 
falls risk and quality of life in patients with lower limb ischaemia.  
Ankle brachial pressure index (ABPI) does not correlate with markers of physical function, 
balance and falls risk, whereas walking distances do correlate with physical function and 
falls. Angioplasty treatment leads to significant improvements in clinical indicators of 
lower limb ischaemia, markers of physical function that include an element of walking, 
history of falling or stumbling, fear of falling and quality of life. Balance is only slightly 
improved by angioplasty at 3 months following treatment. Supervised exercise programme 
treatment leads to significant improvements in walking distances but not ABPI, and 
physical function and a history of stumbles are improved. Balance is markedly improved at 
3, 6 and 12 months from baseline. Quality of life improvements are seen at 3 and 6 months 
but not at 12 months from baseline.  
This study highlights the high frequency of balance abnormalities among claudicants and 
recognises the link between balance abnormalities and falls risk. Treatment with either 
angioplasty or exercise improves markers of physical function, balance, falls risk and 
quality of life but there are differences between the 2 treatment effects. It is important that 
patients are thoroughly assessed in the wider context of their presentation and that 
treatment is targeted to the individual.  
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1 Introduction 
1.1  Aims 
 
Intermittent claudication is the commonest presentation of lower limb ischaemia or 
peripheral arterial disease which is caused by atherosclerosis or occlusion of the arterial 
blood supply. It is a chronic, disabling condition with a prevalence of approximately 5% in 
over 50 year olds, increasing with age. Intermittent claudication typically presents with pain 
in the leg musculature on walking resulting in impaired walking distances and poor quality 
of life. Angioplasty and exercise therapy are the mainstays of treatment once risk factors 
have been modified. Pharmacological therapy is used in some cases but there is debate 
regarding efficacy. Surgery carries a high rate of morbidity and mortality and is reserved as 
a last resort in patients where symptoms cause an extreme impact on their quality life. 
 
In addition, impaired physical function is prevalent among older patients with lower limb 
ischaemia, encompassing balance problems and increased falls risk. Functional morbidity 
carries huge financial and social costs and is thus an important issue to address with our 
ageing population. The identification and treatment of patient groups with poor lower limb 
function, especially those with poor physical function and impaired balance is a priority for 
both individuals and society as a whole, and attempts not only to improve function but also 
quality of life.  
 
The aim of this study is to investigate the impact of standard treatment, through angioplasty 
or exercise therapy, on clinical indicators of lower limb ischaemia, physical function, 
balance, falls risk and quality of life in patients with lower limb ischaemia.  
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1.2 Peripheral arterial disease 
 
1.2.1 Background 
Peripheral arterial disease (PAD) is an occlusive disease of the arteries caused by 
atherosclerosis, most commonly of the lower limbs. PAD may be asymptomatic but 
symptoms become increasingly apparent with progressive arterial occlusion and are 
dependent on the site of vessel obstruction, the speed at which the vessel narrows (stenosis) 
or blocks (occlusion) and the adequacy of collateral blood flow.  
 
The prevalence and incidence of PAD in the UK population has been the subject of much 
research but has proven difficult to ascertain due to the occurrence of asymptomatic 
disease. The Edinburgh Artery Study screened large random samples of the population 
between the ages of 55 and 74 using registers from general practices. This study identified 
symptomatic disease in nearly 5% of the population, major asymptomatic disease causing 
significant impairment to blood flow in 8% and further abnormalities among 16% (Fowkes 
et al. 1991). Recognised risk factors include male gender, increasing age, smoking, 
diabetes, hypertension, and dyslipidaemia (Norgren et al. 2007).  
 
PAD can be classified as acute or chronic. Acute leg ischaemia can be defined as 
deterioration in the blood supply of a previously stable leg of less than 2 weeks duration, 
resulting in ischaemic pain at rest and/or other features of severe ischaemia, such as pallor, 
paralysis, paraesthesia, pulselessness (Earnshaw et al. 2006). The classification of acute 
limb ischaemia incorporates the viability of the limb and can be divided into viable (not 
17 
 
immediately threatened), threatened (which implies reversible ischaemia following 
treatment) and major irreversible ischaemia (which usually requires major amputation)
 
(Rutherford et al. 1997).  
 
Chronic leg ischaemia is also stratified by severity, but is simply divided by symptoms into 
intermittent claudication and critical ischaemia. Intermittent claudication (IC) is ischaemic 
pain, discomfort or weakness experienced in the leg muscles when the arterial supply is 
insufficient to meet the metabolic needs of the musculature during exercise. IC is most 
commonly experienced in the calf but may occur in the foot, thigh, hip or buttocks 
depending on the site of vessel occlusion and the muscle group this vessel supplies. Pain is 
experienced at a consistent walking distance and is alleviated by resting for 1-3 minutes. 
Further key features of IC include no pain at rest or on the first few steps of walking but 
pain that is worsened by walking uphill or walking quickly (McCollum and Ashleigh 
2006).  
 
IC tends to follow a benign course, perhaps due to the development of collateral vessels 
that contribute to lower limb vascularisation. The Basle study reported that at 5 years two 
thirds of surviving patients showed symptom improvement although 63% demonstrated 
progression of disease on angiography (Da Silva et al. 1979). The percentage of IC patients 
who progress to critical ischaemia is small. Despite 25% of IC patients experiencing 
progressive symptoms, only 5% will require revascularisation and only 1-2% will require 
major leg amputation. However of greater importance is that PAD acts as a marker for 
systemic atherosclerosis and thus there is an increased risk of cardiovascular events among 
18 
 
IC, with a 2-4% risk of non-fatal cardiovascular events in the first year following diagnosis 
and a 1-3% subsequent yearly incidence of non-fatal events (TASC 2000).  
Critical ischaemia, however, is not a stable condition and requires prompt treatment to 
avoid the progression of tissue necrosis requiring amputation. Critical ischaemia 
encompasses ischaemic rest pain (severe pain in the toes or forefoot at rest) and tissue loss 
(either ischemic ulceration or gangrene). Critical ischaemia signifies that the blood supply 
to the limb is insufficient to meet the metabolic demands of the tissue at rest and thus 
requires urgent investigation and revascularisation (McCollum and Ashleigh 2006). 
  
For all patients, investigations involve assessing the patient’s cardiovascular risk factors 
and the extent of the presenting PAD. Usually claudicants are managed conservatively with 
risk factor modification, exercise advice and observation in the first instance. If 
claudication becomes disabling the patient would require further investigation. This 
commonly involves colour-flow duplex ultrasound imaging, magnetic resonance 
angiography or catheter angiography (an invasive technique using intravascular contrast 
media and serial X-rays to determine the location and extent of PAD).  
 
The management of PAD extends from conservative treatment and risk factor modification, 
through pharmacological therapy, angioplasty and stenting to surgical treatments. 
Increasing severity of disease tends to require increasingly escalated management. 
Furthermore the potential risks and side effects of treatment also increase with more 
complex interventions. Deciding when to intervene in patients with IC is complex and is 
guided by the impact of their symptoms on their normal life, balanced with the risks of a 
given intervention for the individual.  
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1.2.2 Clinical indicators of lower limb ischaemia 
1.2.2.1 Ankle Brachial Pressure Index 
Insonation of the pedal pulses using a hand held Doppler ultrasound device is of use in 
identifying the presence and nature of arterial signals but is not a quantitative measurement. 
The Ankle Brachial Pressure Index (ABPI) is a simple bedside tool used to estimate blood 
flow to the lower extremity and compares the systolic blood pressure at the ankle with the 
brachial artery systolic pressure. ABPI is calculated using the following equation: 
 
 ABPI = highest ankle systolic pressure/highest brachial systolic pressure
 
 
Clinically, an ABPI of 1.0-1.2 is normal, <0.9 suggests arterial disease, and <0.3 suggests 
critical ischaemia. An ABPI of <0.9 has been shown to be up to 95% sensitive in detecting 
angiogram-positive disease (Bernstein and Fronek 1982; Vowden et al 1996).  
 
1.2.2.2 Exercise challenge 
Repeating ABPI post exercise can often reveal abnormalities not detected in limbs 
examined at rest. This usually occurs in patients with disease of the aorto-iliac arteries with 
collateralisation sufficient to produce pulses at rest. A simple bedside exercise test would 
be to stress the calf muscle by repeatedly rising onto “tiptoes” and returning the heel to the 
floor. An objective exercise test would be to ask the patient to walk on a treadmill and 
report the distance at which they experience pain and when they can no longer tolerate 
walking (maximum walking distance).  
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Mild IC is also indicated with a significant drop in ABPI post exercise testing, usually 
>20mmHg from resting ABPI (Rutherford et al. 1997).  
 
1.2.2.3 Classification of ischaemia 
Chronic lower limb ischaemia has two well-known classification systems: Fontaine (1954) 
and Rutherford (1997). The Fontaine classification system has four progressing stages as 
follows; 
I Mild pain on walking 
II Severe pain on walking (stage IIa >150m, stage IIb<150m) 
III Rest pain, usually in the feet, which worsens on raising the limb 
IV Tissue loss  
 
The Rutherford classification system has superseded Fontaine as it requires further 
objective criteria in the assessment of each patient (Table 1.1).  
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Table 1.1 Rutherford classification of chronic lower limb ischaemia 
Category Clinical description Objective criteria 
0 Asymptomatic – no 
haemodynamically significant 
occlusive disease 
Normal treadmill 
1 Mild claudication Completes treadmill test† 
Ankle pressure post exercise >50 mmHg 
but at least 20 mmHg lower than resting 
value 
2 Moderate claudication Between categories 1 and 3 
3 Severe claudication Cannot complete treadmill test† &  
Ankle pressure post exercise <50 mmHg 
4 Ischaemic rest pain Resting ankle pressure <40 mmHg 
5 Minor tissue loss – non-healing 
ulcer, focal gangrene with 
diffuse pedal ischaemia 
Resting ankle pressure <60 mmHg,  
toe pressures <30mmHg 
 
6 Major tissue loss – extending 
above the transmetatarsal 
(forefoot) level, i.e. functional 
foot no longer salvageable 
Same as category 5 
Categories 4, 5 and 6 are termed chronic critical ischaemia. †Rutherford treadmill test was five minutes at 2 
mph on a 12% incline.  
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1.2.3 Role of angioplasty 
Endovascular treatment of PAD is a rapidly evolving and proven therapeutic option and 
encompasses both balloon angioplasty (opening the lumen of the artery with a balloon) and 
arterial stenting. Stents are metallic tubes that exert a radial force on the vessel wall and 
stay in situ to maintain the vessel lumen. The indications for angioplasty are progressive 
and limiting IC preventing the patient from performing day to day activities and patients 
with critical ischaemia. Assessment, investigation and planning is paramount for all 
patients and discussion at a vascular multidisciplinary team meeting (MDT), which 
involves vascular surgeons and interventional radiologists, is important particularly in 
complex cases.  
  
The distribution of PAD lesions are broadly divided into 3 anatomical regions; aorto-iliac, 
femoro-popliteal and crural disease, which has relevance for treatment. Lesions within each 
region have been further subdivided into TASC lesions A to D, indicating their suitability 
for endovascular treatment (Norgren et al. 2007); 
 
A – represents a lesion which responds well to endovascular treatment 
B – represents a lesion which, when treated endovascularly, yields good results but 
open surgical repair may be appropriate if there are multiple lesions in this area.  
C – represents a lesion which responds better to open surgical repair but 
endovascular treatment may be suitable if they have a high operative risk 
D – such lesions do not yield good enough results to justify endovascular as the 
initial treatment. 
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Crural vessel (below the knee) angioplasty is sometimes performed for patients with critical 
limb ischaemia as an initial salvage treatment, the aim of which is to restore in line blood 
flow to the foot. This is not a treatment for IC due to the increased risks associated with this 
procedure, particularly vessel spasm and acute closure. Given the systemic nature of 
atherosclerotic disease, patients often have multilevel disease, requiring treatment at more 
than one site (Ettles 2006). 
 
Published data suggests lower limb angioplasty patency rates for femoropopliteal disease at 
5 years range between12% and 68%, the best results being for patients with claudication 
and stenotic lesions (Hunink et al. 1994). For aortoiliac disease immediate technical 
success rate is as high as 96% for stenting procedures, but at 4 years patency rates are 
between 54% (for balloon angioplasty treatment of occlusion and 77% (for stent treatment 
of stensosis) (Bosch and Hunink 1997).  
 
ABPI declines due to restenosis or occlusion at the original site of pathology or progression 
of disease at other sites. Restenosis has always been a technical challenge to angioplasty 
treatment and is caused by factors including elastic recoil following angioplasty, late vessel 
remodelling and neointimal hyperplasia. Neointimal hyperplasia is the physiological 
response to trauma to the vessel wall, occurring from 3-6 months after treatment and 
resulting in proliferation of the intimal lining of the vessel wall. Drug eluting stents are 
coated with a polymer matrix which controls the release of pharmaceutical agents aimed 
and maintaining patency. The SIROCCO trial used the immunosuppressant, Sirolimus 
(rapamycin) in comparison with bare nitinol stents for superficial femoral artery lesions. 
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The restenosis rate at 2 years was 22.9% for the sirolimus drug eluting stent and 21.1% for 
the bare nitinol stent (Duda et al. 2006) 
 
1.2.4 Role of exercise therapy 
A 2008 Cochrane review of randomised controlled trials using any exercise programme, 
has confirmed the role for exercise therapy in the treatment of IC showing improved 
walking ability by approximately 50% to 200% (Watson et al. 2008). Compared to usual 
care or placebo exercise leads to improvements in maximum walking times and distances 
without any improvement in ABPI. All studies recommended at least two weekly sessions 
of mostly supervised rather than unsupervised exercise. Classes lasted between 30 and 60 
minutes and included walking and leg exercises or treadmill training. Beneficial effects 
were demonstrated following 3 months of supervised exercise (Watson et al. 2008). 
 
An earlier meta-analysis demonstrated the clinical improvement possible with exercise 
therapy, with treadmill walking distance improvements of 122% (maximum treadmill 
walking distance) to 179% (treadmill walking distance where claudication pain begins) 
(Gardner and Poehlman 1995). This meta-analysis found that the key components among 
exercise programmes were; 
 Session of > 30 minutes each 
 3 sessions per week 
 Exercise programme duration of > 6months 
 Walking focussed exercise programmes (Hiatt et al. 1994) 
 Walking which induced near maximal pain. 
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Accounting for 85-90% of the variance in change in claudication distances was, in order of 
importance; near maximal pain, > 6 month duration and walking programmes rather than 
combination exercise programmes encompassing a variety of exercise modalities. 
Interestingly older patients (64-68 year olds) demonstrated greater increases in treadmill 
distances than their younger counterparts (58-63 year olds), although whether this was due 
to more severe disease was unclear.  
 
Conversely it has been suggested that exercise to maximal pain may make PAD worse by 
inducing ischaemia and thus causing a local inflammatory and oxidative stress response 
(Tisi and Shearman 1998), which may promote atherosclerosis and have a deleterious effect 
on muscle function. However Tisi et al. (1997) confirmed a biochemical inflammatory 
response, but reported a reduction in inflammatory markers and improved symptoms 
following a 4 week supervised exercise programme with encouragement to continue 
exercising at home when compared to a non-exercise group. 
 
Exercise intensity may not be important. Gardner et al. (2005) randomised claudicants to a 
low intensity (40% maximal exercise capacity) or high intensity (80%) groups for 
intermittent treadmill walking at near maximal pain in supervised sessions for 3 days a 
week and found no difference in efficacy provided that a similar volume of exercise is 
performed.  
 
In terms of the type of exercise required, strength and resistance training alone or in 
combination with walking programmes has been studied. A randomised controlled trial of 
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29 patients who underwent 12 weeks (3 hours per week) of treadmill walking or lower limb 
strength training found the walking group improved in peak walking time twice as much as 
the strength group, and they also showed improvement in peak oxygen consumption and 
increased time to the onset of pain, findings which the strength group did not show. 
Sequential or concomitant strength and walking programmes showed similar improvements 
to treadmill walking alone (Hiatt et al. 1994).  
 
Both supervised and unsupervised exercise programmes have been shown to be cost 
effective treatments both for primary and secondary prevention of cardiovascular disease 
(CVD) (Lowensteyn et al. 2000). Even with poor long term compliance, in the region of 
30%, unsupervised exercise was highly cost effective at < 12,000 US$ per life year saved in 
both individuals with and without CVD. Supervised exercise programmes are intuitively 
more expensive. Even with an adherence of 50% in the first year following the exercise 
programme and 30% long term compliance, for all men with CVD and women with CVD 
(over 55 years old) and even for young men without CVD, such programmes are cost 
effective (between 20,000 and 40,000 US$ per life year saved). Lee et al. (2007) identified 
the cost per quality adjusted life year (QALY) over the first year following a 3 month 
exercise programme to be £1780/QALY. Given that the National Institute for Clinical 
Excellence (NICE) identify a cost-effective treatment as falling below £30,000/QALY, 
exercise appears to offer a highly cost-effective treatment option.  
 
The proposed mechanisms of improved walking following exercise therapy are numerous
 
(Stewart et al. 2002). Human studies demonstrating both improved collateral blood flow 
and clinical improvement are limited, with either no or moderate improvements in ABPI. It 
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is therefore proposed that mechanisms other than improved blood flow are responsible. 
Such mechanisms include;  
 Increased aerobic capacity 
 Improved muscle strength and endurance 
 Improved walking ability through improved economy 
 Improvements to the microcirculation, and endothelial function (Brendle et al. 
2001) 
 Improvements in the nature of blood flow, such as reduced viscosity 
 
There is a paucity of data comparing exercise to angioplasty. The Cochrane review 
identified 2 studies separated by 16 years (Watson et al. 2008). These found that 
angioplasty produced a greater improvement in walking times and distances initially but 
this was not sustained at one year (Creasy et al. 1990), although improvements in 
angioplasty techniques over time may have made both treatments more comparable. In 
2008 the MIMIC trial showed a sustained benefit in terms of walking distances for patients 
having undergone both angioplasty and exercise compared to those who had undergone 
exercise alone at 24 months from treatment (Greenhalgh et al. 2008).  
 
TASC recommendations state that exercise therapy should be made available to all patients 
with peripheral arterial disease as an initial treatment strategy. They concur that the most 
effective sessions involve treadmill or track walking of sufficient intensity to induce IC 
pain, with rest periods over a 30 to 60 minute class conducted 3 times a week for 3 months 
(Norgren et al. 2007).  
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1.3 Physical function 
 
1.3.1  Definition of physical function 
“Physical function” can be defined as a complex, generalised measure of performance in 
various functional domains relevant to daily life, and as such is a reflection of overall health 
and the impact of disease on physical ability. Physical function requires multiple 
complementing and coexisting skills such as strength, proprioception, balance, freedom of 
movement and coordination and relies on adequately functioning neuromuscular systems in 
addition to an absence of pain and fear.  
 
Physical function is particularly relevant to elderly populations. A large observational study 
of 1122 older patients without disability found those with the poorest lower extremity 
function at baseline were over 4 times as likely to have disability in both activities of daily 
living and mobility after 4 years of follow up as those with high performance scores on 
tests of walking speed, balance and functional strength (2.4 metre walk, repeated rising 
from a chair and standing balance) (Guralnik et al. 1995). This finding highlights the link 
between poor baseline physical function and potential future decline in older people.  
 
Given the ageing nature of our population the burden of chronic disease such as PAD is set 
to continue, and concomitant rises in frailty, poor mobility and loss of independence 
associated with ageing are likely. Measuring functional decline and disability is important, 
particularly if this allows prediction of future demise to allow intervention.  
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The justification for an in depth assessment of physical function in patients with PAD, in 
addition to assessing walking distance or symptom improvement, is not only to ascertain 
problems with activities of daily living but to recognise patients at potential risk of the 
serious consequences of functional decline. Declining physical function is a predictor of 
future disability
 
(Guralnik et al. 1995) and relates to falls risk (Tinetti et al. 1998). A core 
component of physical function is physical activity and this has alarmingly also been 
shown to be a predictor of all-cause mortality in PAD and IC (Garg et al. 2006; Gardner et 
al. 2008a). 
 
1.3.2  The relationship between physical function and PAD 
As previously described, PAD tends to be a disease of older people and therefore an elderly 
patient cohort is likely to experience the problems of declining physical function seen in 
otherwise healthy elderly people. Yet there is evidence to suggest there may be a greater 
association between physical function and PAD than merely that expected with aging.  
 
Frailty or lack of physical function is associated with sub clinical cardiovascular disease 
(Newman et al. 2001) and an association between poor physical function and PAD, 
specifically, has been demonstrated in several large cross-sectional studies (Garg et al. 
2006; McDermott et al. 2001). Given that walking impairment is the major symptomatic 
complaint of claudicants it follows that with increasing severity of PAD, determined by 
lower ABPI values, a correlation with deteriorating ambulatory function is seen. Patients 
with mild disease (high ABPI group, 0.76-0.9) performed significantly better than those 
with severe disease (low ABPI group, 0.36-0.5) over the 6-minute walk and had higher 
daily physical activity levels (Atkins et al. 2004). Such findings extend beyond just walking 
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related function. A multi-centre observational study of 740 individuals of whom 460 had 
PAD (33% with IC) found that lower ABPI values were associated with lower measures of 
functional strength and balance, in addition to poor ambulatory function (McDermott et al. 
2002). Even among asymptomatic patients with low-normal (1.00 to 1.09) or borderline 
(0.9-0.99) ABPI values there is evidence of functional decline in a large prospective 
observational study (McDermott et al. 2009b), thus suggesting that the decline in function 
cannot be solely explained by pain when walking.  
 
A potential pathological explanation for deteriorating physical function in patients with 
peripheral arterial disease is thought to be loss of strength consistent with ischaemic muscle 
changes. Histological analysis of gastrocnemius muscle from PAD patients has shown 
significantly increased evidence of angular fibres, indicative of chronic denervation, and 
significantly decreased type II muscle fibre area which is associated with greater strength 
deficits as type II fibres are larger, faster and stronger than type I fibres (Regensteiner et al. 
1993).  
 
Intuitively there are many other contributing factors which may account for poor 
performance among claudicants. Oka et al. performed a multiple regression analysis on 
data from 97 PAD patients to determine predictors of physical function, demonstrating; 
education, absolute walking distance, social support, arthritis and age to be the strongest 
predictors of physical function (Oka et al. 2004).  
 
Deteriorating ABPI cannot therefore be relied on as a surrogate marker to detect declining 
physical function in a lower limb ischaemia population. This is supported by a study of 
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older males which found that despite no deterioration in ABPI, declines in walking 
function, physical activity, physical function (balance, lower limb functional strength and 
4-metre walking velocity), and calf blood flow were noted over a period of 18 months 
follow up (Gardner et al. 2004). 
 
The relationship between physical function and PAD is complex and not yet fully 
elucidated. Further understanding of how to identify patients at risk of deteriorating 
physical function is therefore important. Consequently identification of individuals with 
poor function allows targeted interventions towards those most in need and those most at 
risk of further decline. This may be particularly pertinent among patients with lower limb 
ischaemia as baseline functional performance has been shown to be a predictor for the rate 
of self-reported mobility loss among persons with PAD (hazard ratio 1.63, 95% CI 1.03 to 
2.56) when compared to controls (McDermott et al. 2007). 
 
1.3.3 Assessment of physical function 
Physical function could be measured via a vast array of tests and assessments. Frailty, for 
example, has been assessed by measures of weight loss, low grip strength, low energy, slow 
gait speed and low physical activity (Newman et al. 2001). However there are many simple 
objective measures of physical function that could be used by any health care professional. 
Lower limb physical functional assessment is relevant to a cohort with lower limb disease.  
 
To assess physical performance and to compile data on lower extremity function in non-
disabled older people, Guralnik et al. (1995) used tests of standing balance, walking speed 
and the ability to rise from a chair. They assimilated their data to form a summary 
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performance score for each individual tested by dividing the results of their 5000 plus 
cohort into performance quartiles on each test. The validity of this summary score has been 
shown to correlate with an increasing of risk of admission to a nursing home and mortality 
with increasingly poor scores. The tests themselves incorporate assessment of balance, 
lower limb functional strength, and coordination. Such tests have been used in PAD 
patients in several studies (Arseven et al. 2007; Gardner and Montgomery 2001b; Gardner 
et al. 2004; McDermott et al. 2001; McDermott et al. 2002; McDermott et al. 2006;) and 
have been shown to be more strongly associated with physical activity levels during daily 
life than treadmill walking assessments (McDermott et al. 2008b).  
 
Treadmill walking tests specifically for PAD have been discussed in Chapter 1.2 and are of 
relevance in measuring disease severity as well as physical function. Other walking tests 
are of value in the assessment of physical function such as the 6 minute walk test 
(McDermott et al. 2008b) which allows the individual to select their preferred walking 
velocity, thus offering a potentially more realistic portrayal of actual walking performance. 
 
Balance is a key component of physical function and is explored in further detail in Chapter 
1.4. Risk of falling is also intimately linked to poor physical function and this is expanded 
on in Chapter 1.5.  
 
1.3.4 Exercise therapy and physical function  
High levels of physical activity or exercise may be protective in preventing poor physical 
function in lower limb ischaemia. In a prospective cohort study of 417 patients with PAD, 
after adjusting for variables, found that patients who walked for exercise 3 or more times 
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per week, particularly if they exercise for more than 90 minutes per week, had a 
significantly smaller average annual decline in 6 minute walking distance compared to 
those who walked less frequently (McDermott et al. 2006). Despite an encouraging trend, 
there was no significant slowing of functional decline in other measures such as tandem 
balance and chair stand testing suggesting that these aspects of function may require 
different exercise training regimens.  
 
A well conducted randomised controlled trial has demonstrated that even a short 5-week 
“circuit-style” exercise class performed twice weekly improved stepping balance, 
functional strength (sit to stand test), gait velocity and walking distance over six minutes, 
over those with no intervention in older mobility-impaired participants (mean age 74.9) 
(Sherrington et al. 2008a). There was no significant improvement in standing balance or 
lower limb strength, explained by a lack of strength training within the exercise classes. 
Modifications to the exercises performed or increasing the duration of the treatment may 
have demonstrated further functional improvement although this assumption is unproven. 
 
Interventions aimed at improving physical activity levels are likely to be crucial in 
maintaining adequate physical function and preventing functional decline. Further research 
is required to delineate the exact components of an exercise regime that best suit 
individuals in terms of objective gains in physical function and the prevention of 
deterioration.  
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1.4 Balance 
 
1.4.1  Background 
Balance can be defined as the ability to maintain the body’s centre of gravity over the base 
of support and is required for safe functional activity
 
(Panzer et al. 1995) and thus the 
prevention of falls. Balance is both static and dynamic, requiring not only maintenance of 
position, but also postural control during transfer to a new base of support during voluntary 
activities such as walking (Howe et al. 2007) and overcoming involuntary perturbations to 
prevent falling.  
 
Balance is complex, requiring interplay between different sensory systems, primarily 
somatosensory, visual and vestibular systems. The somatosensory system is responsible for 
proprioception and the awareness of the body’s position in space. This is achieved through 
sensory pressure receptors and muscle and joint proprioceptors. The visual system enhances 
balance by orientating the body in space and providing information about the challenges or 
obstacles around. The vestibular system detects movement in space and triggers 
neuromuscular responses to rotations and translations experienced.  
 
Impairment of balance occurs due to a wide range of aetiologies but the goal of 
management is to maintain function and minimise disability, particularly minimising the 
risk of falls and associated injury. Balance has recently been viewed as a learned neuro-
motor skill rather than purely a reflex or reactive sense (Horak et al. 1997), which indicates 
potential for rehabilitation and improvement of balance.  
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1.4.2 The relationship between balance and PAD 
The link between poor physical function and PAD was explored in section 1.3.2. Balance is 
one of the key components of physical function and therefore of specific relevance for 
further investigation. Suominen et al. (2008) established that older individuals with PAD 
exhibited a significantly increased amount of movement of their centre of pressure on 
standing, indicative of poor balance. Gardner and Montgomery (2001a) have shown that 
PAD patients have 28% shorter single leg stance times, 86% higher prevalence of 
stumbling and unsteadiness on walking and 73% more prevalent history of falling than non-
PAD counterparts.  
 
One explanation for poor balance in patients with PAD is similar to that for poor physical 
function, in that, PAD patients have ischaemic muscle changes that correspond with poor 
functional strength (Regensteiner et al. 1993) and poor motor neurone performance 
(Gardner and Montgomery 2001a). Whether the presence of PAD is indicative of central 
balance control impairment is difficult to ascertain, but the systemic atherosclerosis 
associated with PAD patients may cause central and cerebral changes which contribute to 
balance impairment.  
 
1.4.3 Assessment of balance 
The adequate assessment of balance begins with a clear patient history, including perceived 
balance problems and previous falling. Physical examination to elucidate coexisting 
medical conditions that affect balance is conducted followed by specific balance tests. 
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Romberg’s test is a simple test to identify abnormal proprioception. The patient stands with 
their feet together and eyes closed. If instability is detected (swaying, falling or stepping) 
the test is positive (Clarke 1999).  
 
Tinetti (1986) described the performance oriented assessment of mobility (POMA) 
assessment tool to quantify mobility problems in elderly patients. The balance component 
assesses 8 tasks such as sitting, standing and turning. Each task is scored out of 2 points 
with a maximum of 16 for the test, a higher score equates to better balance. POMA also 
includes a gait assessment with a maximum score of 12. Patients are stratified in terms of 
falls risk based on the combined score; ≤18 = high risk, 19-23 = moderate risk, ≥24-28 = 
low risk. The limitations of POMA are firstly, it is cognitively challenging with a number 
of instructions to be followed making it difficult for patients with cognitive impairment. 
Secondly it must not be considered to be a comprehensive falls assessment tool alone, as it 
does not account for all falls risk factors (Lewis and Shaw 2005). 
 
Koch et al. (1994) showed high inter-rater reliability for a tool similar to the POMA tool 
for impairment and disability for community living older persons in which their balance 
assessment incorporates observing the patient conducting balance procedures during 
normal daily activities such as stand to sit, sit to stand, bending, reaching and carrying 
objects. The assessor records the number of attempt to complete the task, loss of balance, 
excessive leaning, unsafe positioning and the need for help or support. This tool also 
assesses strength, range of motion, gait and foot problems and is designed to be 
representative of activities of daily living but is not quantitative in terms of balance 
assessment. Berg balance score is a 56 point scale assessing similar functional tasks to the 
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POMA (Berg et al. 1992). The test is similarly cognitively challenging and takes 
approximately 20 minutes to complete which may induce fatigue and even IC pain in PAD 
patients.  
 
Simple, quick and quantitative measures of balance are also described in the assessment of 
physical function and include the balance aspects of the summary performance score 
(Guralnik et al. 1995), for example the measurement of semi-tandem and full-tandem 
stance, and the Timed up and Go test (TUG) (Podsiadlo and Richardson 1995, Bohannon 
2006). Tandem stance tests require the patient to stand with their heel of one foot beside the 
big toe of the other foot (semi-tandem) and the heel of one foot directly in front of the other 
foot (full-tandem) and loss of balance is recorded (Guralnik et al. 1995). The TUG test 
requires the patient to rise from a chair, walk 3 metres and turn, return and sit down again. 
The time taken to complete this is recorded and reference values have been determined to 
identify abnormal test scores (Bohannon 2006).  
 
1.4.4 Computerised dynamic posturography 
Computerised dynamic posturography (CDP) is the standard quantitative method for 
isolating and assessing the sensory and motor components of balance in the standing human 
(Black 2001). CDP testing is unique in that it measures a patient’s postural sway by 
incorporating movement or perturbation of the support surface and is capable of isolating 
the contributions of different sensory components from the visual, vestibular and 
somatosensory systems and providing quantified data (Monsell et al. 1997). CDP 
incorporates aspects of clinical testing such as Rombergs, but has the unique advantage of 
providing quantitative data. This improves on simple clinical balance assessments in the 
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ability to perform repeated measurements to assess progress or response to treatment. CDP 
requires both sensory and motor impairment assessment and uses the Sensory Organisation 
Test (SOT) and motor coordination tests such as the Motor Control Test (MCT) (Black 
2001). CDP, as described by Monsell et al. (1997) in their technology assessment for the 
American Academy of Otolaryngology-Head and Neck surgery Foundation, is based 
mostly on studies using the Equitest device manufactured by NeuroCom International, 
Clackamas, Oregon.  
 
CDP measures the forces exerted by a patient standing on a platform, which is capable of 
movement controlled by the device’s computer. Several test conditions exist to challenge 
the patient’s mechanisms of postural control through alteration of somatosensory and visual 
input and consequently vestibular input. Data is compared with age matched control data to 
identify abnormalities.  
 
Validity and reliability of CDP has been confirmed (Ford Smith et al. 1995; Monsell et al. 
1997; Carter et al. 2001). The most reliable data from the SOT on test retest analysis is the 
composite score and the number of episodes of loss of balance (falls) during the test (Ford 
Smith et al. 1995).  
 
Other similar tests include electronystagmography and rotational chair tests but both of 
these are limited to assessing visual and vestibular systems. Foam posturography (standing 
on a foam surface) can identify both normal and abnormal balance including patterns of 
abnormality but subtle abnormalities can be missed (Monsell et al. 1997).  
 
39 
 
There are a wide number of current and potential uses of CDP. Clinically CDP can 
determine whether or not a balance problem is present and if so whether the problem lies 
with sensory inputs, central integration or motor output, or indeed a combination of systems 
(Black 2001). For elderly and aging populations CDP is useful in the assessment of balance 
control and recovery of function. In particular CDP has been used in monitoring of balance 
rehabilitation programmes and to identify patients who fall from non-fallers (Whitney et al. 
2006).  
 
1.4.5 Exercise therapy and balance 
A Cochrane review has concluded that exercise therapy improves balance when compared 
to usual activities in older people (Howe et al. 2007). Types of exercise interventions 
studied varied from walking and cycling to strengthening and resistance training, to specific 
balance training exercises, dance, yoga and tai chi. Of most benefit were interventions 
involving walking, balance training, coordination and functional exercises, muscle 
strengthening and combination sessions, and can be evaluated by indirect measures of 
balance such as single leg stance tests. However it is not clear as to whether the benefits of 
exercise therapy, which was typically a 3 month programme, are long lasting (Howe et al. 
2007). 
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1.5 Falls 
 
1.5.1 Falls and PAD 
Risk factors for falls are multiple and include several domains of physical function, such as 
strength, and balance. The link between poor lower limb function or impaired balance and 
gait and falls risk is well recognised (Tinetti et al. 1988; Gardner and Montgomery 2001a). 
Vice versa known fallers have also demonstrated significantly poorer objective measures of 
ambulatory function, physical activity, lower limb functional strength (chair stand test), and 
impaired balance (single leg stance and full-tandem stance) (Gardner and Montgomery 
2001b). 
 
As PAD patients have been shown to have poor physical function an increased risk of falls 
would be expected although this has not been uniformly proven (Arseven et al. 2007). In a 
retrospective study of symptomatic patients, 26% of claudicants fell which differed 
significantly from 15% of controls (P<0.001). There was a significant relationship between 
falling and other aspects of poor physical function including balance, but ABPI was 
unrelated to falling (Gardner and Montgomery 2001a). A pilot study of 43 community 
dwelling older male claudicants which demonstrated functional decline despite no drop in 
ABPI also showed a significant increase in the percentage of patients reporting ambulatory 
stumbling and unsteadiness at 18 months (43% versus 28% at baseline) implying that men 
with PAD may experience gradual loss of stability over time which may increase their risk 
for falls. There was no perceived change in self-perceived health or reporting of symptoms 
over time, thus possibly rendering patients more susceptible to falls due to lack of insight 
towards their deterioration (Gardner et al. 2004).  
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1.5.2 Falls assessment 
Most importantly all patients should be assessed on an individual basis in the wider context 
of their presentation with a full medical history and appropriate examination. If concerns 
are raised patients should be referred for a thorough falls assessment from an appropriate 
specialist.  
 
The published guidelines for the prevention of falls in older persons by the American 
Geriatric Society advocates a simple assessment of falls risk as a screening tool, the timed 
“Up and Go test”, (TUG) (American Geriatrics Society 2001); . During the TUG test the 
patient is observed and timed while he or she rises from a chair, walks 3 meters, turns and 
walks back and sits down again, with an abnormal result when the test completion is greater 
than 16 seconds (Figure 1.1) (Podsiadlo and Richardson 1991). 
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Figure 1.1 Timed Up and Go test (TUG) 
The patient is observed and timed while he or she rises from a chair, walks 3 meters, turns and walks back and 
sits down again (Podsiadlo and Richardson 1991). 
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Assessment of falls and balance are closely linked in clinical balance and therefore there is 
overlap in their assessment. Chapter 1.4 concentrates on balance and its assessment, 
although several tests are described they are also used as measures of falls risk.  
 
Fear of falling should also be considered in falls assessment as fear and activity avoidance 
are likely to significantly contribute to impaired quality of life. Fear of falling can be 
measured in a number of ways including: the Falling Efficacy Scale (FES), the Geriatric 
Fear of Falling Measurement (GFFM) and the Activities-Specific Balance Confidence 
Scale (ABC), which have all been shown to have strong internal consistency (Huang and 
Wang 2009). The ABC-UK assessment addresses more challenging balance tasks in its 
questioning and is specifically targeted at British participants (Parry et al. 2001). 
 
1.5.3 Exercise therapy and falls 
The role of exercise in the management of elderly persons aimed at reducing falls incidence 
has been explored in depth and both a Cochrane review (Gillespie et al. 2003) and more 
recent meta-analysis have concluded there is benefit of exercise on reducing falls rates 
(Sherrington et al. 2008b). This meta-analysis found that exercise reduced the rate of 
falling by 17% (44 trials with 9603 participants) with key recommendations being 
programs including a high total dose of exercise (>50 hours over the trial period) and 
challenging balance exercises (on one foot or with feet close together) (Sherrington et al. 
2008b).  
 
It seems timely that the crossover between research into elderly persons and patients with 
symptomatic and asymptomatic PAD is made, in terms of recognising and managing poor 
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physical function, to improve functional outcomes, particularly falls. Exercise, when 
specific and targeted has been shown to improve both symptoms of PAD but also falls risk 
among the elderly thus improving overall physical function.  
 
Given that PAD patients are already exposed to increased morbidity and mortality 
associated with systemic atherosclerosis, poor functional outcomes and a possible increased 
risk of falls is an additional worrisome health burden for this population and a drive 
towards improving management including exercise training schemes for those at risk is 
paramount. 
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1.6 Quality of life 
 
1.6.1 Quality of life and PAD 
Patients with symptomatic PAD are known to have been shown to have impaired quality of 
life (QOL) with increasing severity of lower limb ischaemia corresponding to significant 
deterioration in QOL. Furthermore QOL improves with treatment (Chetter et al. 1999). 
Disease specific tools show greater sensitivity to symptomatic improvement following 
treatment (de Vries et al. 2005; Guidon and McGee 2010).  
 
1.6.2 Measurement of quality of life 
There are numerous measures of QOL, designed for generic and disease specific 
measurement. The Nottingham Health Profile (NHP), EuroQol (EQ-5D) and Short Form 36 
(SF36) have been shown to be valid and reliable measures of generic QOL in PAD patients 
(Chetter et al. 1998). Domains examined are similar but specifically the NHP measures; 
energy, pain, emotional reaction, sleep, social isolation and physical mobility. The EQ-5D 
measures: mobility, self-care, usual activities, pain and anxiety/depression. Lastly, the SF36 
measures: physical function, physical role, pain, general health, vitality, social functioning 
and mental health. SF36 is most sensitive to changes in psychological status and is 
therefore recommended as the most appropriate generic QOL assessment tool in PAD and 
for widespread use in vascular surgery to standardise reporting outcomes. More recently the 
Short Form 8 (SF8) when compared to SF36 has been found to be a valid and reliable 
measure, with the advantage of less questions and therefore rendering it easier and quicker 
to complete (Gulati et al. 2009). 
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There are a number of disease specific measures of QOL for PAD. The peripheral arterial 
occlusive disease 86 (PAVK-86) questionnaire (Bullinger et al. 1996) was validated in 
German and has 86 questions making it time consuming to complete. The IC questionnaire 
(ICQ)
 
(Chong et al. 2002) is a 16 point questionnaire giving a single health domain. The 
sickness impact profile-IC scale (SIP)
 
(Arfvidsson et al. 1993) and CLAU-S (Spengel et al. 
1998) are both further disease specific measures for use in IC. The VascuQol is a 25 
question assessment of limb ischaemia quality of life providing 5 domain scores (pain, 
activities, emotional, social and symptoms) (Morgan et al. 2001). VascuQol is unique in 
that it encompasses all lower limb ischaemia rather than just IC which is of increased value 
as symptoms progress towards severe lower limb ischaemia and has been shown to be more 
responsive than CLAU-S or SIP (Mehta et al. 2006). VascuQol has been recommended for 
assessment of disease specific QOL in PAD (de Vries et al. 2005; Mehta et al. 2006). 
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1.7 Hypothesis 
 
The aim of this study is to investigate the impact of standard treatment, through angioplasty 
or exercise therapy, on clinical indicators of lower limb ischaemia including walking 
distances (both pain free and total walking distances), physical function, balance and 
quality of life in patients with lower limb ischaemia.  
 
The specific research questions and hypotheses are: 
1. Is increasing lower limb ischaemia associated with impairments of physical 
function and balance? 
 
Hypothesis 1: Prior to treatment, increasing severity of lower limb ischaemia will 
correlate with increasingly impaired physical function and balance.  
 
2. What effect does angioplasty treatment have on outcome measures (i.e. clinical 
indicators of lower limb ischaemia, physical function, balance and quality of life) 
in patients with lower limb ischaemia? 
 
Hypothesis 2: Patients undergoing angioplasty treatment will demonstrate 
improved outcome measures after treatment.  
 
3. What effect does exercise therapy treatment have on outcome measures (i.e. 
clinical indicators of lower limb ischaemia, physical function, balance and quality 
of life) in patients with lower limb ischaemia? 
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Hypothesis 3: Patients undergoing exercise therapy treatment will demonstrate 
improved outcome measures after treatment.  
 
4. How do angioplasty and exercise therapy compare in the impact on outcome 
measures (i.e. clinical indicators of lower limb ischaemia, physical function, 
balance and quality of life) in patients with lower limb ischaemia? 
 
Hypothesis 4: There will be no difference between angioplasty and exercise 
treatments in improving outcome measures. 
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2 Methods 
2.1 Study design and patient recruitment 
 
2.1.1 Study description 
A prospective case series study was performed on an out-patient population in one 
geographical area to investigate the role of two treatment groups on physical function, 
balance and quality of life in patients with lower limb ischaemia. Patients for the two 
treatment groups (angioplasty and supervised exercise programme) were concurrently 
recruited from the district served by the Hull and East Yorkshire Teaching Hospitals 
National Health Service (NHS) Trust.  
 
2.1.2 Ethical approval and permissions 
Local Research Ethical Committee (LREC) approval for the study was granted in addition 
to approval from the Research and Development Departments of the University of Hull, 
and Hull and East Yorkshire Hospitals NHS Trust (LREC reference numbers 07/Q1105/12, 
07/Q1105/13, 07/H1305/83). Patients, referred by the consultant vascular surgeon in charge 
of their care, volunteered and provided written informed consent at Hull Royal Infirmary to 
participate in the study. 
 
2.1.3 Sample size calculations 
Sample sizes calculated for each treatment arm were based on the composite equilibrium 
score from the Sensory Organisation Test (SOT) of the EquiTest System (NeuroCom, 
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Clackamas, OR, USA; see section 2.5). For the angioplasty treatment group, initial pilot 
data from 19 patients with a mean baseline SOT score of 59.8% (sd 24.8) was used. The 
minimum expected clinically significant improvement chosen was a score of 72.9% (sd 
5.4), which represents the lowest normal mean score for NeuroCom healthy controls in the 
70-79 year age category. The calculated sample size was 29 based on 80% power to detect 
this difference in the SOT means (difference of 13) using a paired t-test with a 0.05 two-
tailed significance level. For the exercise group, the initial pilot data had a mean baseline 
score of 65.3% (sd 12.5) that required a calculated sample size required of 22 to detect a 
difference in means of 7.5. Assuming a 25% drop out rate from both groups the target 
samples were 37 for the angioplasty group and 28 for the supervised exercise group.  
 
2.1.4 Study design 
Patients underwent nine potential stages in the research study (Figure 2.1). The first three 
stages involved patient selection. Potential patients were identified at outpatient clinics by 
their consultant vascular surgeon and suitable treatment (angioplasty or supervised 
exercise) was assigned at this stage or following further discussion at the multi-disciplinary 
team meeting (MDT) comprising interventional radiologists and vascular surgeons. 
Subsequently a patient information sheet and letter of invitation was sent to the patient 
(Appendix 1). The second two stages of the study involved written informed consent and 
baseline data capture. The last four stages of the study involved the intervention and 
follow-up measurements conducted at 3, 6 and 12 months after commencing exercise 
treatment or undergoing angioplasty.  
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Figure 2.1 Flow diagram illustrating patient assessment and involvement in the study  
MDT; multi-disciplinary team meeting comprising interventional radiologists and vascular surgeons 
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2.1.5 Patient selection 
Potential patients identified by the study investigators at the vascular outpatient clinic at 
Hull Royal Infirmary, were confirmed as claudicants by clinical assessment in the clinic by 
the referring consultant. Confirmation was provided by documented current symptoms of 
intermittent claudication with an Ankle Brachial Pressure Index (ABPI) of <0.9 or >20 
mmHg drop in ankle pressure post exercise testing (see section 2.3.1) or documented 
haemodynamically significant atherosclerosis on radiological imaging (angiogram or 
Duplex ultrasound).  
 
2.1.6 Baseline visit 1 and inclusion/exclusion criteria 
The baseline visit involved two stages. First, patients responding to the invitation visited 
the Vascular Laboratory at Hull Royal Infirmary where, at this initial appointment, written 
informed consent was obtained, and a detailed general medical and vascular surgical 
history was taken using a purpose designed proforma (Appendix 2). The following general 
inclusion/exclusion criteria were applied to all patients.  
 
The inclusion criteria were: 1) confirmed as claudicants by the referring consultant 
following clinical assessment in out-patient clinic (section 2.1.5); 2) lived independently in 
the local community; 3) did not require assistance for general activities of daily living 
including shopping, cleaning and self-care; 4) over 50 years of age; 5) English speaking, 
and; 6) able to comply with simple study protocol instructions.  
 
The exclusion criteria were: 1) inability to safely perform balance testing and to comply 
with the study protocol as determined by the referring consultant or study doctor (for 
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example; coexisting neurological or limiting cardio-respiratory or other significant medical 
problems); 2) significant peripheral neuropathy (Toronto clinical neuropathy score of >8 
(Bril and Perkins 2002)); 3) life limiting conditions (such as active cancer); 4) mobility 
problems (such as major limb amputations, wheelchair use and hemiplegia), and; 5) 
dementia.  
 
On confirmation of eligibility to the study, patients then underwent a thorough assessment 
both at the Vascular Laboratory and at the Sports Science Laboratory at the University of 
Hull (sections 2.2-2.5). Patients were seen at both locations within a 7 day period. Patient 
demographics were detailed in section 3.  
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2.2 Patient assessment 
 
2.2.1 Medical history 
A full medical history was performed by a study doctor to elucidate any serious co-
morbidities as potential further exclusion criteria at baseline. This assessment was repeated 
at subsequent visits to identify any changes or potential exclusions during the study time 
period. Patients were specifically asked about any history of ischaemic heart disease, 
hypertension, hypercholesterolaemia or statin therapy, cerebrovascular disease, diabetes 
mellitus, arthritis, balance problems, neurological disease and smoking history (Appendix 
2).  
 
2.2.2 Medical examination 
A full medical examination was conducted by a study doctor, including neurological 
examination and visual acuity assessment at 3 metres using a 3 metre Snellen
 
(Turner and 
Blackwood 1998) chart. An assessment of peripheral neuropathy was made using the 
Toronto (Bril and Perkins 2002) scoring system (Table 2.1). Patients with a Toronto score 
of >8 were deemed as having moderate to severe peripheral neuropathy and were excluded 
from the study.  
 
Simple anatomical measurements were taken. Circumferences of both calves were 
measured at the mid tibial point to assess any differences between symptomatic and 
asymptomatic legs. Height (wearing flat shoes) and weight (wearing light clothing) were 
measured and Body Mass Index (BMI) was calculated.    
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Table 2.1 Toronto clinical neuropathy scoring system 
Symptom scores Reflex scores Sensory test scores 
Foot 
- Pain 
- Numbness 
- Tingling 
- Weakness 
Knee reflexes 
Ankle reflexes 
Pinprick 
Temperature 
Light touch 
Vibration 
Position sense 
Ataxia   
Upper limb symptoms   
Sensory testing was performed on the great toe. Symptom scores were calculated as; present = 1, absent = 0. 
Reflex scores were calculated as; absent = 2, reduced = 1, normal = 0. Sensory test scores were calculated as; 
abnormal = 1, normal = 0. The maximum total score was 19.  
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2.3 Clinical indicators of lower limb ischaemia 
 
The ankle brachial pressure index at rest (ABPI) was calculated using a hand held Doppler 
(Parks Medical Electronics, Inc. Oregon, USA). ABPI post exercise (ABPI-PE) was 
calculated for each patient immediately following the treadmill test (section 2.3). Post 
exercise the ankle pressure from the symptomatic leg was recorded and used to classify 
disease severity using the Rutherford criteria (Table 1.1) (Rutherford et al. 1997). 
 
At baseline, and at months 3, 6 and 12, patients completed a modified Rutherford treadmill 
test involving walking at 1.6 mph at a 10 degree inclination for a maximum of 5 minutes. 
The test was modified by reducing the speed to 1.6 mph as the original 2 mph had been 
found in clinical practice to be too fast for a good proportion of our local population. The 
treadmill test was used to calculate the: intermittent claudication distance (ICD), which was 
the time when patients experienced the onset of their usual claudication pain, and; the 
maximum walking distance (MWD) when patients could walk no further. A small number 
of patients were unable to walk at 1.6 mph and were allowed to walk at slower speeds for 
safety purposes (1.0 mph or 1.2 mph). All patients were allowed to use handrails on the 
treadmill for balance. They were instructed not to hold themselves up or push down onto 
the handrails. Times (in seconds) were recorded at ICD and MWD, and converted into 
distances (in metres). 
 
57 
 
2.4 Physical function assessments  
 
2.4.1 Short physical performance battery 
Data were collected from the usual paced 4-metre walk, the chair stand test and semi 
tandem and tandem balance tests to derive scores for the short physical performance battery 
(SPPB) as a global measure of lower limb physical function (McDermott et al. 2007). 
Patients were assigned a score of 0 for each task they were unable to complete and scores 
of 1-4 were assigned for the remaining tasks, based upon quartiles of performance for over 
6000 patients in the Established Populations for the Epidemiologic Study of the Elderly. 
Patients’ scores were then added to obtain an overall score between 0 and 12 (Guralnik et 
al. 1995).  
 
2.4.2 Four metre walk test 
The time taken to walk in a straight line for 4 metres was measured in seconds and walking 
velocity in metres per second was calculated. Patients were asked to walk at their “usual” 
and then their “fastest” paces. Each walk was performed twice and the faster times were 
used for analyses (McDermott et al. 2008b). 
 
2.4.3 Chair stand test 
To assess functional lower limb strength and coordination to correlate with other measures 
of physical function assessment, patients were asked to sit in a straight backed chair 
(approximate seat height 42cm) with their arms folded across their chest and were 
requested to stand up and sit down five times as quickly as possible (Guralnik et al. 1995). 
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The total time taken to complete five chair stands was measured in seconds. This test was 
repeated after 3 minutes and the average score calculated.  
 
2.4.4 Semi tandem and full tandem stance  
To assess standing balance to correlate with dynamic balance test results, patients were 
asked to hold two standing positions each for a maximum of 30 seconds (Figure 2.2). The 
semi tandem position required the feet to be parallel, with the toes of one foot adjacent to 
and touching the heel of the opposite foot. The full tandem stance position requires one foot 
to be completely in front of the other but touching heel to toe
 
(Guralnik et al. 1995). 
Duration of stance was recorded in seconds up to a maximum of 30 seconds.  
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Figure 2.2 Semi tandem (A) and full tandem (B) stance 
The semi tandem position required the feet to be parallel, with the toes of one foot adjacent to and touching 
the heel of the opposite foot. The full tandem stance position requires one foot to be completely in front of the 
other but touching heel to toe
 
(Guralnik et al. 1995). 
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2.4.5 Hand grip strength 
To assess general frailty and as a measurement of upper limb strength to correlate with 
lower limb tests, hand grip strength
 
was assessed (Newman et al. 2001). Using a hand 
dynamometer (Takei Digital Display, Kogyu, Japan) (Figure 2.3), patients were asked to 
grip as tightly as possible, and the maximum grip strength was recorded in kilograms. Each 
hand was used three times and the average grip strength recorded. Hand dominance was 
also recorded. 
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Figure 2.3 Hand grip dynamometer 
(Image taken from www.hab.co.uk). Patients were asked to grip as tightly as possible, and the maximum grip 
strength was recorded in kilograms. 
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2.4.6 Six minute walk test  
Patients were asked to walk at their usual walking pace away and back over a 20 metre 
path. They were instructed to cover as much ground as possible during the 6 minute time 
period. During the test the distance and time at which intermittent claudication was first felt 
was recorded (ICD), which involved the patients alerting the researcher to the onset of their 
pain. The maximum walking distance (at which the patient could not walk any further) and 
time were also recorded (MWD and MWD time) (McDermott et al. 2008b). Distances were 
recorded to the nearest 5 metres.  
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2.5 Assessment of balance 
 
2.5.1 Computerised Dynamic Posturography 
CDP was undertaken using the EquiTest system (NeuroCom International Inc., Clackamas, 
OR, USA). This comprises a standing platform with dual force plates (Figure 2.4), which 
can undergo angular translations to tip the patient forwards (toes down) and backwards 
(toes up), termed “sway-referenced support”. In addition the force plates can undergo linear 
translation to move the patient in an anterior or posterior direction. The patient’s feet were 
centred on the force plates in a standard position facing a brightly coloured visual surround 
capable of movement relative to the patient (termed “sway-referenced surround”) (Figure 
2.4). The patient wore an appropriately sized safety harness throughout testing (Figure 2.4). 
The computer monitor within the visual surround was on during testing. Data were 
collected and analysed using NeuroCom International software (NeuroCom System 
Version 8.1.0., 1996-2006, NeuroCom International Inc.). The CDP comprised of the 
Sensory Organisation Test (SOT) and the Motor Control Test (MCT). If the patient was 
physically unable to continue with testing due to pain or fatigue CDP was terminated 
immediately. 
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Figure 2.4 The NeuroCom EquiTest system 
This comprises a standing platform with dual force plates, a visual surround capable of sway-referenced 
movement against a stable frame, a monitor and a safety harness. 
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Data captured using CDP was compared to the historical healthy controls from the 
NeuroCom database (Clackamas, OR, USA), which were stratified into three age groups: 
20-59 years, 60-69 years and 70-79 years. For any patients over the age of 79 years their 
scores were compared to the 70-79 age group controls due to the absence of older age 
control data. Scores for both SOT and MCT which fell outside of those obtained by 95% of 
controls were described as abnormal i.e. those falling below the 5
th
 percentile. Historical 
controls had no symptoms or history of disequilibrium or motor problems, and specifically 
met the following criteria: 
1. No current or past medical diagnosis or injury affecting balance 
2. No medications affecting the central nervous system or known to affect 
balance/coordination 
3. No symptoms of dizziness or lightheadedness 
4. No symptoms suggestive of vestibular or neurologic disorders 
5. No psychological disorders including depression 
6. No history of two or more unexplained falls within the past 6 months 
7. Normal vision with or without glasses 
 
2.5.1.1 Sensory Organisation Test 
The sensory organisation test (SOT) assesses the patients’ ability to effectively use different 
sensory systems (somatosensory, visual and vestibular) to maintain balance during sensory 
conflict conditions. Sensory conflict situations were created by movement of the visual 
surroundings or standing platform in response to the patients’ sway (calibrated sway 
referencing) either with the patients’ eyes open or closed.  
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Sensory analysis 
To identify functional impairment within each sensory system 6 different conditions were 
tested and compared (Figure 2.5). Before each condition, patients were provided with a 
brief explanation to clarify their expectations and to reduce any anxiety. Each sensory 
condition was repeated 3 times (3 trials), with each trial lasting for 20 seconds, and the 
mean data per condition was used. The measurements recorded were: 
 The somatosensory score (SOM), which measures the patients’ ability to use input 
from the somatosensory system or support surface to maintain balance, was 
calculated as a ratio of condition 2 to condition 1.  
 The visual score (VIS), which identifies the patients’ ability to use visual inputs to 
maintain balance, was calculated as a ratio of condition 4 to condition 1.  
 The vestibular score (VEST), which assesses the patients’ ability to use input from 
the vestibular system to maintain balance, was calculated as a ratio of condition 5 to 
condition 1. 
 The preference score (PREF), which measures the degree to which a patient relies 
on visual information to maintain balance even if the visual information was 
inaccurate or incorrect, was calculated as the ratio of the sum of conditions 3 and 6 
to the sum of conditions 2 and 5.  
 
NeuroCom software indicates the normality or abnormality of each of these sensory 
components, meaning that even with a normal composite score, one or more aspects of 
balance may be abnormal when compared to NeuroCom historic control patients.  
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Figure 2.5 Six conditions used in the Sensory Organisation Test (SOT) using the 
NeuroCom 
The sensory conditions were as follows; 1. Normal sensory input, 2. Absent visual input, 3. Inaccurate visual 
input, 4. Inaccurate somatosensory input, 5. Inaccurate somatosensory input and absent visual input, 6. 
Inaccurate visual and somatosensory inputs. The symbols  indicate which aspect of the 
sensory system (visual, vestibular or somatosensory, respectively) were receiving accurate (uncircled) or 
inaccurate (circled) inputs. If a symbol is not pictured for a condition then there is no input for that system e.g. 
conditions 2 and 5 require the patient to close their eyes thus removing a visual input. Figure used courtesy of 
NeuroCom® International, Inc. 
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Composite equilibrium SOT score 
A healthy patient can exhibit an anterior to posterior sway over a total range of 12.5 
degrees without losing balance (Nashner et al. 1989; NeuroCom 2001). The equilibrium 
score for each trial was calculated by comparing the difference between the patients 
calculated maximum displacement to the theoretical maximum and was expressed as a 
percentage, with 100 being perfect stability and 0 representing a fall. The composite 
equilibrium score provides a measure of overall performance in terms of postural stability 
during the test. It was calculated as a weighted average of the scores of all 6 conditions 
tested. The weighted average was the: average score for condition 1 added to the average 
score for condition 2 added to the scores of each trial of conditions 3-6, and this sum 
divided by 14. The composite equilibrium score was identified as abnormal when results 
were lower than scores of 95% of age matched, healthy control patients. For the composite 
SOT the minimum normal scores for each age group were 70% (20-59 year olds), 68% (60-
69 year olds) and 64% (70-79 year olds) (NeuroCom 2001). 
 
Movement strategies 
Movement strategies were calculated by comparing the patient-generated horizontal shear 
force of the centre of gravity (COG) accelerations to the maximum possible shear of 25 lbs 
or 11.4 kg. Strategy scores were plotted in relation to the equilibrium score obtained for 
each patient. Data falling outside the expected range was described as an abnormal “hip 
strategy” or “ankle strategy”. If a patient used a stepping strategy, i.e. they moved their feet, 
this trial would be categorised as a fall with a score of 0. Scores for each condition 
approaching 100 equate to a 100% reliance on the ankle strategy to maintain balance, 
whereas a score of 0 indicates 0% reliance on ankle strategy and therefore a hip strategy 
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was employed to maintain balance. This indicates a disproportionate reliance on either the 
ankle or the hip and upper body to maintain balance during the test and highlights 
discordance between the movement strategy being used and the degree of instability of the 
patient. Scores in between 0 and 100 represent a mixture of strategies (NeuroCom 2001). 
 
SOT falls 
A fall was recorded on the SOT test when the patient lost balance and needed to touch the 
walls of the visual surround, or take a step to regain balance, or when the test was stopped 
by the operator as the patient required stabilising using the harness. All falls were recorded 
and the condition on which the fall occurred was noted.  
 
2.5.1.2 Motor Control Test 
The motor control test (MCT) requires the patient to stand on the dual force plates where 
the patients’ foot position was standardised and all patients were required to wear a safety 
harness. A brief and basic explanation of the test was given to patients just before the test 
started to ensure correct completion of the task and to minimise any anxiety. The force 
plates (AMTI, Advanced Mechanical Technology Inc, Watertown, MA, USA) measured 
230x460mm and were connected by a pin joint that allowed the right and left plates to 
move separately and record independently the forces exerted by each leg on the support 
surfaces. The force plates were supported by 4 force transducers (strain gauges), mounted 
symmetrically on a supporting centre plate, which measure forces in three-dimensions. A 
fifth transducer bracketed to the centre plate beneath the pin joint allowed measurement of 
shear forces along the Y axis, i.e. parallel to the floor and anterior-posterior to the patient. 
The data were sampled at 100 Hz (NeuroCom 2001). 
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During the MCT test 9 translations occurred in a backward direction and 9 in the forward 
direction. This comprised of 3 small, 3 medium and 3 large force plate translations of the 
patients’ centre of gravity graded as small, medium and large duration scaled to the 
patient’s height (measured in inches) calculated as follows;  
 Small translations: amplitude (inches) = 0.5 * (height÷72), and have a duration of 
250ms 
 Medium translations: amplitude (inches) = 1.25 * (height÷72), duration 300ms 
 Large translations: amplitude (inches) = 2.25 * (height÷72), duration 400ms 
 
The “centre of force” traces for each force plates were used to monitor the instantaneous 
level of muscular effort exerted about the ankle joint for each leg. These measurements 
were used to calculate weight symmetry, onset times (latency) and response strengths of the 
active force automatically generated by the patient (as defined below). Only data for 
medium and large translations were used for analysis.  
 
Weight symmetry 
Weight symmetry was measured by the distribution of total body weight over each leg 
during the force plate translations. Abnormal weight symmetries, towards the left or right 
leg, were recorded during both backward and forward graded translations of the force plate.  
 
Response latency 
Latency was the time in milliseconds between the onset of force plate translation and the 
initiation of the active force response of the leg. The NeuroCom measures the centre of 
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force (COF) trace during each translation and four multiple slope detection algorithms were 
used to determine the point at which the COF position first begins to change rapidly 
following translation. The MCT was repeated if no take-off points could be identified by 
any of the four search algorithms or if each algorithm defined a different take off point.  
 
Response strength 
The measurement of strength of response reflects the ability of the patient to produce a 
level of force appropriate for the degree of force plate linear translation. The response 
strengths were measured separately for each leg during each trial and normalised to body 
height and weight. Patients response strengths were measured and compared to NeuroCom 
historic control patients and documented as increased or reduced in one or both legs.  
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2.6 Assessment of falls 
 
2.6.1 History of falls or stumbles 
A history of falls and stumbles within the year preceding baseline visit 1 and at each 
subsequent visit was documented. A fall was defined as unintentionally coming to the 
ground or to another lower level, not as a result of an overwhelming hazard that would 
result in a fall by most young, healthy people (Tinetti et al. 1988). A stumble was defined 
as a near fall where the patient lost balance but was able to right themselves and prevent a 
true fall. Patients were asked their falls and stumbles history at each clinical assessment.  
 
2.6.2 Fear of Falling 
This was assessed using the 16-item Activities-specific Balance Confidence (ABC-UK) 
scale, demonstrated to be a valid and reliable measure of a fear of falling. Using a visual 
analogue scale patients score 16 scenarios analysing their confidence in performing tasks 
that may result in a fall. Each question was scored from 0 to 100, with 100 being total 
confidence and 0 being no confidence at all. The total score was an average of all 16 
responses. Scenarios questioned increase in difficulty and range from “walking around the 
house” to, the most difficult being, “walking on an icy pavement” (Appendix 3) (Parry et 
al. 2001). 
 
2.6.3 Timed Up and Go test 
The Timed Up and Go test, (TUG) is a simple assessment of falls risk (Podsiadlo and 
Richardson 1995). During the TUG test the patient was observed and timed as they rise 
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from a standard chair (seat height 46cm, and arm height of 65cm), walk 3 meters, turn 
around and walk back to the chair and sit down again. An abnormal result was when time to 
complete the test was greater than age matched norms (Figure 1.1), specifically if they 
exceed: 9.0 seconds for 60-69 year olds, 10.2 seconds for 70-79 year olds and 12.7 for 80-
99 year olds (Bohannon 2006).  
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2.7 Quality of life assessment 
 
All patients were asked to complete three questionnaire assessments of their quality of life 
(QOL). Generic QOL was measured using both the Short Form-36 and Short Form-8, both 
known to be reliable and valid in the PAD population (Gulati et al. 2009). Disease specific 
QOL was measured using the Kings’ Vascuqol questionnaire (Morgan et al. 2001). 
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2.8 Intervention  
 
2.8.1 Angioplasty 
All angioplasties were performed in the interventional radiology suite of Hull Royal 
Infirmary in accordance with all clinical patients. The procedure was performed within a 
month of the baseline visit, and the follow up visits at 3, 6 and 12 months were performed 
at times measured from the angioplasty. Procedures were performed by interventional 
radiologists using local anaesthetic infiltration and femoral artery puncture in the groin. In 
addition to percutaneous transluminal balloon angioplasty, arterial stents were used where 
clinically indicated in lesions thought to be at high risk of primary failure or distal 
embolisation. Patients were admitted to the vascular ward on the morning of the procedure 
and discharged the following morning after overnight observation, vital sign monitoring 
and groin check by the clinical team. 
 
2.8.2 Supervised Exercise Programme  
The supervised exercise programme (SEP) took place on three afternoons per week for a 
period of 12 weeks (total course per patient = 36 sessions) from the baseline to 3-month 
visit. If patients missed a session due to illness or holiday they were allowed to make up the 
sessions at the end of the course. Each session lasted for a minimum of 30 minutes from 
4pm on Mondays, Wednesdays and Fridays. SEP was conducted in groups of up to 12 
patients and attendance was taken at each session. SEP was directed by the principal study 
doctor or other vascular research doctors. The SEP is described in (Figure 2.6), and all 
exercises were performed at a low intensity.  
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Warm up & stretching
Heel raises
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walk
Cool down & 
stretching
A
Warm up, cool down 
& stretching
1 minute of marching on the spot
1 minute of stepping side to side
1 minute of marching on the spot
2 minutes of walking
Stretching – thigh, calf, hamstring, deltoid, hamstring
Heel 
raises
Holding onto wall bars for stability, standing on a step, rising onto ball of 
foot for 5 seconds then releasing and repeating for 2 minutes
Step ups
Standing 
knee bends
Using a 20cm high step, stepping on and off, alternating lead leg after 10 
step ups. Repeated for 2 minutes.
While standing on one leg with support from parrallel hand rails the 
patient flexes and extends the weight bearing knee for 10 repetitions 
before changing legs. Repeated for 2 minutes. 
Patients sit on a high stool with a 2kg weight strapped to the ankle and 
fully extend the knee and flex for 10 repetitions before changing legs. 
Repeated for 2 minutes.
Holding 2kg dumbells patients flex and extend their elbows for 2 minutes.
Sitting knee 
extensions
Biceps curl 
(rest station)
Static 
exercise bike
At self selected resistance at a target revolution per minute of 60-80, 
patient cycles on the bike for 2 minutes.
B
 
Figure 2.6 Structured exercise programme   
A. Outline of each session during weeks 1-6, from week 7 an additional station was repeated each week until 
the patient completes 2 full circuits. B. Description of each station.  
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Each session began with a gentle 5 minute warm up and stretching and finished with 5 
minutes of cool down with further stretching. The sessions comprised a circuit of 6 exercise 
stations each lasting for 2 minutes, which were alternated with 2 minutes of walking. 
Patients could perform the exercises in any order they preferred. After 6 weeks, for each 
additional week of the class completed, the patients repeated one exercise so that by week 
12 they were completing 2 full circuits of the exercise stations.  
 
2.8.3 Follow up 
Assessments comprised repeating all tests and examinations performed at baseline (see 
sections 2.2-2.5) and were conducted at 3, 6 and 12 months after commencing the exercise 
programme or undergoing angioplasty.  
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2.9 Statistical analysis 
 
Data sets were exported into SPSS v19.0 (IBM SPSS version 19) for statistical analysis. An 
alpha value of 0.05 was used to determine statistical significance in the data set. Data were 
checked for normality using a Shapiro-Wilks test, and as the majority were found to be not 
normally distributed non-parametric statistics were used throughout. Correlations were 
performed between clinical indicators of lower limb ischaemia and measures of physical 
function, balance and falls using Spearman rank correlation coefficient (ρ). To compare 
data within each group at different time points Wilcoxon signed ranks test was used for 
continuous data and Chi squared test for categorical data. To compare the angioplasty 
group with the exercise group the Mann Whitney U test was used at each time point.  
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3 Results 
3.1 Correlation between lower limb ischaemia and physical 
function and balance 
 
The first aim of this work was to explore whether worsening lower limb ischaemia is 
associated with impairments of physical function and balance. Table 3.1 shows the 
demographics and clinical indicators of lower limb ischaemia for the study population as a 
whole at baseline (Appendix 4). There were 98 patients with intermittent claudication 
included in the study and this comprised 67 males and 31 females.  
 
Spearman rank correlation coefficient (ρ) was performed to assess whether there were any 
significant correlations. Both pre and post exercise ABPI demonstrated a significant 
correlation with semi tandem stance, but with no other measure of physical function or 
falls. These correlations with semi tandem stance were weak; pre exercise ABPI (ρ = -.206, 
P = 0.043), post exercise ABPI (ρ = -.202, P = 0.049). However treadmill ICD and MWD 
correlated well with almost all continuous measures of physical function and falls (Table 
3.2). The subjective measure of patient reported walking distance only significantly 
correlated with the SPPB (ρ= .306, P = 0.004) and the chair stand test (ρ = - .338, P < 
0.001).  
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Clinical indicators of lower limb ischaemia did not correlate well with measures of balance 
(Table 3.3). The only significant correlation found between pre exercise ABPI and balance 
was with the mean equilibrium score for condition 1 on the SOT (ρ = .240, P = 0.018). 
There were no significant correlations found between post exercise ABPI, treadmill ICD or 
MWD and measures of balance. ABPI both pre and post exercise did not show any 
signifcant correlation with any measure of falls. However significant correlations between 
both ABC-UK score and TUG score were seen with ICD and MWD (Table 3.3).  
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Table 3.1 Patient demographics at baseline for all study patients  
 All Patients 
Number 98 
Age (years) 
- Median (IQR) 
 
69 (64-75) 
Age group (N) 
- 20-59 years 
- 60-69 years 
- 70-79 years 
- 80+ years 
 
12 
40 
34 
12 
Gender (N) M:67 F:31 
Medical history (N)* 
- Ischaemic heart disease (Y/N) 
- Hypertension (Y/N) 
- On statin therapy (Y/N) 
- CVA or TIA (Y/N) 
- Diabetes (Y/N) 
- Smoker (current / ex / never) 
- OA lower limb / other / none 
 
42 / 55  
71 / 26  
79 / 18  
18 / 79  
24 / 73  
27 / 56 / 14  
34  21 / 42 
Height (cm) Median (IQR) 167 61-173) 
Weight (kg) Median (IQR) 78 69-91) 
BMI (kg/m
2
) Median (IQR) 28 (26-31) 
Visual acuity 
- 6/6 or 6/9 
- 6/12 
- worse than 6/12 
 
53 
13 
14 
Pre exercise ABPI - median (IQR) 
- Right leg 
- Left leg 
- Symptomatic leg 
 
0.79 (0.64-0.94) 
0.79 (0.58-0.93) 
0.69 (0.55-0.86) 
Post exercise ABPI - median (IQR) 
- Right leg 
- Left leg 
- Symptomatic leg 
 
0.46 (0.28-0.75) 
0.53 (0.24-0.84) 
0.32 (0.22-0.52) 
Post exercise ankle pressure (mmHg) 52 (38-82) 
Rutherford categories (N) 
- Mild claudication 
- Moderate claudication 
- Severe claudication 
 
5 
52 
38 
Treadmill ICD (m) Median (IQR) 39.5 (24.75-60.38) 
Treadmill MWD (m) Median (IQR)  74.7 (47.43-129) 
PRWD (m) Median (IQR) 135 (90-274) 
 
Values are expressed as median (IQR, interquartile range) or as numbers (N). M (male), F (female), BMI 
(body mass index). * 1 subject did not declare their medical history and therefore there is one set of missing 
data throughout the medical history section. Yes / No. (Y/N). Cerebrovascular accident (CVA), transient 
ischaemic attack (TIA). Osteoarthritis (OA). Visual acuity fractions; 6/6 is normal vision, 6/9 indicated that at 
6 metres the smallest row of letters the tested eye can discern would be what a normal eye can read at 9 
metres, this applies to 6/12 but represents what a normal eye can read at 12 metres. ABPI (ankle brachial 
pressure index, ICD (intermittent claudication distance), MWD (maximum walking distance), PRWD (patient 
reported walking distance). 
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Table 3.2 Physical function correlated with treadmill walking distances at baseline  
 All Patients ICD correlation MWD correlation 
Short performance physical battery - 
median (IQR) 
- 0-6 (N) 
- 7-9 (N) 
- 10-12 (N) 
- missing 
 
10 (9-11) 
6 
34 
55 
3 
 
ρ = .455 P < 0.001 
 
ρ = .544 P < 0.001 
4 metre walk at usual pace (m/s) 
- Median (IQR) 
 
1.01 (0.84-1.15) 
 
ρ = .423 P < 0.001 
 
ρ = .503 P < 0.001 
4 metre walk at fastest pace (m/s) 
- Median (IQR) 
 
1.07 (1.33-1.54) 
 
ρ = .413 P < 0.001 
 
ρ = .517 P < 0.001 
Chair stand test (s) 
- Median (IQR) 
 
14.86 (11.73-
19.07) 
 
ρ = - .406 P < 
0.001 
 
ρ = - .440 P < 
0.001 
Semi tandem stance (s) – median (IQR) 
- < 10 seconds (N) 
- 10-29 seconds (N) 
- 30 seconds (N) 
- missing 
30 (30-30) 
6 
12 
79 
1 
ρ = .263 P = 0.012 ρ = .339 P = 0.001 
Full tandem stance (s) – median (IQR) 
- < 10 seconds (N) 
- 10-29 seconds (N) 
- 30 seconds (N) 
- missing 
30 (12.99-30) 
16 
26 
55 
1 
ρ = .145 P = 0.174 ρ = .282 P = 0.006 
Handgrip strength (kg) – median (IQR) 
- Right hand 
- Left hand 
 
30.9 (19.8-39.6) 
29.9 (19.1-36.8) 
 
ρ = .215 P = 
0.069ρ = .277, P = 
0.018 
 
ρ = .312, P = 0.006 
ρ = .377, P = 0.001 
6 minute walk – median (IQR) 
- ICD distance (m) 
- MWD distance (m) 
- ICD time (s) 
- MWD time (s) 
 
100 (60-160) 
240 (160-400) 
58.5 (92.5-135.5) 
221 (132.5-360) 
 
ρ = .570, P < 0.001 
ρ = .385, P < 0.001 
ρ = .528, P < 0.001 
ρ = .277, P = 0.010 
 
ρ = .543, P < 0.001 
ρ = .513, P < 0.001 
ρ = .472, P < 0.001 
ρ = .389, P < 0.001 
Values are expressed as median (IQR, interquartile range) or as numbers (N). ICD (intermittent claudication 
distance, MWD (maximum walking distance). ρ (Spearman rank correlation coefficient), NS  
(non significant). P values are given and highlighted in bold if significant (P< 0.05). 
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Table 3.3 Balance and falls correlated with treadmill walking distances at baseline 
 All Patients ICD correlation MWD correlation 
SOT composite score 
- Median (IQR) 
 
68 (57.5-76) 
ρ = .069, P = 
0.520 
ρ = .059, P = 0.571 
SOT mean trial score for each condition 
- Median (IQR) 
- Condition 1 
- Condition 2 
- Condition 3 
- Condition 4 
- Condition 5 
- Condition 6 
 
 
94.67 (93.00-
95.66) 
90.33 (86.92-
92.75) 
88.67 (83.25-
92.33) 
81.17 (70.33-
85.67) 
47.33 (22.33-
61.42) 
41.34 (14.34-
60.58) 
 
 
ρ = .073, P = 
0.492 
ρ = .115, P = 
0.279 
ρ = .029, P = 
0.785 
ρ = .208, P = 
0.059 
ρ = .051, P = 
0.635 
ρ = .041, P = 
0.699 
 
 
 ρ = .184, P = 0.76 
ρ = .022, P = 0.832 
ρ = -.060, P = 
0.565 
ρ = .159, P = 0.126 
ρ = .062, P = 0.550 
ρ = .048, P = 0.649 
MCT composite score 
- Median (IQR) 
 
141 (134-150) 
ρ = .128, P = 
0.232 
ρ = .047, P = 0.658 
ABC-UK score 
- Median (IQR) 
 
80.6 (64.6-92.75) 
 
ρ = .419, P < 
0.001 
 
ρ = .335, P = 0.001 
Timed Up and Go test score (s) 
- Median (IQR) 
 
9.16 (7.49-11.18) 
 
ρ = .450, P < 
0.001 
 
ρ = .494, P < 0.001 
Values are expressed as median (IQR, interquartile range). SOT (sensory organisation test), MCT (motor 
control test), ABC-UK (activities-specific balance confidence scale). ICD (intermittent claudication distance, 
MWD (maximum walking distance). ρ (Spearman rank correlation coefficient), NS (non significant). P values 
are given and highlighted in bold if significant (P< 0.05).  
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3.2 The effect of percutaneous transluminal angioplasty on 
outcome measures 
 
The second aim of this work was to investigate the effect of angioplasty treatment on 
clinical indicators of lower limb ischaemia, physical function, balance, falls and quality of 
life in patients with lower limb ischaemia.  
 
3.2.1 Patient demographics 
Table 3.4 shows the basic demographics for the angioplasty group. There were 47 patients 
who underwent angioplasty, with a median age of 69 (IQR 63-76). The majority of patients 
were male (N = 33) with 14 females included.  
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Table 3.4 Patient demographics at baseline for the angioplasty group  
 Angioplasty  
Number 47 
Age (years) 
- Median (IQR) 
 
69 (63-76) 
Age group (N) 
- 20-59 years 
- 60-69 years 
- 70-79 years 
- 80+ years 
 
6 
21 
13 
7 
Gender (N) M:33 
F:14 
Medical history (N) 
- Ischaemic heart disease (Y/N) 
- Hypertension (Y/N) 
- On statin therapy (Y/N) 
- CVA or TIA (Y/N) 
- Diabetes (Y/N) 
- Smoker (current / ex / never) 
- OA lower limb / other / none 
- Previous vascular intervention 
- - same leg angioplasty 
- - other leg angioplasty 
- - same leg surgery 
- - other leg surgery 
- - none 
- - unknown 
 
20 / 27  
32 / 15  
35 / 12  
10 / 37  
9 / 38  
12 / 29 / 6  
20 / 10 / 17 
 
8 
6 
1 
0 
26 
6 
Height (cm) 
- Median (IQR) 
 
169 (159-173) 
Weight (kg) 
- Median (IQR) 
 
80 (69-93) 
BMI (kg/m
2
) 
- Median (IQR) 
 
28 (25-31) 
Visual acuity 
- 6/6 or 6/9 
- 6/12 
- worse than 6/12 
- unknown 
 
33 
4 
4 
6 
 
Values are expressed as median (IQR, interquartile range) or as numbers (N). M (male), F (female), BMI 
(body mass index). Yes / No. (Y/N). Cerebrovascular accident (CVA), transient ischaemic attack (TIA). 
Osteoarthritis (OA). Visual acuity fractions; 6/6 is normal vision, 6/9 indicated that at 6 metres the smallest 
row of letters the tested eye can discern would be what a normal eye can read at 9 metres, this applies to 6/12 
but represents what a normal eye can read at 12 metres.  
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3.2.2 Clinical indicators of lower limb ischaemia 
Clinical indicators of lower limb ischaemia were assessed for patients in the angioplasty 
group at baseline and were compared to values at each of the other time points (3, 6 and 12 
months) (Appendix 5). From baseline there was a significant improvement in both pre and 
post exercise ABPI of the symptomatic leg at 3 months (baseline pre exercise ABPI 0.78 
(0.61-0.92) improved to 0.90 (0.77-0.99) Figure 3.1) and post exercise 0.38 (0.25-0.63) 
improved to 0.63 (0.43-0.82), (Figure 3.2). The improvement from baseline persists post 
exercise (Figure 3.2) but not pre exercise, where the ABPI deteriorated between 3 and 12 
months (Figure 3.1). 
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Figure 3.1 Pre exercise ankle brachial pressure index (ABPI) at baseline, 3, 6 and 12 
months for the angioplasty group 
Boxes represent the interquartile range, thick horizontal lines represent the median and whiskers represent the 
range. Each time point was compared to another using Wilcoxon signed ranks test (P < 0.05). A significant 
improvement between baseline and 3 months is indicated by “a”. A significant deterioration between 3 
months and 12 months is indicated by “e”.  
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Figure 3.2 Post exercise ankle brachial pressure index (ABPI) at baseline, 3, 6 and 12 
months for the angioplasty group 
Boxes represent the interquartile range, the thick horizontal lines represent the median and whiskers represent 
the range with outliers represented by circles. Each time point was compared to another using Wilcoxon 
signed ranks test (P < 0.05). A significant improvement between baseline and 3 months is indicated by “a”. A 
significant improvement persisting between baseline and 12 months is indicated by “c”.  
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Walking distances improved following angioplasty. Figure 3.3 shows a significant 
improvement from baseline to 3 months in ICD distance on the treadmill. There was a 
further significant improvement from 3 to 6 months and from baseline to 6 months. At 12 
months there was no longer a significant difference to baseline but there remained a 
significant improvement when compared to 3 months. At baseline there is very little range 
in the ICD achieved by the study cohort, however after treatment, and particularly at 12 
months, there is a much greater range in walking distances achieved.  
 
Maximum walking distances on the treadmill also improved following angioplasty. Figure 
3.4 shows that there was a significant improvement between baseline and each of the 
individual time points following angioplasty (3, 6 and 12 months). Patient reported walking 
distances also improved from baseline to each of the individual time points (P < 0.05) 
(Appendix 5). 
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Figure 3.3 Treadmill intermittent claudication distance (ICD) at baseline, 3, 6 and 12 
months for the angioplasty group 
Boxes represent the interquartile range and the thick horizontal lines represent the median, whiskers represent 
the range with outliers represented by circles and extreme outliers as stars. Each time point was compared to 
another using Wilcoxon signed ranks test (P < 0.05). A significant improvement between baseline and 3 
months is indicated by “a” and between baseline and 6 months is indicated by “b”. Further significant 
improvements between 3 months and 6 months and 3 months and 12 months are indicated by “d” and “e” 
respectively.  
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Figure 3.4 Treadmill maximum walking distance (MWD) at baseline, 3, 6 and 12 
months for the angioplasty group 
Boxes represent the interquartile range and the thick horizontal lines represent the median, whiskers represent 
the range. Each time point was compared to another using Wilcoxon signed ranks test (P < 0.05). A 
significant improvement between baseline and 3 months is indicated by “a”. A significant improvement 
persisting between baseline and 6 months is indicated by “b” and a significant difference between baseline 
and 12 months is represented by “c”.  
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3.2.3 Effect of angioplasty on markers of physical function 
The short performance physical battery scores (SPPB) were derived from the usual paced 
4-metre walk, the chair stand test and the semi and full tandem balance tests. The scores 
can range between 0 and 12, with 12 being the best score possible. There was a significant 
improvement between baseline and 3 months scores for the angioplasty group, with a 
median of 9 (IQR 8-11) compared to a median of 10 (IQR 9-12) at 3 months (P = 0.011). 
The significant improvement was maintained at 6 (median of 10.5 (IQR 8-11)) and 12 
months (median of 10 (IQR 9-11)) (P = 0.001 and P = 0.002 respectively) (Appendix 6). 
 
Following angioplasty there were significant improvements in the 4 metre walk speed at 
usual pace from baseline to 6 and 12 months and at fastest pace, from baseline to 3, 6 and 
12 months in turn (P < 0.05) (Table 3.5). The chair stand test results improved significantly 
between baseline and 3 months and baseline and 6 months. The improvement was not 
maintained and a significant deterioration was noted between baseline and 12 months 
(Table 3.6) (Appendix 6).  
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Table 3.5 Four metre walk speeds at usual and fastest pace for angioplasty patients 
 Baseline 3 months 6 months 12 months 
Usual pace (m/s) 
Median (IQR) 
1.00 (0.74-1.15) 1.05 (0.83-1.19) 1.02 (0.83-1.15)* 1.03 (0.81-1.19)* 
Fastest pace (m/s) 
Median (IQR) 
1.31 (0.93-1.53) 1.36 (1.03-1.56)* 1.33 (0.96-1.48)* 1.27 (1.00-1.60)* 
 
Values are expressed as median (IQR, interquartile range). Time points post angioplasty were compared using 
the Wilcoxon signed ranks test and a P value of < 0.05 is indicated by * when compared to baseline.  
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Table 3.6 Chair stand test for angioplasty patients 
 Baseline 3 months 6 months 12 months 
Chair stand test (s) 
median (IQR) 
17.02 
(12.31-20.55) 
13.53 
(9.82-16.2)* 
13.5 
(11.16-16.54)* 
13.27 
(11.91-22.08)** 
 
Values are expressed as median (IQR, interquartile range). Time points post angioplasty were compared using 
the Wilcoxon signed ranks test and a P value of < 0.05 is indicated by * when compared to baseline. A 
significant change is noted between 6 and 12 months by**.  
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There was no significant difference in semi tandem and full tandem stance between 
baseline and 3 and 6 months (score 0-30 seconds; worst to best). However between baseline 
and 12 months there was a significant improvement in both semi tandem stance (median 30 
seconds (IQR 19.4-30) improving to 30 (30-30)) and full tandem stance times (median 29 
seconds (IQR 8.9-30) improving to 30 (11.1-30)), (P < 0.05) (Appendix 6). 
 
Hand grip strength did not alter significantly across the study period in the angioplasty 
group except for 2 time points. There was a significant improvement in right hand grip 
between baseline and 6 month but deterioration was noted between baseline and 12 months 
for the left hand grip strength (Appendix 6). 
 
The angioplasty group showed significant improvements in walking distances determined 
using the six minute walk test following treatment (Figures 3.5 and 3.6). In terms of time 
until onset of claudication (ICD time), there were only significant improvements between 
baseline and 3 months and baseline and 6 months (Appendix 6). The maximum time 
patients were able to walk (MWD time) also improved significantly between baseline and 3 
months and baseline and 6 months. There was a further significant improvement in 
maximum walking time between 3 and 6 months.  
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Figure 3.5 Six minute walk test intermittent claudication walking distance (ICD) at 
baseline, 3, 6 and 12 months for the angioplasty group 
Boxes represent the interquartile range and the thick horizontal lines represent the median, whiskers represent 
the range with outliers represented by circles and extreme outliers as stars. Each time point was compared to 
another using Wilcoxon signed ranks test (P < 0.05). Significant improvements between baseline and 3 
months, 6 months and 12 months are indicated by “a”, “b” and “c” respectively. A further significant 
improvement between 3 and 6 months is indicated by “d”.  
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Figure 3.6 Six minute walk test maximum walking distance (MWD) at baseline, 3, 6 
and 12 months for the angioplasty group 
Boxes represent the interquartile range and the thick horizontal lines represent the median, whiskers represent 
the range with outliers represented by circles and extreme outliers as stars. Each time point was compared to 
another using Wilcoxon signed ranks test (P < 0.05). A significant improvement between baseline and 3 
months is indicated by “a”.A significant improvement persisting between baseline and 6 months is indicated 
by “b”. A further significant improvement between 3 and 6 months is indicated by “d”.  
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3.2.4 Effect of angioplasty on measures of balance 
After angioplasty there was no significant improvement in the proportion of patients who 
passed the Sensory Organisation Test (SOT) (Appendix 7). The median SOT composite 
scores improved significantly between baseline and 3 months as shown in Figure 3.7. There 
was no other significant change between groups. There was a significant correlation 
between composite SOT scores and age at 3 months (ρ = -0.369, P = 0.017). This was not 
maintained at 6 or 12 months ( 6 months ρ = -0.238, P > 0.05, 12 months ρ = -0.326, P > 
0.05).  
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Figure 3.7 Composite sensory organisation test (SOT) scores at baseline, 3, 6 and 12 
months for the angioplasty group 
Boxes represent the interquartile range and the thick horizontal lines represent the median, whiskers represent 
the range with outliers represented by circles and extreme outliers as stars. Each time point was compared to 
another using Wilcoxon signed ranks test (P < 0.05). A significant improvement between baseline and 3 
months is indicated by “a”. 
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When scores for the individual conditions were assessed there was no significant change 
between any time points except during condition 4 of the SOT (where the somatosensory 
input was altered as the standing platform moved). There were significant improvements 
from baseline at 3, 6 and 12 months during condition 4 (Figure 3.8). 
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Figure 3.8 Sensory organisation test (SOT) score for condition 4 at baseline, 3, 6 and 
12 months for the angioplasty group 
Boxes represent the interquartile range and the thick horizontal lines represent the median, whiskers represent 
the range with outliers represented by circles and extreme outliers as stars. Each time point was compared to 
another using Wilcoxon signed ranks test (P < 0.05). A significant improvement between baseline and 3 
months is indicated by “a”.A significant improvement persisting between baseline and 6 months is indicated 
by “b” and between baseline and 12 months is indicated by “c”. 
102 
 
There was no difference between time points in terms of the sensory breakdown analysis. 
Hip strategy was employed differently between baseline and 12 months (Appendix 7). The 
motor control test latency outcome did not improve across the study period for the 
angioplasty group. MCT composite scores improved significantly between 3 and 12 months 
and 6 and 12 months (Appendix 7). 
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3.2.5 Effect of angioplasty on falls incidence and risk of falling 
At baseline 12 of the 47 patients reported a history of falls and 12 reported a history of 
stumbles. There was a significant reduction in the number of patients reporting falls and 
stumbles at 3 months (3 and 7 patients respectively) but no other significant differences 
were found between any other time points (Appendix 8). There was a significant 
improvement in Activities-specific Balance Confidence (ABC-UK) score between baseline 
and 3 months but there were no other significant changes across the time period as shown 
in Figure 3.9. 
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Figure 3.9 Activities-specific balance confidence scale (ABC-UK) score at baseline, 3, 
6 and 12 months for the angioplasty group 
Boxes represent the interquartile range and the thick horizontal lines represent the median, whiskers represent 
the range with outliers represented by circles and extreme outliers as stars. Each time point was compared to 
another using Wilcoxon signed ranks test (P < 0.05). A significant improvement between baseline and 3 
months is indicated by “a”. 
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TUG test scores improved after treatment and continued to improve at each visit when 
compared to baseline. There was also a significant improvement between 3 and 6 months in 
TUG scores, Figure 3.10. The proportion of patients who passed the TUG scores when age 
adjusted, also significantly improved at 3 and 12 months compared to baseline (Appendix 
8). 
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Figure 3.10 Timed up and go test (TUG) score at baseline, 3, 6 and 12 months for the 
angioplasty group 
Boxes represent the interquartile range and the thick horizontal lines represent the median, whiskers represent 
the range with outliers represented by circles and extreme outliers as stars. Each time point was compared to 
another using Wilcoxon signed ranks test (P < 0.05). A significant improvement between baseline and 3 
months is indicated by “a” , baseline and 6 months by “b” and baseline and 12 months by “c”. A further 
significant improvement between 3 and 6 months is indicated by “d”.  
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3.2.6 Effect of angioplasty on patient reported quality of life 
Table 3.7 indicates the improvements recorded in QOL after angioplasty. The disease 
specific VascuQol quality of life measure showed improvement in every domain at 3, 6 and 
12 months when compared to baseline. Short form 36 indicated significant changes from 
baseline 14 times whereas short form 8 showed 11 significant changes from baseline as 
indicated by the shaded results in Table 3.7. The VascuQol showed improvements in the 
social domain which was not seen with SF36. Despite improvements in physical function, 
no improvement in general health was seen with SF36 or SF8.  
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Table 3.7 Quality of life data for the angioplasty group 
 Baseline 3 months 6 months 12 months P 
 
SF36 
- Physical function 
- Role physical 
- Bodily pain 
- General health 
- Vitality 
- Role emotional 
- Mental health 
- Social function 
- Physical summary 
 
- Mental summary 
 
35 (28.75-50) 
0 (0-50) 
36.5 (31-51) 
47 (35-69.5) 
50 (30-65) 
50 (33.3-87.5) 
67.35 (48-100) 
73.5 (50-87.63) 
30.1 (25.2-33.9) 
 
51.2 (40.3-60.9) 
 
55.5 (37.5-80) 
50 (0-100) 
62 (41-77) 
57 (38.5-72) 
60 (42.5-75) 
100 (16.65-100) 
76 (62-88) 
75 (50-100) 
41.8 (27.75-
48.95) 
52.7 (42.85-
60.7) 
 
52.5 (35-71.25) 
25 (0-100) 
41 (31-88) 
45 (35-67) 
55 (38.75-70) 
79.35 (0-100) 
80 (52-92) 
75 (50-100) 
31.8 (27.4-
48.55) 
51.2 (39.85-
59.7) 
 
52.5 (33.75-80) 
0 (0-100) 
46 (23.5-62) 
46 (28.75-72) 
50 (40-75) 
66.7 (0-100) 
76 (56-84) 
62.5 (50-90.63) 
32.3 (24.05-
48.6) 
51.4 (41.05-
57.7) 
 
a,b<0.001, c0.001 
a<0.001, b0.046, c0.056 
a<0.001,b0.019, c0.290 
a0.202, b0.459, c0.922 
a0.008,b0.011,c0.013 
a0.024, b0.431, c0.352 
a0.270, b0.338, c0.352 
a0.208, b0.331, c0.383 
a<0.001,b0.001, c0.010 
 
 a0.287, b0.313, c0.456 
 
VascuQol 
- Pain 
- Social 
- Activities 
- Symptoms 
- Emotional 
- Total 
 
4.0 (2.75-4.63) 
4.0 (3.5-5.5) 
3.63 (3.19-4.32) 
4.75 (4-5.75) 
4.57 (3.57-5.5) 
4.32 (3.22-5.02) 
 
5.63 (3.94-6.56) 
6.5 (4.38-7) 
5.44 (3.72-6.88) 
6 (5.25-6.75) 
6.36 (4.43-7) 
5.9 (4.19-6.66) 
 
5.25 (3.75-6.25) 
6.5 (4-7) 
5.25 (3.38-6.13) 
5.75 (4.5-6.5) 
6.14 (4.29-6.86) 
5.68 (3.96-6.36) 
 
5 (3.75-6) 
6 (4.5-6.5) 
4.25 (3.38-6.13) 
5.75 (4.75-6.25) 
6 (4.43-6.86) 
5.2 (4.08-6.32) 
 
a,b,c<0.001 
a<0.001, b0.008, c0.003 
a,b<0.001, c0.002 
a,b,c<0.001 
a,b,c<0.001 
a,b,c<0.001 
SF8 
- Physical function 
- Role physical 
- Bodily pain 
- General health 
 
- Vitality 
- Role emotional 
 
- Mental health 
 
- Social function 
- Physical summary 
 
- Mental summary 
 
30.3 (30.3-40.1) 
38.7 (28.3-46.9) 
40.1 (31.5-40.1) 
38.4 (38.4-46.4) 
 
45.2 (45.2-55.6) 
45.7 (32.85-
52.4) 
49.6 (36.55-
56.80) 
40.4 (29.5-49.5) 
34.65 (29.18-
40.38) 
46.3 (38.58-
57.38) 
 
40.1 (30.3-48.3) 
3.87 (28.3-46.9) 
40.1 (40.1-53.4) 
38.4 (38.4-46.4) 
 
45.2 (35.8-55.6) 
48.3 (38.1-52.4) 
 
49.6 (46.9-56.8) 
 
49.5 (29.5-55.3) 
40.7 (33.7-
49.33) 
52.85 (44.18-
56.98) 
 
40.1 (30.3-48.3) 
38.7 (38.7-54) 
40.1 (40.1-53.4) 
38.4 (38.4-46.4) 
 
45.2 (35.8-45.2) 
52.4 (38.1-52.4) 
 
49.6 (41.5-56.8) 
 
40.4 (40.4-55.3) 
36.5 (32.4-50.1) 
 
52.4 (40.8-57.5) 
 
40.1 (30.3-48.3) 
38.7 (28.3-46.9) 
40.1 (31.5-47.7) 
38.4 (34.05-
46.4) 
45.2 (45.2-55.6) 
45.7 (38.1-52.4) 
 
49.6 (41.5-56.8 
) 
40.4 (40.4-55.3) 
38.6 (26.9-48.9) 
 
49.7 (40.5-54.7) 
 
a0.425, b0.006, c0.037 
a0.781, b0.006, c0.161 
a0.306,b0.017, c0.860 
a0.838, b0.075, c0.639 
 
a0.375, b0.857, c0.253 
a0.046, b0.032, c0.145 
 
a0.037, b0.093, c0.138 
 
a0.525, b0.035, c0.007 
a0.005, b0.001, c0.135 
 
a0.082, b0.548, c0.282 
 
Values are expressed as median (IQR, interquartile range). Each time point was compared to baseline using 
Wilcoxon signed ranks test. P values are shown and highlighted in bold if <0.05. 
a
Wilcoxon 0-3, 
b
Wilcoxon 
0-6,
c
Wilcoxon 0-12. SF36 (Short Form 36), SF8 (Short Form 8). Significant improvements from baseline 
indicated by highlighted text. 
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3.3 The effect of a supervised exercise programme on outcome 
measures 
 
The third aim of this work included investigating the effect of a supervised exercise 
programme (SEP) on clinical indicators of lower limb ischaemia, physical function, 
balance, falls and quality of life in patients with lower limb ischaemia.  
 
3.3.1 Patient demographics 
Table 3.8 shows the basic demographics for the angioplasty group. There were 51 patients 
who participated in SEP, with a median age of 70 (IQR 64-74). The majority of patients 
were male (N = 34) with 17 females included.  
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Table 3.8 Patient demographics at baseline for the SEP group 
 SEP 
Number 51 
Age (years) 
- Median (IQR) 
 
70 (64-74) 
Age group (N) 
- 20-59 years 
- 60-69 years 
- 70-79 years 
- 80+ years 
 
6 
19 
21 
5 
Gender (N) 
- M 
- F 
 
34 
17 
Medical history (N) 
- Ischaemic heart disease (Y/N) 
- Hypertension (Y/N) 
- On statin therapy (Y/N) 
- CVA or TIA (Y/N) 
- Diabetes (Y/N) 
- Smoker (current / ex / never) 
- OA lower limb / other / none 
- Previous vascular intervention 
- - same leg angioplasty 
- - other leg angioplasty 
- - same leg surgery 
- - other leg surgery 
- - none 
- - unknown 
 
22 / 28  
38 / 11 
44 / 6  
8 / 42  
15 / 35  
15 / 27 / 8  
14 / 11 / 25 
 
10 
2 
2 
2 
30 
5 
Height (cm) 
- Median (IQR) 
 
167 (162-173) 
Weight (kg) 
- Median (IQR) 
 
77 (68-86) 
BMI (kg/m
2
) 
- Median (IQR) 
 
27.7 (25.63-30.4) 
Visual acuity 
- 6/6 or 6/9 
- 6/12 
- worse than 6/12 
- unknown 
 
20 
9 
10 
12 
Values are expressed as median (IQR, interquartile range) or as numbers (N). SEP (structured exercise 
programme), M (male), F (female), BMI (body mass index). Yes / No. (Y/N). Cerebrovascular accident 
(CVA), transient ischaemic attack (TIA). Osteoarthritis (OA). Visual acuity fractions; 6/6 is normal vision, 
6/9 indicated that at 6 metres the smallest row of letters the tested eye can discern would be what a normal eye 
can read at 9 metres, this applies to 6/12 but represents what a normal eye can read at 12 metres.  
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3.3.2 Clinical indicators of lower limb ischaemia 
Ankle Brachial Pressure Index (ABPI) did not significantly alter across the study period in 
the SEP group as shown in Figures 3.11 and 3.12.  
 
Walking distances did improve following exercise. The treadmill ICD distance improved 
significantly between baseline and 3 months and baseline and 6 months (Figure 3.13). The 
maximum walking distance on the treadmill (MWD) improved significantly between 
baseline and 3 months (Figure 3.14). Patient reported walking distances also improved 
from baseline to each of the individual time points (3, 6 and 12 months) (P < 0.05) 
(Appendix 9). 
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Figure 3.11 Pre exercise ankle brachial pressure index (ABPI) at baseline, 3, 6 and 12 
months for the SEP group 
Boxes represent the interquartile range and the thick horizontal lines represent the median, whiskers represent 
the range with outliers represented by circles. Each time point was compared to another using Wilcoxon 
signed ranks test (P < 0.05). There were no significant differences between any of the time points. SEP 
(structured exercise programme).  
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Figure 3.12 Post exercise ankle brachial pressure index (ABPI) at baseline, 3, 6 and 12 
months for the SEP group 
Boxes represent the interquartile range and the thick horizontal lines represent the median, whiskers represent 
the range with outliers represented by circles. Each time point was compared to another using Wilcoxon 
signed ranks test (P < 0.05). There were no significant differences between any of the time points. SEP 
(structured exercise programme).  
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Figure 3.13 Treadmill intermittent claudication distance (ICD) at baseline, 3, 6 and 12 
months for the SEP group 
Boxes represent the interquartile range and the thick horizontal lines represent the median, whiskers represent 
the range with outliers represented by circles and extreme outliers as stars. Each time point was compared to 
another using Wilcoxon signed ranks test (P < 0.05). A significant improvement between baseline and 3 
months is indicated by “a” and between baseline and 6 months by “b”. SEP (structured exercise programme).  
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Figure 3.14 Treadmill maximum walking distance (MWD) at baseline, 3, 6 and 12 
months for the SEP group 
Boxes represent the interquartile range and the thick horizontal lines represent the median, whiskers represent 
the range with outliers represented by circles and extreme outliers as stars. Each time point was compared to 
another using Wilcoxon signed ranks test (P < 0.05). A significant improvement between baseline and 3 
months is indicated by “a”. SEP (structured exercise programme).  
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3.3.3 Effect of a SEP on markers of physical function  
The short performance physical battery scores (SPPB) were derived from the usual paced 
4-metre walk, the chair stand test and the semi and full tandem balance tests (score 0-12; 
worst to best). For the SEP group, a significant improvement was noted between baseline 
and 3 months, with a median of 10 (IQR 9-11.25) at baseline compared to a median of 11 
(IQR 10-12) at 3 months (P = 0.005). This improvement was not maintained at later time 
points (Appendix 10).  
 
Patients performed much better on the 4 metre walk test at both usual and fastest pace after 
SEP treatment. Significant improvements were seen at 3 and 6 months, compared to 
baseline, for both paces and at 12 months a further improvement was noted from baseline 
for the usual paced 4 metre walk (Table 3.9). There was no significant change in chair stand 
test results at any time point after SEP treatment, despite faster 4 metre walk test results 
(Appendix 10).  
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Table 3.9 Four metre walk speeds at usual and fastest pace for the SEP group 
 Baseline 3 months 6 months 12 months 
Usual pace (m/s) 
Median (IQR) 
1.03 (0.92-1.16) 1.11 (1.04-1.27)* 1.15 (1.00-1.31)* 1.16 (0.98-1.37)* 
Fastest pace (m/s) 
Median (IQR) 
1.39 (1.14-1.60) 1.43 (1.26-1.64)* 1.45 (1.20-1.75)* 1.52 (1.12-1.81) 
 
Values are expressed as median (IQR, interquartile range). Time points were compared using the Wilcoxon 
signed ranks test and a significant P value of <0.05 is indicated by * when compared to baseline. SEP 
(structured exercise programme).  
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Semi tandem and full tandem stance times were not significantly different from baseline at 
any of the time points. However, full tandem stance times significantly deteriorated 
between 3 and 12 months and 6 and 12 months (Appendix 10).  
 
Hand grip strength deteriorated significantly between baseline and 3 months for SEP 
patients in both hands. This deterioration was maintained at 6 months in the left hand only 
but at 12 months there was no difference in hand grip strength when compared to baseline 
(Appendix 10).  
 
The SEP group showed significant improvements in walking distances during the six 
minute walk test following treatment at 3 and 6 months (Figures 3.15 and 3.16). Maximum 
walking distance deteriorated between 3 and 12 months (Figure 3.16). In terms of time until 
the onset of claudication (ICD time) there was only a significant improvement between 
baseline and 3 months. The maximum time patients were able to walk (MWD) did not 
change during the study period (Appendix 10). 
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Figure 3.15 Six minute walk intermittent claudication distance (ICD) at baseline, 3, 6 
and 12 months for the SEP group 
Boxes represent the interquartile range and the thick horizontal lines represent the median, whiskers represent 
the range with outliers represented by circles and extreme outliers as stars. Each time point was compared to 
another using Wilcoxon signed ranks test (P < 0.05). A significant improvement between baseline and 3 
months is indicated by “a” and between baseline and 6 months is indicated by “b”. ICD (intermittent 
claudication distance); SEP (structured exercise programme). 
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Figure 3.16 Six minute walk maximum walking distance (MWD) at baseline, 3, 6 and 
12 months for the SEP group 
Boxes represent the interquartile range and the thick horizontal lines represent the median, whiskers represent 
the range with outliers represented by circles and extreme outliers as stars. Each time point was compared to 
another using Wilcoxon signed ranks test (P < 0.05). A significant improvement between baseline and 3 
months is indicated by “a” and between baseline and 6 months is indicated by “b”. A significant deterioration 
is indicated by “e” between 3 months and 12 months. SEP (structured exercise programme).  
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3.3.4 Effect of SEP on measures of balance 
Following SEP there was a significant improvement in the proportion of patients who 
passed the Sensory Organisation Test (SOT) at all 3 time points when compared to baseline 
(P < 0.05) (Appendix 11). The median SOT composite score improved significantly 
between baseline and all 3 time points as shown in Figure 3.17. There was no significant 
correlation between composite SOT scores and age at any time point (3 months ρ = -0.177, 
P > 0.05, 6 months ρ = -0.332, P > 0.05, 12 months ρ = -0.316, P > 0.05). 
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Figure 3.17 Composite sensory organisation test (SOT) scores at baseline, 3, 6 and 12 
months for the SEP group 
Boxes represent the interquartile range and the thick horizontal lines represent the median, whiskers represent 
the range with outliers represented by circles and extreme outliers as stars. Each time point was compared to 
another using Wilcoxon signed ranks test (P < 0.05). Significant improvements between baseline and 3 
months are indicated by “a” and between baseline and 6 months by “b” and between baseline and 12 months 
by “c”. SOT (sensory organisation test); SEP (structured exercise programme).  
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When individual conditions were analysed there was no improvement seen between 
baseline and 3, 6 or 12 months in conditions 1, 2 and 3. However a significant improvement 
was seen in condition 4 between baseline and 3 and baseline and 6 months (Figure 3.18). 
For conditions 5 and 6 significant improvements were seen between baseline and all 3 time 
points (Figures 3.19 and 3.20). In addition significant improvements were seen between 3 
and 12 months for condition 5, and 6 and 12 months for condition 6 (Appendix 11). 
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Figure 3.18 Sensory organisation test (SOT) score for condition 4 at baseline, 3, 6 and 
12 months for the SEP group 
Boxes represent the interquartile range and the thick horizontal lines represent the median, whiskers represent 
the range with outliers represented by circles and extreme outliers as stars. Each time point was compared to 
another using Wilcoxon signed ranks test (P < 0.05). Significant improvements between baseline and 3 
months are indicated by “a” and between baseline and 6 months indicated by “b”. SEP (structured exercise 
programme).  
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Figure 3.19 Sensory organisation test (SOT) score for condition 5 at baseline, 3, 6 and 
12 months for the SEP group 
Boxes represent the interquartile range and the thick horizontal lines represent the median, whiskers represent 
the range with outliers represented by circles and extreme outliers as stars. Each time point was compared to 
another using Wilcoxon signed ranks test (P < 0.05). Significant improvements between baseline and 3 
months are indicated by “a” and between baseline and 6 months is indicated by “b” and baseline and 12 
months by “c”. There was also a significant improvement between 3 and 12 months indicated by “e”. SEP 
(structured exercise programme).  
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Figure 3.20 Sensory organisation test (SOT) score for condition 6 at baseline, 3, 6 and 
12 months for the SEP group 
Boxes represent the interquartile range and the thick horizontal lines represent the median, whiskers represent 
the range with outliers represented by circles and extreme outliers as stars. Each time point was compared to 
another using Wilcoxon signed ranks test (P < 0.05). Significant improvements between baseline and 3 
months are indicated by “a” and between baseline and 6 months is indicated by “b” and baseline and 12 
months by “c”. There was also a significant improvement between 6 and 12 months indicated by “f”. SEP 
(structured exercise programme).  
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The SOT analysis was further divided into sensory components. Over the study period 
there was no difference in the proportion of patients passing the somatosensory, visual or 
preferential analysis. However there were significant improvements in the proportion of 
patients passing the vestibular analysis between baseline and all 3 time points (P < 0.05, 
Appendix 11). There was no difference in falls during the SOT or in any aspect of the MCT 
throughout the study period in the SEP group.  
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3.3.5 Effect of SEP on falls incidence and risk of falling 
At baseline 8 patients reported a history of falls and 18 reported a history of stumbles (total 
n = 51). There was no significant difference in the number of patients reporting a history of 
falls over the study period from the SEP group, although there was a significant decrease in 
the number reporting stumbles between baseline (n=18) and 3 months (n=7) (P < 0.05) 
(Appendix 12).  
 
There was no significant difference in ABC-UK score across the study period. The TUG 
test was performed significantly faster at 3, 6 and 12 months when compared to baseline 
(Figure 3.21) although there was no significant difference in the proportion of patients 
passing the TUG based on their age adjusted scores (Appendix 12).  
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Figure 3.21 Timed up and go test (TUG) score at baseline, 3, 6 and 12 months for the 
SEP group 
Boxes represent the interquartile range and the thick horizontal lines represent the median, whiskers represent 
the range with outliers represented by circles and extreme outliers as stars. Each time point was compared to 
another using Wilcoxon signed ranks test (P < 0.05). A significant improvement between baseline and 3 
months is indicated by “a” , baseline and 6 months by “b” and baseline and 12 months by “c”. One extreme 
outlier was excluded from the figure (TUG score >20 at baseline and >60 at 3 months) but not from the 
analysis. SEP (structured exercise programme).  
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3.3.6 Effect of SEP on patient reported quality of life 
Table 3.10 indicates the improvements recorded in quality of life after SEP. Improvements 
in physical domains were noted at 3 and 6 months but no significant improvements were 
seen at 12 months when compared to baseline. No emotional or social domain scores 
improved in either SF8 or SF36, however significant improvements in the emotional 
domain scores of VascuQol were seen at 3 and 6 months, and an improvement in social 
domain scores was seen at 6 months (Table 3.10). Short form 36 indicated significant 
changes from baseline 8 times whereas short form 8 showed 5 significant changes from 
baseline as indicated by the shaded results in Table 3.10. 
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Table 3.10 Quality of life data for the SEP group 
 Baseline 3 months 6 months 12 months P 
 
SF36 
- Physical function 
- Role physical 
- Bodily pain 
- General health 
- Vitality 
- Role emotional 
- Mental health 
- Social function 
- Physical summary 
 
- Mental summary 
 
45 (33.75-55) 
0 (0-56.25) 
42 (41-64) 
55 (41-68.5) 
55 (40-65) 
75 (50-100) 
100 (33.3-100) 
78 (71-92) 
31.9 (25.55-37.3) 
 
56.7 (46.45-62.1) 
 
49.94 (35-60) 
25 (0-100) 
56.5 (38.75-74) 
53.5 (39.25-67) 
60 (45-65) 
100 (33-100) 
76 (63-92) 
87.5 (59.38-100) 
35.3 (27.2-42.35) 
 
56.8 (48.75-60.6) 
 
52.5 (25-60) 
12.5 (0-100) 
56.5 (38.5-76.5) 
51 (38.75-67) 
60 (40-71.25) 
66.7 (24.75-100) 
84 (67-92) 
87.5 (62.5-100) 
35.7 (25.28-41) 
 
57.3 (41.3-60.33) 
 
45 (22.5-62.5) 
0 (0-87.5) 
42 (31-67) 
47 (43.5-69.5) 
55 (40-57.5) 
66.7 (16.65-100) 
76 (62-84) 
75 (62.5-100) 
30.4 (24.55-
40.05) 
54 (44.65-57.55) 
 
a0.029, b0.038, c0.985 
a0.009, b0.039, c0.072 
a0.015, b0.016, c0.077 
a0.893. b0.992, c0.722 
a a0.186. b0.135, c0.570 
a0.301. b0.294, 
c0.456a0.926. b0.575, 
c0.881a0.015, b0.020, 
c0.177a0.904. b0.694, 
c0.955 
VascuQol 
- Pain 
- Social 
- Activities 
- Symptoms 
- Emotional 
- Total 
 
4.25 (3.5-5.25) 
5.5 (4-6.5) 
4.13 (3.47-5) 
5.5 (4.94-6.06) 
5.14 (4.68-5.86) 
4.84 (4.13-5.35) 
 
5 (3.56-5.5) 
5.88 (4.63-6.5) 
4.63 (4.25-5.72) 
5.63 (5-6.25) 
5.71 (4.75-6.29) 
5.22 (4.64-5.88) 
 
5.0 (3.63-5.88) 
6.0 (4.5-7) 
4.63 (3.88-5.44) 
6.0 (5.13-6.38) 
5.71 (4.78-6.57) 
5.4 (4.38-5.9) 
 
4.75 (4-5.5) 
6.0 (3.5-7) 
4.13 (3.32-5.5) 
5.75 (5-6.25) 
5.71 (4.43-6.57) 
5.08 (3.98-5.94) 
 
a0.010, b0.018, c0.079 
a0.088, b0.026, c0.358 
a0.001, b0.002, c0.212 
a0.760, b0.347, c0.207 
a0.009, b0.028, c0.230 
a0.005, b0.011, c0.159 
SF8 
- Physical function 
- Role physical 
- Bodily pain 
- General health 
- Vitality 
- Role emotional 
- Mental health 
- Social function 
- Physical summary 
 
- Mental summary 
 
40.1 (30.3-42.15) 
38.7 (38.7-46.9) 
40.1 (40.1-47.7) 
46.4 (38.4-46.4) 
45.2 (45.2-55.6) 
52.4 (38.1-52.4) 
49.6 (41.5-56.8) 
49.5 (40.4-55.3) 
39.25 (30.7-44.2) 
 
53.4 (42.48-59) 
 
40.1 (40.1-48.3) 
42.8 (38.7-46.9) 
43.9 (40.1-53.4) 
46.4 (38.4-46.4) 
45.2 (45.2-55.6) 
49.05 (45.7-52.4) 
49.6 (41.5-56.80) 
49.5 (40.4-55.3) 
41.35 (35.4-47.5) 
 
54.1 (44.98-
58.83) 
 
40.1 (30.3-48.3) 
42.8 (38.7-48.68) 
40.1 (40.1-53.4) 
42.4 (38.4-46.4) 
45.2 (45.2-55.6) 
45.7 (38.1-52.4) 
49.6 (49.6-56.8) 
49.5 (40.4-55.3) 
40.65 (34.2-
46.38) 
52.2 (46.13-
57.48) 
 
40.1 (30.3-48.3) 
38.7 (33.5-46.9) 
40.1 (40.1-50.55) 
46.4 (38.4-46.4) 
45.2 (45.2-45.2) 
45.7 (38.1-52.4) 
49.6 (41.5-56.8) 
49.5 (40.4-55.3) 
39.2 (30.2-46.2) 
 
51.9 (43.75-
56.40) 
 
a0.044, b0.010, c0.132 
a0.541, b0.072, c0.722 
a0.017, b0.105, c0.122 
a0.263, b0.861, c0.353 
a0.037,b0.319, c0.785 
a0.935, b0.743, c0.782 
a0.688, b0.304, 
c0.720a0.222, b0.064, 
c0.125 
a0.003, b0.120, c0.114 
a0.312, b0.521, c0.972 
 
Values are expressed as median (IQR, interquartile range). Each time point was compared to baseline using 
Wilcoxon signed ranks test. P values are shown and highlighted in bold if <0.05. 
a
Wilcoxon 0-3, 
b
Wilcoxon 
0-6,
c
Wilcoxon 0-12. SF36 (Short Form 36), SF8 (Short Form 8). Significant improvements from baseline 
indicated by highlighted text. 
 
132 
 
3.4 Comparison between the effects of angioplasty and exercise 
therapy 
 
The final aim of this work was to compare the effects of both angioplasty and exercise 
treatments on clinical indicators of lower limb ischaemia, physical function, balance, falls 
and quality of life in patients with lower limb ischaemia. 
 
3.4.1 Baseline data 
Initially a comparison was made between the angioplasty and the exercise groups to 
determine, whether at baseline, there were any important differences. There was no 
significant difference between the 2 groups in terms of basic demographics; age, gender, 
medical history, height, weight or BMI (P > 0.05) (Appendix 4).  
 
There were, however, significant differences between the 2 groups in clinical indicators of 
lower limb ischaemia at baseline. The exercise group had worse ankle brachial pressure 
index (ABPI) results both pre and post exercise (P < 0.05) (Figure 3.22, Appendix 13). 
Despite their post exercise ankle pressure and ABPI results, the angioplasty group walked 
for shorter distances before the onset of pain (intermittent claudication distance, ICD) 
compared to the exercise group at baseline (Appendix 13). There was no difference in 
maximum walking distance (MWD) on the treadmill, or in patient reported walking 
distance (PRWD) (Appendix 13).  
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Figure 3.22  Ankle brachial pressure index at baseline for the angioplasty and SEP 
groups 
Boxes represent the interquartile range and the thick horizontal lines represent the median, whiskers represent 
the range with outliers represented by circles and extreme outliers as stars. Exercise and angioplasty groups 
were compared to another using Mann Whitney U test and P values are given for each variable.  
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The short performance physical battery scores were derived from the usual paced 4-metre 
walk, the chair stand test and the semi and full tandem balance tests. The scores can range 
between 0 and 12, with 12 being the best score possible. There was a significant difference 
at baseline between the angioplasy and exercise groups, with a median of 9 (IQR8-11) for 
the angioplasty and a higher median score of 10 (IQR 9-11) for the exercise group (P = 
0.007) (Figure 3.23, Appendix 14).  
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Figure 3.23  Short performance physical battery score at baseline for the angioplasty 
and SEP groups 
Boxes represent the interquartile range and the thick horizontal lines represent the median, whiskers represent 
the range with outliers represented by circles and extreme outliers as stars. Exercise and angioplasty groups 
were compared to another using Mann Whitney U test and P values are given.  
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The 4 metre walk at usual pace and at fastest pace were not significantly different between 
the angioplasty and exercise groups. The chair stand test was significantly worse for the 
angioplasty group at baseline, with a median time of 17 seconds (IQR 12-21) compared to 
14 seconds (IQR 11-17) for the exercise group (P = 0.044). The semi tandem stance was 
poorer for the angioplasty group (angioplasty: median 30 seconds (IQR 19-30), exercise: 
median 30 seconds (IQR 30-30) P = 0.004) but there was no significant difference in full 
tandem stance times between groups. There was no significant difference in hand grip 
strength between the angioplasty and exercise groups. During the six minute walk test the 
angioplasty group demonstrated shorter intermittent claudication distances (P < 0.05) and 
more rapidly reached the onset of intermittent claudication compared to the exercise group 
(P < 0.05) (Figure 3.24). However there was no significant difference between the two 
groups in maximum walking distance or the time when maximum walking distance was 
achieved (Appendix 14). 
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Figure 3.24  Six minute walk intermittent claudication distance at baseline for the 
angioplasty and SEP groups 
Boxes represent the interquartile range and the thick horizontal lines represent the median, whiskers represent 
the range with outliers represented by circles and extreme outliers as stars. Exercise and angioplasty groups 
were compared to another using Mann Whitney U test and P values are given.  
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At baseline 46 of the 98 patients tested failed the Sensory Organisation Test (SOT) 
(Appendix 15). Scores range from 0-100 (worst to best). There was no significant 
difference between the angioplasty or exercise groups. The median SOT composite score 
for the whole population tested was 68 (IQR 58-76), for the angioplasty group was 70 (IQR 
61-79) and for the exercise group was 65 (IQR 54-75), (P > 0.05) (Figure 3.25). Scores for 
each of the 6 SOT conditions were assessed. The angioplasty group performed significantly 
worse in condition 3 (inaccurate visual input as the visual surround moves relative to the 
patient), yet there was no difference between groups for the other conditions tested. The 
sensory analysis breakdown showed that all claudicants performed poorly in vestibular 
testing with less than half of patients (46 of the 98 patients) passing the vestibular 
assessment. This was significantly different between the groups with 60% (28 of 47) 
passing the vestibular assessment in the angioplasty group and 35% (18 of 52) passing in 
the exercise group (P = 0.012). Exercise patients were found to fall on the SOT test 
significantly more often (35 of the 52) than the angioplasty patients (20 of 47, P = 0.009) 
and an abnormal ankle strategy was employed more often by the SEP group (31 vs 11, P 
<0.001). The Motor Control Test (MCT) was performed well by claudicants with weight 
symmetry, latency and response strength being normal in over 70% of patients. There was 
no significant difference between groups in any outcome except response strength to 
forward translations,where exercise patients performed better than angioplasty patients, P = 
0.005, (exercise: 43 passed and 7 failed, angioplasty: 28 passed and 18 failed) (Appendix 
15). 
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Figure 3.25  Composite sensory organisation test (SOT) scores at baseline for the 
angioplasty and SEP groups 
Boxes represent the interquartile range and the thick horizontal lines represent the median, whiskers represent 
the range with outliers represented by circles and extreme outliers as stars. Exercise and angioplasty groups 
were compared to another using Mann Whitney U test and P values are given. Non significance is highlighted 
by (NS) if P > 0.05.  
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Normal and abnormal balance groups (those that passed or failed composite SOT) were 
compared. There was no difference in age, comorbidities or height, weight and bmi 
between those with normal or abnormal balance. However there was a much higher 
proportion of female patients in the abnormal balance group, of 31 females only 11 passed, 
whereas 41 males of 67 passed (P = 0.018). There was no difference between normal and 
abnormal balance groups, in any of the clinical indicators of lower limb ischaemia. In terms 
of physical function, those with abnormal balance had significantly longer times to 
claudication during the 6 minute walk test (median 113 minutes, IQR 85-154 mins) 
compared to those with normal balance (median 66 minutes, IQR 53-117 mins), P = 0.007). 
There was no difference in falls history or quality of life between the 2 balance groups.  
 
In all patients there was a history of falls from 20 patients and a history of stumbles from 
30 patients. There was no significant difference in falls history or history of stumbling 
between the angioplasty and exercise groups at baseline. The median Activities-specific 
Balance Confidence (ABC-UK) score for the cohort was 80.6% (IQR 64.6-92.8) where 
100% would be no fear at all. There was no significant difference at baseline between the 
ABC-UK score for angioplasty or exercise patients.  
 
The median Timed Up and Go (TUG) test score for the cohort was 9.16 seconds (IQR 7.49-
11.18) with no signifcant difference at baseline between the angioplasty or exercise patients 
(Figure 3.26, Appendix 16). However once TUG scores were adjusted by age there was a 
significant difference between the pass and fail rates between groups. Overall 58 of the 98 
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patients passed the TUG test based on age adjusted normative values. Angioplasty patients 
performed significantly worse than exercise patients in terms of age adjusted pass fail rates 
with 21 of 47 passing compared to 37 of 52 exercise patients passing (P = 0.005) 
(Appendix 16).  
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Figure 3.26  Timed up and go test (TUG) scores at baseline for the angioplasty and 
SEP groups 
Boxes represent the interquartile range and the thick horizontal lines represent the median, whiskers represent 
the range with outliers represented by circles and extreme outliers as stars. Exercise and angioplasty groups 
were compared to another using Mann Whitney U test and P values are given. Non significance is highlighted 
by (NS) if P > 0.05.  
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The angioplasty group demonstrated poorer quality of life than the exercise group in 
multiple domains from the Short Form 36, VascuQol and Short Form 8 at baseline (Figure 
3.27, Appendix 17). 
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Figure 3.27  Total VascuQol quality of life score at baseline for the angioplasty and 
SEP groups 
Boxes represent the interquartile range and the thick horizontal lines represent the median, whiskers represent 
the range with outliers represented by circles and extreme outliers as stars. Exercise and angioplasty groups 
were compared to another using Mann Whitney U test and P values are given. Non significance is highlighted 
by (NS) if P > 0.05.  
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3.4.2 Post treatment comparison between angioplasty and exercise 
Sections 3.2 and 3.3 individually discuss the effect of treatment for the angioplasty group 
and the SEP group respectively. This study was a pragmatic observational study and as 
such there were obvious differences between groups at baseline as highlighted above. 
However, these were only evident in certain outcome measures and as such the groups are 
comparable for a number of other measures. As such, a comparison between groups was 
undertaken post intervention for both treatment groups (angioplasty and exercise) at each of 
the time points. The variables used were chosen as they had identified the greatest 
improvements in either the angioplasty or exercise groups after treatment from each of the 
different categories of outcomes measured (clinical indicators of lower limb ischaemia, 
physical function, balance, falls and quality of life) (Table 3.11).  
 
Pre exercise ABPI and treadmill ICD were used as measures of ischaemia. It had been 
highlighted at baseline that the angioplasty group had better pre exercise ABPI but worse 
treadmill ICD compared to the SEP group. The angioplasty group showed improvements in 
ABPI whereas the SEP group had a stable median ABPI and therefore the significant 
difference between the two groups persisted at each time point (Figure 3.28, Table 3.11). 
ICD also significantly improved after angioplasty, and despite no improvement in ABPI, 
the SEP group also showed a significant improvement at 3 and 6 months. There was a 
significant difference between the two groups at baseline and 3 months for treadmill ICD 
(greater ICD for the SEP group), but by 6 months the improvement made by the 
angioplasty group made the difference non significant and this persisted at 12 months 
(Figure 3.29, Table 3.11).  
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Figure 3.28  Pre exercise ankle brachial pressure index (ABPI) for the angioplasty and 
SEP groups at each study time point 
Boxes represent the interquartile range and the thick horizontal lines represent the median, whiskers represent 
the range with outliers represented by circles and extreme outliers as stars. Exercise and angioplasty groups 
were compared to another using Mann Whitney U test at each time point. P values are given under the SEP 
box for each comparison with angioplasty. Non significance is highlighted by (NS) if P > 0.05.  
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Figure 3.29  Treadmill intermittent claudication distance (ICD) for the angioplasty 
and SEP groups at each study time point 
Boxes represent the interquartile range and the thick horizontal lines represent the median, whiskers represent 
the range with outliers represented by circles and extreme outliers as stars. Exercise and angioplasty groups 
were compared to another using Mann Whitney U test at each time point. P values are given under the SEP 
box for each comparison with angioplasty. Non significance is highlighted by (NS) if P > 0.05.  
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The short performance physical battery (SPPB) score was used as a measure of physical 
function as this encompassed both the walking and simple balance tests. At baseline there 
was a significant difference between the two groups, with the SEP group performing better 
(Figure 3.23). The difference between the groups diminished after treatment and was no 
longer significant at 3, 6 or 12 months due to the improvements made by the angioplasty 
group (Table 3.11). 
 
Balance and falls risk were not significantly different between the two treatment groups at 
baseline and this non significant difference was maintained at each of the time points post 
treatment (Table 3.11). However the median composite SOT scores were higher in the 
angioplasty group until 12 months when the SEP group had a higher median score.  
 
Quality of life was significantly better for the SEP group at baseline compared to the 
angioplasty group, although following treament the significance was reversed as the 
angioplasty data improved alongside that of the SEP group (Table 3.11). 
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Table 3.11 Comparison between angioplasty and exercise groups over time 
Variable Time point Angioplasty group Exercise group P 
Pre exercise 
ABPI  
(symptomatic leg) 
 
Baseline 0.78 (0.61-0.92) 0.60 (0.49-0.83) 0.001 
3 months 0.90 (0.77-0.99) 0.58 (0.48-0.77) <0.001 
6 months 0.81 (0.61-0.99) 0.57 (0.44-0.77) <0.001 
12 months 0.85 (0.76-0.90) 0.61 (0.45-0.75) <0.001 
 
Treadmill ICD  
 
Baseline 32.6 (19.13-53.95) 46.5 (27-68.03) 0.046 
3 months 36.0 (26.5-45.25) 60.0 (42.0-85.75) 0.003 
6 months 47.0 (37.5-140.5) 59.0 (38.0-95.5) NS (0.984) 
12 months 46 (34.0-78.0) 55.0 (39.25-93.25) NS (0.633) 
 
SPPB  
 
  
Baseline 9 (8-11) 10 (9-11.25) 0.007 
3 months 10 (9-12) 11 (10-12) NS (0.153) 
6 months 10.5 (8.75-11) 11 (10-11) NS (0.296) 
12 months 10 (9-11) 10 (9.5-12) NS (0.135) 
 
SOT composite 
score  
 
Baseline 70 (61-79) 65 (54-75) NS (0.063) 
3 months 73 (64.75-82) 69 (60.5-77.5) NS (0.151) 
6 months 74 (61-76.5) 73 (66-78) NS (0.754) 
12 months 68 (62.5-76) 74 (68-77) NS (0.161) 
 
TUG score  
 
Baseline 10.13 (7.50-12.50) 8.65 (7.44-10.19) NS (0.059) 
3 months 8.70 (7.04-10.97) 7.48 (6.80-9.64) NS (0.213) 
6 months 9.25 (7.57-10.58) 8.03 (6.69-9.75) NS (0.095) 
12 months 8.29 (7.20-11.43) 8.06 (5.87-10.47) NS (0.207) 
 
Total VascuQol 
score 
 
Baseline 4.32 (3.22-5.02) 4.84 (4.13-5.35) 0.007 
3 months 5.9 (4.19-6.66) 5.22 (4.64-5.88) NS (0.055) 
6 months 5.68 (3.96-6.36) 5.4 (4.38-5.9) NS (0.532) 
12 months 5.2 (4.08-6.32) 5.08 (3.98-5.94) NS (0.611) 
Values are all expressed as median (IQR, interquartile range). Angioplasty and exercise groups were 
compared at each time point using Mann Whitney U test (MWU) and P values are shown if < 0.05 or if > 0.05 
expressed as non significant (NS), with P values given in brackets. Data highlighted in bold indicates a better 
result than the other group. ABPI (ankle brachial pressure index), SPPB (short physical performance battery 
score), SOT (sensory organisation test), TUG (timed up and go test), VascuQol (disease specific quality of 
life measure).  
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4 Discussion 
 
The discussion is structured according to the format of the results chapter, beginning with a 
discussion of the correlation between lower limb ischaemia and physical function and 
balance. Secondly the effects both treatment arms (angioplasty and exercise) are discussed 
and lastly the comparison between the angioplasty and exercise groups is made. Limitations 
and future directions are also discussed in this chapter.  
 
4.1 Correlation between lower limb ischaemia and physical 
function and balance 
 
The initial aim of this work was to explore the hypothesis that prior to treatment; increasing 
severity of lower limb ischaemia will correlate with increasingly impaired physical function 
and balance. Yet in this study worsening lower limb ischaemia, as determined by lower 
ABPI, did not translate into worsening physical function, balance or falls risk. However 
treadmill walking distances, as a measure of lower limb ischaemia, were found to correlate 
much more accurately with almost all measures of physical function and falls, but not 
objective measures of balance.  
 
It has previously been recognised in the literature that there is an association between lower 
limb ischaemia and poor physical function (Gardner et al. 2004), and even in asymptomatic 
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patients with low-normal (1.00 to 1.09) or borderline (0.9-0.99) ABPI values, a decline in 
physical function has been found (McDermott et al. 2009). However, as with the findings 
in this study (section 3.1), ABPI itself has not been found to be a reliable marker of poor 
physical function (Atkins and Gardner 2004), suggesting that the degree of limb ischaemia 
alone is not the only causative factor for poor function in this cohort of patients. An 
alternative explanation for poor function may be reduced physical activity and it has been 
demonstrated that daily physical activity levels are a more significant factor in determining 
physical function (Atkins and Gardner 2004) rather than ABPI.  
 
Simple tests of balance have previously also indicated a specific connection between PAD 
and poor balance (Suominen et al. 2008) but no significant correlation between ABPI or 
walking distances and objective balance measures have been found. Worsening ABPI has 
been previously found to be unrelated to falls risk (Gardener and Montgomery 2001a). This 
suggests that in claudicants, walking distance impairment or physical function impairment 
may be better predictors of falls risk and balance than arterial disease severity, as found in 
this work. Those with more severe disease as measured by ABPI may still have good 
function in terms of walking (Appendix 13) which enables them to keep up a more active, 
exercise rich lifestyle which leads to reduced falls risk through a training effect.  
 
The walking related clinical indicators of lower limb ischaemia, ICD and MWD, correlated 
well with all measures of physical function (e.g. MWD correlated with SPPB, ρ = .544, P < 
0.001). PRWD was a less useful indicator and therefore treadmill tests may be of increased 
value in confirming or identifying those at risk of poor physical function. It seems logical 
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that the distance an individual can walk, both without pain (ICD) and before stopping 
(MWD), will relate to their performance in measures of physical function. Most measures 
require an individual to walk, if only for a short time and if walking is painful it is likely 
that such pain will impair the individuals’ ability to complete the functional task. Moreover 
if an individual avoids walking, for fear of inducing pain, they will likely become less 
accustomed to performing tasks involving walking and their muscle strength will diminish 
through lack of training. The explanation for both poor physical function and balance may 
rest in ischaemic muscle changes causing muscle atrophy and poor functional strength and 
consequent poor motor neurone performance. Regensteiner et al. (1993) found PAD 
patients had gastrocnemius muscle changes which correlated with functional strength and 
with peak walking time on the treadmill. The histological changes consisted of a reduction 
in the cross sectional area of type II muscle fibres and muscle denervation. They also found 
that those with less severe PAD (mild claudicants) did not demonstrate changes in 
morphology of skeletal muscle but all PAD patients showed evidence of denervation. 
Muscle denervation severity has been shown to correlate with the severity of vascular 
disease (England et al. 1992) and that denervation caused by ischaemia is one of the 
contributory factors to poor performance. Muscle biopsies were not taken in this current 
study but this may prove an interesting area of future research particularly to compare the 
differences in PAD patients at baseline, their response to treatment and their correlation 
with physical ability.  
 
The maximum walking distance correlated with hand grip strength, which cannot be 
directly explained by mechanisms resulting from reduced lower limb blood flow or muscle 
denervation. It seems from this study that a decline in physical function affects the whole 
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body, or at least the upper limbs, despite there being no known pathology in that location. 
The explanation may be related to training and that a lack of walking has a knock on effect 
on lack of whole body activities which would otherwise maintain upper limb function, such 
as carrying shopping or household chores. This conclusion is in contrast to that of 
McDermott et al. (2008a) who found no association between PAD and upper limb strength, 
although they used ABPI as a marker of PAD rather than walking distance. The contrast in 
conclusions may have occurred because of this difference in methodology. The current 
study correlated both ABPI and walking distances with hand grip strength, ABPI was not 
found to correlate, but MWD correlated with both right ρ = .312, P = 0.006) and left hand 
grip strength ρ = .377, P = 0.001). 
 
This study confounds previous findings that walking distance may be a useful predictor of 
impaired physical function. A significant correlation between walking distances and falls 
risk was also found. Previous studies have had conflicting results in that PAD is both 
associated with a higher (Gardner and Montgomery 2001a) and lower risk of falling 
(Arseven et al. 2007), but what these studies have not specifically correlated is claudication 
treadmill walking distances with measures of falls risk. As individuals are able to walk less 
and less far due to pain, they are likely to be at increased risk of falls for the same reasons 
as poor balance and impaired physical function. Lack of muscle strength and training may 
again contribute to falls risk. In the study that found a lower risk of falling it was 
hypothesised that reduced levels of physical activity and avoidance of walking may account 
for reduced falls risk due to there being less opportunity to fall (Arseven et al. 2007). 
Arseven et al. (2007) conducted their study prospectively and while there are certainly 
advantages of a prospective study in that falls should be reported more reliably, the 
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prospective design may have impacted on their results by patients’ awareness of falls risk 
being triggered and thus them purposefully avoiding falls risk situations. Correlation with 
daily physical activity either subjectively, through patient diaries or objectively through 
devices such as pedometers, may identify a link between physical activity levels and falls 
frequency.  
 
The implications from the initial part of this study for PAD patients are that clinicians 
cannot rely on ABPI as an indication of an individual’s level of performance, physical 
function, balance or falls risk. There must be other aspects of their assessment to identify 
potential deficits in these areas. Asking patients how far they can walk is notoriously 
unreliable in terms of actual distance a patient is able to walk (Watson et al. 1997). 
However it may still be a useful question for a clinician to ask as this study did find a 
correlation between patient reported walking distance (PRWD) and two measures of 
physical function, the SPPB and the chair stand test. Without access to a treadmill this may 
supplement the history taking in terms of identifying potential functional impairment. A 
simple treadmill test will not only give a useful and objective measure of walking distance 
but has been found in this study to correlate well with physical function performance and 
falls risk on many different measures. It may be appropriate, then to target such individuals 
with poorer walking distances with treatment measures designed not only to improve their 
ABPI but to improve walking distance, physical function and falls risk.  
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4.2 Angioplasty data 
 
The second aim of this work was to investigate the hypothesis that patients undergoing 
angioplasty treatment will demonstrate improvements in clinical indicators of lower limb 
ischaemia, physical function, balance, falls and quality of life in patients with lower limb 
ischaemia.  
 
4.2.1 Clinical indicators of lower limb ischaemia 
Following angioplasty treatment, as expected, patients were found to have a significant 
improvement in ABPI at 3 months when compared to baseline. This is explained as 
angioplasty restores inflow and consequently improves pressure in the lower limb arterial 
tree. However early success did not persist long term. Even at 6 months our data shows no 
significant improvement in resting ABPI from baseline (Figure 3.1). Yet post treadmill 
exercise ABPI did continue to show an improvement at 12 months (Figure 3.2). It might be 
assumed that either; restenosis, occlusion or disease progression at other sites may occur to 
account for the decline in resting ABPI. Why post exercise ABPI continued to improve 
while resting ABPI deteriorated was not explored in this study but may be as a result of 
partially failed angioplasty resulting in altered haemodynamics due to incomplete 
restoration of the vessel lumen (Rutherford et al. 1997). ABPI was used as a surrogate 
marker of radiological success rather than Duplex ultrasound as this imaging modality is 
not routinely used to follow up angioplasty treatment sites.  
 
156 
 
Smoking plays an important part in disease progression and restenosis (Jonason and 
Ringqvist 1985). At baseline 25% of angioplasty patients and 29% of exercise patients were 
current smokers, a difference which was not statistically significant (compared to 20% of 
the general population in 2010, Office for National Statistics 2012). Smoking rates at later 
visits were not explored but all patients were given advice to stop smoking. It may be that 
continued smoking had a part to play in late angioplasty failure rates. In addition the 
adherence to statin and antiplatelet therapy was assessed at baseline but not at later visits. 
Those patients not on statins or antiplatelet agents were advised to contact their GP to 
ensure secondary prevention measures were addressed; in addition it is standard practice to 
put the need for aspirin and statin in a letter to the GP from the initial clinical visit.  
 
Coupled with improvements in ABPI there were significant improvements in walking 
distances (both ICD and MWD) at 3 months compared to baseline. It follows that 
revascularisation and treatment of the occluded or stenosed vessel would result in an 
improved ability to walk, as the causative factor for claudication has been successfully 
treated. Despite the return to baseline in ABPI, ICD distances on the treadmill were not 
only maintained but showed significant improvement even from the 3 month data at both 6 
and 12 months. MWD distances improved from baseline to each of the time points and 
there was also a statistically significant improvement in patient reported walking distances. 
This is hugely encouraging in that although a degree of restenosis or disease progression 
may occur this does not necessarily translate into a return to baseline in symptoms. The 
explanation for this may lie in the fact that once treated, the angioplasty group were then 
able to walk and improve their tolerance to ischaemia and in effect they produced an 
exercise therapy result themselves. McDermott et al. 2006 found that PAD patients who 
157 
 
exercised for 3 or more times a week demonstrated smaller annual declines in walking tests 
(6 minute walk, 4 metre walk tests) suggesting that self-directed exercise (> 3 times a 
week) has a potential benefit on walking function, compared to less frequent exercise. 
Objective assessment of physical activity, by using exercise diaries or pedometers, may 
have proven this link to increased physical activity in the current study.  
 
4.2.2 Physical function 
The short performance physical battery scores (SPPB), which involve walking tests, 
improved significantly for the angioplasty group between baseline and 3 months. This 
improvement was maintained at the 6 and 12 month visits. When broken down into the 
components of SPPB, significant improvements were seen in all areas of the test. Standing 
balance did improve, but only at 12 months was there a significant improvement from 
baseline in the semi tandem and full tandem stance times. Given the improvements seen in 
ABPI and treadmill walking, the tests involving an element of walking should and did 
improve following treatment. The improvements were maintained, which as with treadmill 
walking, indicates that once able to walk post angioplasty patients must continue to 
exercise to a degree which allows preservation of walking function, despite declining 
ABPI. As described above McDermott et al. (2006) showed a decline in deterioration in the 
walking tests of physical function used in the present study (6 minute walk, 4 metre walk 
tests) among patients who reported a higher frequency of self-directed walking exercise. 
The decline in function could be explained in their group as their patients had not 
undergone angioplasty treatment or formal exercise treatment, as with this current study 
(sections 3.2.3 and 3.3.3). Yet the fact that the decline in function was less than that 
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observed among patients who exercised less than 3 times a week suggests continuing to 
exercise through walking has a positive effect on PAD patients rather than not walking. The 
implication is that encouraging self-directed exercise in all patients as an additional 
treatment should be promoted, not only to improve claudication symptoms but to improve 
global physical function. The vascular adage “stop smoking and keep walking” has 
relevance for function as well as symptom improvement.  
 
It could be implied that improvement noted in standing balance at 12 months is due to 
exercise effects rather than revascularisation as there was no improvement early post 
treatment. Certainly exercise has been proven to improve balance (Howe et al. 2007), but 
angioplasty treatment and balance has not been previous studied. This study did not 
confirm that angioplasty patients were taking more exercise post treatment, it is an assumed 
effect of successful treatment and further work to confirm or refute increased levels of 
exercise would be of benefit.  
 
There was no discernible pattern or explanation for the two significant changes noted in 
hand grip strength (Appendix 6) and the clinical relevance of these findings may be 
minimal. The changes may have been related to increased exercise and physical function 
but the decline seen in left hand grip is more difficult to explain. The left hand was non-
dominant hand in 88% of patients and therefore the decline in function may be related to 
lack of use but is not proven.  
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As expected, 6 minute walking distances at all times points were significantly improved 
compared to baseline, except for the maximum walking distance at 12 months (Figures 3.5 
and 3.6). Time taken until claudication arose, and maximum walking times were also 
recorded. Angioplasty patients were able to walk for longer both pain free and with pain 
after treatment (ICD time and MWD time respectively) and this was significant at 3 and 6 
months compared to baseline. There was a further significant improvement in maximum 
walking time between 3 and 12 months. This suggests that at 12 months patients were not 
covering the same distances but were walking for longer and therefore had possibly adapted 
slower walking speeds to cope with restenosis or deteriorating disease as indicated by a 
decline in ABPI to near baseline levels. Mockford et al. (2010) demonstrated that patients 
make significant temporospatial gait adaptations to claudication pain such as; reduced 
walking speed, reduced step frequency and increased time spent in the double support 
phase of gait, with the onset and progression of pain. It may have been that at 12 months 
patients had a degree of recurrent symptoms that were induced during the 6 minute walk 
and therefore explaining the reduction in walking distance but increase in walking time. 
This is supported by the decline in median ICD between 6 and 12 months and the wide 
variability in ICD recorded at 12 months (Figure 3.5).  
 
4.2.3 Balance 
As with standing balance, great improvements in CDP balance were not seen in angioplasty 
patients post treatment. There was no improvement in the proportion of patients who passed 
the SOT, although the median composite SOT score improved significantly between 
baseline and 3 months. This may be a function of improved vascular supply and more 
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closely related to ABPI in this group, than to walking distances as improvements followed 
the same pattern of significant change (Figures 3.1 and 3.7). It seems that on-going 
improved walking distances did not impact on balance in this group as SOT scores showed 
no significant improvement at 6 or 12 months (Figure 3.7). No previous work has studied 
the effect of lower limb angioplasty on balance but exercise has been shown to improve 
objective markers of balance such as SOT scores (Wallmann et al. 2009; Alpert et al. 
2009). In the previous section it was hypothesised that improvements in physical function 
beyond 3 months may be due to patients engaging in self-directed exercise to maintain 
function. If this is the case, it seems that the exercise undertaken is not sufficient or 
appropriate to improve balance. Exercise programmes aimed at improving balance do not 
necessarily recommend walking. Sherrington et al. (2008b) found that the most successful 
programmes for minimising falls did not include walking and an explanation may be that 
walking takes time away from balance challenging exercises which have a greater effect on 
falls reduction. Education for patients aimed at improving global function after angioplasty 
intervention should include self-directed exercise (“stop smoking and keep walking”) but 
should also include measures to improve balance and physical function. Exactly which 
exercises will benefit this group most has not yet been clarified.  
 
Condition 4 of the SOT involves the base plate rotating (angular translations) and therefore 
requires the patient to engage their calf musculature to maintain their stability. This section 
of the SOT did show significant improvements from baseline at 3, 6 and 12 months. This 
may be a reflection of both improved vascular supply and improved muscle conditioning 
with increased levels of exercise once angioplasty patients were able to walk. The sensory 
analysis was not affected by treatment at any of the time points.  
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The MCT latency outcome did not change over the study period. The composite MCT 
score improved between 3 and 12 months, and 6 and 12 months. This is difficult to explain 
by either improved vascular flow or by increased levels of exercise, unless it is a delayed 
effect as improvements were not seen between baseline and 3 months. This finding may not 
be related to revascularisation but to an event after treatment, such as an exercise effect 
occurring once patients are able to walk pain free. Another explanation may revolve around 
possible improvements in muscle structure or muscle denervation after angioplasty. The 
severity of muscle denervation correlates with the severity of vascular disease (England et 
al. 1992) and denervation should be associated with poor performance on the MCT test. It 
should follow that if neuromuscular function improves with improving vascular disease, 
MCT performance may also improve. These suggested changes in muscle histology may 
take longer to manifest, which would explain a delay in improvement.  
 
4.2.4 Falls 
The number of falls and stumbles reported by patients fell at 3 months compared to 
baseline but no other changes were seen. This is likely to be due to improved walking 
ability and to greater confidence post revascularisation. Confidence did improve at 3 
months as measured by a significant improvement in Activities-specific Balance 
Confidence (ABC-UK) score (baseline: 79.56 (IQR 53.92-90.72), 3 months: 87.60 (IQR 
73.84-97.26) P < 0.001), although this improvement was not maintained at later time 
points. This may reflect the sudden improvement seen in walking distances with 
angioplasty revascularisation and may translate into improved confidence with falls related 
activities due to more confident walking. This finding is supported by Gardner and 
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Montgomery’s (2001) observation that self-reported ambulatory function relates to 
measures of falls. In the present study confidence declined at 6 months back to baseline 
levels. This decline in confidence at 6 months matches the return to baseline seen in SOT 
scores at 6 months, highlighting the link between balance and falls risk (American 
Geriatrics Society 2001). As with SOT, ABC-UK scores may be more closely related to 
ABPI or the consequences of improved lower limb perfusion rather than related to 
improved walking distances.  
 
The TUG test is a recommended assessment for falls risk (American Geriatrics Society 
2001). As seen with some measures of physical function, TUG test scores improved after 
treatment and continued to improve at each visit when compared to baseline (Figure 3.10). 
The TUG test is again a walking test and therefore improved walking ability is likely to 
lead to improved TUG times. This is an encouraging finding in that angioplasty treatment 
may lead to a reduction in falls risk through improvements in walking function, 
demonstrated by TUG improvements.  
 
4.2.5 Quality of Life 
As expected there were significant improvements in quality of life following angioplasty 
treatment. The disease specific VascuQol quality of life measure showed improvement in 
every domain at 3, 6 and 12 months when compared to baseline. The literature has long 
since recognised that patients with symptomatic PAD have impaired quality of life and that 
such impairments improve with treatment (Chetter et al. 1999). It has also been 
acknowledged that disease specific tools such as the VascuQol are more sensitive to 
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improvements following treatment (de Vries et al. 2005). In this study VascuQol did 
identify improvements in non-physical domains not identified by generic QOL measures 
and therefore it seems appropriate to use this tool in PAD populations.  
 
Quality of life assessment was included in this study to assist in identifying global factors 
associated with physical function and balance impairment, and falls risk. It may be prudent 
in the future to combine quality of life assessment with assessment of physical function and 
falls risk targeting improvements in patients’ perception of their lives as well as in 
diminishing objective falls risk. Improving an individuals’ physical function alone without 
consequent improvements in quality of life might be perceived as of little value for some 
individuals. It may be possible to construct further quality of life tools that are even better 
targeted to physical function, balance and falls risk related quality of life.  
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4.3 Exercise data 
 
In addition to angioplasty treatment, the effects of a structured exercise programme on 
clinical indicators of lower limb ischaemia, physical function, balance, falls and quality of 
life in patients with lower limb ischaemia were examined hypothesising that patients 
undergoing exercise therapy will demonstrate improved outcome measures after treatment.  
 
4.3.1 Clinical indicators of lower limb ischaemia 
Ankle Brachial Pressure Index (ABPI) did not significantly alter across the study period in 
the SEP group, and this was to be expected. SEP does not revascularise the limb and 
therefore major changes in blood flow to affect ABPI do not occur (Watson et al 2008). 
Despite not improving ABPI, exercise treatment has been previously proven to be of value 
in improving walking ability (Watson et al. 2008). In this study, objective walking 
distances did improve following exercise. The treadmill ICD distance improved 
significantly between baseline and 3 months and baseline and 6 months (Figure 3.13) and 
the maximum walking distance on the treadmill improved significantly between baseline 
and 3 months (Figure 3.14). Patient reported walking distances also improved from 
baseline to each of the individual time points (3, 6 and 12 months) (Appendix 9).  
 
The mechanisms thought to be involved in improving walking distances include not only 
improvements to collateral blood flow but increased aerobic capacity, improved muscle 
strength and endurance, improved walking economy, improvements to endothelial function 
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and the microcirculation and improvements in the nature of blood flow (Stewart et al. 2002; 
Brendle et al. 2001). Muscle biopsies were not taken in the current study but would be an 
interesting avenue of future research, particularly after treatment and to compare treatment 
effects.  
 
4.3.2 Physical function 
With improved walking distances an improvement in measures of physical function is 
expected. At 3 months many aspects of physical function had improved (SPPB, 4 metre 
walk test at usual and fastest pace, and 6 minute walking distances and times, Appendix 
10). All of these tests involve an element of walking and therefore as the SEP patients 
improved their walking distances, it follows that the measures of physical function directly 
involving walking should also improve. McDermott et al. (2009a) have also investigated 
the effect of exercise on function, although they only found improvements in the 6 minute 
walk test rather than in SPPB. This may have been due to the nature of their exercise 
programmes which were either treadmill walking based or resistance training based. The 
SEP group in this study took part in a circuit based programme involving walking and 
strength training stations and the combination seems to show better gains in terms of 
function. 
 
However the chair stand test and semi and full tandem balance tests did not improve with 
exercise treatment in this study. This may be a reflection of not specifically training to 
improve these elements of physical function in the exercise programme. McDermott et al. 
(2009a) found an improvement in stair climbing ability with their resistance programme not 
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found with their walking programme. It seems that in this study the strength training 
aspects of the SEP programme were not sufficient to produce a meaningful improvement in 
the chair stand test, which requires good quadriceps function.  
 
The physical function indicators suggest that balance may also not have been adequately 
trained in this study as semi and full tandem balance did not improve. However these tests 
of standing balance were not very sensitive in that at baseline most patients were able to 
complete both tests (semi tandem N = 79 and full tandem N = 55). This finding was also 
noted by Sherrington et al. (2008a) who observed improvements in step balance tests, sit to 
stand, gait, and the 6 minute walk after circuit style exercise but no significant change in 
semi tandem or tandem stance.  
 
Furthermore, hand grip strength deteriorated with the SEP programme. Both the right and 
left hand grip strength deteriorated between baseline and 3 months, and this significant 
deterioration remained at 6 months in the left hand (Appendix 10). Upper limb function 
was not a priority for the SEP programme but there was a 2 minute upper limb station 
within the programme, aimed at providing a rest for the legs while giving patients a focus 
by performing biceps curls (Figure 2.6). This station was not intended to produce 
improvements in hand grip strength. However the promotion of general health through SEP 
could have led to an increased uptake of self-directed exercise and therefore perhaps a 
reduction in general frailty demonstrated by improved hand grip strength. This did not 
appear to be the case with this patient group and rather than any improvement, a 
deterioration was seen during the SEP course. The explanation may be that the SEP patients 
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were so focussed on their symptomatic lower limbs that they ignored potentials for 
improving their whole body function and specifically their hand grip strength during the 
initial 3-6 months of the study. Given that there were no longer term significant differences 
in grip strength from baseline, it may be that as the SEP finished, and particularly for those 
who had improved their walking ability, patients were then able to consider improving their 
general health and therefore grip strengths returned to baseline levels. Of note the 
overwhelming right hand dominance of the study population (88%) implies that the right 
hand would be prioritised for everyday functional tasks and that decline in function should 
be less apparent in the right hand. This fits with no deterioration from baseline at 6 months 
in the right hand grip strength but an on-going decline in the left hand at this time point.  
 
4.3.3 Balance 
Interestingly, although the simple static measures of balance semi tandem and tandem 
stance did not improve after SEP, this study found an improvement in CDP balance post 
treatment. The proportion of patients who passed the Sensory Organisation Test (SOT) 
(Appendix 11) and the mean composite score for SOT improved significantly at all 3 time 
points after treatment (Figure 3.17), when compared to baseline. Exercise treatment has 
previously been shown to improve balance particularly when programmes involve a 
combination of interventions including walking, balance training and functional exercises 
(Howe et al. 2007) and in particular have resulted in objective improvements in SOT scores 
(Wallmann et al. 2009; Alpert et al. 2009). The exercise programme in this study, however, 
was not specifically aimed at balance. In fact it was not altered at all from the standard 
supervised exercise programme offered to claudicants at this NHS trust, in order not to 
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deviate from standard treatment. This is hugely encouraging and with further improvements 
to the exercise programme it may be that more gains can be made in terms of balance 
improvement with potential consequent improvements in function and falls risk.  
 
When individual conditions of the SOT were analysed, there was a significant improvement 
noted at 3 and 6 months for condition 4 and a significant improvement at all 3 time points 
for conditions 5 and 6. Furthermore, improvements continued to occur after the exercise 
programme had finished in condition 5 (significant improvement from 3 to 12 months) and 
condition 6 (significant improvement from 6 to 12 months). Conditions 4, 5 and 6 are the 
most challenging of the SOT, with therefore more room for improvement in scores. In 
condition 4 the platform rotates via angular translations (Figure 2.5) and the individual 
must engage their lower limb musculature to stabilise themselves. The same occurs in 
condition 5 but the individual also has their eyes closed, thus removing visual feedback and 
leaving vestibular and somatosensory systems to cope with the perturbation. Condition 6 
involves both the standing platform and the visual surround moving thus giving incorrect 
somatosensory and visual input and requiring an accurate vestibular system to trigger the 
correct response from the lower limb musculature to maintain an upright stance. The 
improvements seen in these 3 conditions after SEP suggests that SEP affords more than just 
an improvement in lower limb muscular function that could be obtained by walking. These 
same improvements were not seen in angioplasty patients, suggesting that the SEP may 
challenge and even train balance or the vestibular system to some degree in addition to 
improving leg function. This may result from activities as simple as stretching in the warm 
up phase whereby claudicants stood on one leg and stretched their quadriceps by holding 
the contralateral ankle behind them at the base of their gluteals. As described in previous 
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sections histological muscle changes may account for improvements seen in balance, 
particularly of interest would be changes to muscle denervation in terms of responding to 
perturbations. Muscle biopsies after exercise treatment in PAD populations have not been 
carried out either in this study or in the published literature, although may give information 
about the mechanism of improvement in balance after exercise treatment.  
 
Although the NeuroCom does not give a diagnosis or a specific system impairment it 
computes sensory ratios between the average condition scores on specific paired results i.e. 
for vestibular function condition 5 and condition 1 are paired, a low score implies that the 
patient is unable to utilise vestibular cues (NeuroCom 2001). The sensory breakdown 
analysis confirms that improvements were found in vestibular component of balance 
assessment between baseline and 3 months. A significantly higher proportion of patients 
passed the vestibular analysis at 6 and 12 months compared to baseline. There was no 
difference in falls during the SOT or in any aspect of the MCT throughout the study period 
in the SEP group. Therefore the improvements noted with angioplasty were not found in 
the SEP group suggesting revascularisation may be aiding the neuromuscular component of 
balance. This study found significant objective improvements in balance outcome measures 
with SEP, not seen with angioplasty treatment suggesting that exercise therapy may be an 
effective treatment for those claudicants with impaired balance.  
 
4.3.4 Falls 
SEP patients did not report a significant change in falls history over the study period. 
However there was a significant improvement in the number reporting stumbles between 
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baseline and 3 months. Exercise programmes have been found to be effective preventative 
treatments for fallers in reducing falls rates (Gillespie et al. 2003; Sherrington et al. 2008b) 
and perhaps more of a reduction in falls history would be expected. The limitation of 
questioning patients retrospectively is that they may not adequately recall falls events or 
even the timing of falls therefore falls may be both under reported or inaccurately reported 
in relation to the treatment period. A future study could use a diary system of 
documentation or send out reminder cards to patients on a frequent basis to trigger accurate 
reporting (Arseven et al. 2007). Although prospective triggering of a potential falls risk 
may lead to behaviour aimed avoiding potential situations which may cause a fall that 
would otherwise be undertaken.  
 
Fear of falling did not drop with the exercise programme as there was no significant 
difference in ABC-UK scores across the study period (Appendix 12). Despite the fact that 
this group reported less stumbles, perhaps the improvements were gradual and therefore 
any possible improvements in confidence were not perceived by individuals in the SEP 
group.  
 
The TUG test was performed significantly faster at 3, 6 and 12 months when compared to 
baseline (Figure 3.21), which as with other walking tests, may be a reflection of improved 
walking ability after the SEP treatment. This confounds results from a previous study 
showing improvements in TUG scores with exercise therapy in a non-PAD population 
(Jacobson et al. 2011). TUG is recommended as a screening tool for falls risk (American 
Geriatrics Society 2001; Rao 2005) and thus improving TUG scores can be seen as an 
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encouraging marker of potential reduced falls risk after SEP and is comparable to the 
improvement seen with angioplasty.  
 
4.3.5 Quality of life 
Quality of life improvements were noted for the SEP group but were not sustained at 12 
months (Table 3.10). Disease specific VascuQol was a more sensitive measure of quality of 
life, as expected (de Vries et al. 2005; Mehta et al. 2006). VascuQol has been shown to 
correlate better with clinical indicators of lower limb ischaemia in patients with PAD both 
pre and post treatment (angioplasty and exercise) than generic QOL tools (Mazari et al. 
2010).  
 
 No emotional or social domain scores improved in either SF8 or SF36, however significant 
improvements in the emotional domain scores of VascuQol were seen at 3 and 6 months, 
and an improvement in social domain scores was also seen at 6 months. It is not surprising 
that at 12 months quality of life in the SEP group reverted back to baseline, in that treadmill 
and six minute walking distances were not significantly different at 12 months compared to 
baseline. Once the primary symptom of claudication was not significantly improved it 
follows that quality of life would also deteriorate. No gains in function with falls risk or 
balance had enough impact on quality of life to make any significant difference. Perhaps a 
more balance orientated QOL measure would have identified small changes had these been 
present.   
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4.4 Comparison between the effects of angioplasty and exercise 
therapy 
 
The final aim of this work was to compare the effects of both angioplasty and exercise 
treatments on clinical indicators of lower limb ischaemia, physical function, balance, falls 
and quality of life in patients with lower limb ischaemia. It was hypothesised that there 
would be no difference between angioplasty and exercise treatments in improving outcome 
measures.  
 
4.4.1 Baseline data  
This was not a randomised study as patients were referred for either angioplasty or exercise 
treatment based on their symptoms, disease morphology and previous treatment. Full 
clinical assessment and treatment planning was carried out by the referring Consultant 
Vascular Surgeon prior to study inclusion. Therefore the 2 patient groups on inclusion into 
the study were different, requiring different treatments for their peripheral arterial disease. 
The 2 groups were compared in detail at baseline to identify differences which may explain 
differing responses to treatment. In terms of basic demographics they were comparable in 
terms of age, gender, medical history, height, weight and BMI.  
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4.4.1.1 Clinical indicators of lower limb ischaemia 
Those patients who were referred for exercise had poorer baseline vascular function in 
terms of ankle brachial pressure indices both pre and post treadmill exercise, although were 
able to walk further on the treadmill before complaining of pain (intermittent claudication 
distance) than their angioplasty peers. Both groups walked for a similar maximum distance 
and both reported similar patient reported walking distances (Appendix 13). 
  
It might be expected that a poorer ABPI should correlate with a shorter walking distance 
before the onset of pain; however this was not the case in this study and is well recognised 
(Da Silva et al. 1979; Gardner et al. 2008b). ABPI values are not absolute indicators for 
treatment; moreover treatment planning is based on symptoms and patient determined 
quality of life factors, balanced with risk and potential benefit of intervention. Both clinical 
and patient based factors are recommended assessment criteria for claudicants (Norgren et 
al. 2007). It is known that claudication is often a stable condition without significant 
deterioration in symptoms over time in the majority of patients. This may be due to 
collateral vessel development which is difficult to measure objectively and is not 
measureable by ABPI. The Basle study reported that at 5 years two thirds of surviving 
patients showed symptom improvement although 63% demonstrated progression of disease 
on angiography (Da Silva et al. 1979). ABPI alone is therefore not a good indicator of 
walking function, as found in this work.  
 
Demonstrating a significant difference in clinical indicators of lower limb ischaemia, in 
particular ABPI and walking distances, between the two groups studied suggests a different 
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morphology of disease. The study patients were not classified at baseline in terms of pattern 
of disease, nor did they all undergo investigation using the same imaging modality prior to 
referral and therefore disease morphology was not retrospectively analysed.  
 
4.4.1.2 Physical function 
Walking and physical function are intimately related and most of the measures of physical 
function required patients to walk. This may explain the poorer performance from 
angioplasty patients compared to exercise patients given that they suffered from 
claudication related pain on walking at shorter distances. Although not all physical function 
tests require a walk long enough to induce pain, a poorer tolerance to walking in general 
may lead to poorer overall physical function through lack of exercise. Not explained by 
walking, standing balance was also poorer in angioplasty patients, suggesting that those 
patients who are less able to walk may have impaired muscle strength and consequently 
balance.  
 
4.4.1.3 Balance 
In objective balance assessment using CDP, this study demonstrated that global balance 
abnormalities are extremely common in claudicants occurring in 47% of this study 
population compared to 5% of NeuroCom control patients (NeuroCom 2001). Despite the 
finding that angioplasty patients performed worse in standing balance tests there was no 
difference between exercise and angioplasty groups in terms of their CDP scores. Poor 
balance was particularly evident in the sensory analysis breakdown at baseline with 53% of 
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patients failing the vestibular assessment. None of the patients recruited complained of 
balance problems and all led functionally independent lives. Therefore the detection of a 
potential risk factor for falls in an asymptomatic group of vascular patients, such as this 
cohort, highlights the common nature of balance problems and the lack of awareness 
among patients. This has been shown in other studies, Cohen et al. (1996) tested 94 
independently-living healthy control subjects who were all able to perform self-care tasks 
unaided and among their population SOT scores did vary, even to the extent of being 
abnormal in some patients, despite a lack of symptoms. Acknowledging that people may be 
functionally independent but still have abnormal balance scores is important. Abnormal 
balance assessment may be seen as a warning sign of potential future problems and that 
these are the very people to target in order to prevent or minimise further decline, falls risk 
and serious injury. Given that coupled with poorer physical function, intervention to 
improve balance is particularly pertinent. Indeed current functional competence may allow 
patients the freedom to participate in programmes to improve stability and may also 
directly motivate patients to maintain their current state of independence. Furthermore 
balance is thought to deteriorate with age and this has been objectively demonstrated by 
decreasing SOT scores among older populations with a continued deterioration even into 
the ninth decade (Cohen et al. 1996). This study, however, showed no significant 
correlation between composite SOT scores and age at baseline, suggesting factors other 
than age had greater influence over SOT than age. This also indicates that age alone is not 
necessarily a risk factor for balance in claudicants and should be considered along with 
functional performance.  
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The explanation for impaired balance, as with physical function, is likely to be 
multifactorial. Particularly older claudicants often have multiple co-morbidities which may 
result in confounding reasons for impaired balance. Patients in this study were selected to 
be older (>50 years of age) in order to gain information on an age group known to be at 
high risk of falls, however, no significant variation in co-morbidities was observed between 
patients with abnormal and normal balance in our study population. Impaired muscle 
function among claudicants is likely to be a significant contributing factor. One explanation 
for poor balance in patients with PAD is similar to that for poor physical function, in that, 
PAD patients have ischaemic muscle changes that correspond with histological muscle 
changes and poor functional strength (Regensteiner et al. 1993). Whether the presence of 
PAD is indicative of central balance control impairment is difficult to ascertain, but the 
systemic atherosclerosis associated with PAD patients may cause central and cerebral 
changes which contribute to balance impairment.  
 
Whether impaired balance can be directly attributed to peripheral vascular disease remains 
unproven, but potential avenues of research must include central causes such as small and 
large vessel cerebrovascular disease and peripheral causes such as proprioceptive pathways 
and muscle weakness limiting the adaptive response.  
 
Claudicants may be expected to have a higher frequency of somatosensory balance 
abnormality due to peripheral neuropathy and impaired sensation as a reflection of their 
vascular disease, particularly those with diabetes (who exhibited no significantly increased 
rate of abnormal balance). Rather than predominantly somatosensory dysfunction, this 
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study identified a high incidence of balance abnormalities secondary to vestibular 
dysfunction in patients with claudication (Appendix 15). The functional impact of an 
impaired vestibular score on a firm support surface in the presence of normal vision is 
negligible, as other systems will compensate. Conversely, on irregular surfaces and in 
conditions of low lighting such patients will experience instability. This is hugely 
significant for elderly, falls risk patients in situations such as getting out of bed at night, 
and when out of the house walking on irregular paving. The high incidence of vestibular 
dysfunction in this group was unexpected as a direct aetiological link between vestibular 
dysfunction and peripheral arterial disease has not previously been established. However, 
among people with balance disorders, vestibular dysfunction is common and represents up 
to 50% of cases (Cohen et al. 1996). While our high rate of vestibular dysfunction may be a 
reflection of the spectrum of balance dysfunction within society, it may also be linked to 
high rates of systemic atherosclerosis including micro vascular disease among claudicants. 
Vestibular dysfunction has previously been linked to atherosclerosis, in particular 
vertebrobasilar insufficiency (Alekseeva 2004) although research in this area is sparse. The 
purpose of the SOT and indeed this work was to highlight a potential area of deficiency 
rather than to offer an absolute diagnosis. The sensory analysis results must be interpreted 
with the clinical assessment of each individual.  
 
Of further note we found a significant difference between male and female claudicants in 
terms of balance scores. Overstall et al. (1977) measured anterior-posterior sway using an 
ataxiameter on 306 elderly people noting an increase in sway with age and in particular, 
increased sway among women. They suggested a decline in central postural control and 
loss of proprioceptive information with age and hypothesised that women’s increased sway 
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may be a function of body weight to muscle mass ratio. The present study did not 
specifically focus on the difference between male and female claudicants though there was 
no difference in height, weight or BMI found between different balance outcomes. Future 
work on elucidating the aetiology of abnormal balance and the difference between the 
genders will be of use in developing targeted treatments to allow functional improvement.  
 
The Motor Control Test (MCT) was performed well at baseline. Less than 30% of 
claudicants showed abnormalities in weight symmetry and latency, indicating that despite 
having one poorer functioning limb they were able to distribute their weight evenly during 
the MCT and were able to react in a timely fashion. Prolonged latency times have been 
associated with peripheral neuropathy and delayed central nervous system processing 
secondary to ageing or cerebral atrophy (Horak et al. 1997). A strong correlation has been 
described between short MCT latency time and the ability to recover from sudden minor 
slips (Lockhart 2002), thus these were positive findings for the claudicants in the current 
study in that they were able to recover from or respond quickly to perturbations. In 
addition, it also suggests, that abnormal MCT latency was not a strong contributing factor 
to impaired balance and increased risk of falls in claudicants.  
 
The incidence of abnormally weak response strength during MCT testing was 19% for 
backward translations (n = 18) and 26% for forward translations (n = 25) among our 
subjects. The functional impact of poor response strength is likely to be significant; in that a 
poor response strength result from either leg suggests difficulty in recovering from 
instability, such as that which occurs when stumbling. Thus, even with adequate latency 
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timing, if the response strength is suboptimal a patient may still be susceptible to falling. 
The relationship between response strength and latency to exercise training is not known, 
particularly in this patient group. It may be hypothesised that strength training, for example, 
would be associated with improvements in response strength results. There was no 
significant difference between angioplasty and SEP groups in any outcome on the MCT 
except response strength to forward translations, where exercise patients performed better. 
The reason for this finding is unclear and identifying the causes of differences between 2 
such groups may be an avenue for future research. It may be related to tolerance to 
ischaemia or as a reflection of poorer function.  
 
4.4.1.4 Falls history 
Falls history was frequent among this study group with 20/98 patients having fallen in the 
previous year and no significant difference between the 2 groups. This may be expected 
given the findings of impaired balance and previous studies which have indicated higher 
falls risk in PAD (Gardner and Montgomery 2001a). Impaired composite SOT scores have 
been demonstrated to be useful in identifying not only patients with balance disorders but 
also those at risk of falling with two papers confirming a relationship between poor SOT 
scores and a history of falling (Wallmann 2001; Whitney et al. 2006). The relevance of 
poor balance and increased falls risk is of prime concern among the elderly, as they, with 
potentially a multitude of other contributory risk factors, are more susceptible to morbidity 
associated with falls.  
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Conversely the ABC-UK scores for the baseline population were good and again no 
difference was found between either treatment group. This is perhaps more worrying as a 
lack of insight may give rise to increased risk. This has been noted previously in a study of 
43 community dwelling elderly men who experienced a decline in walking function, 
physical activity and function as well as an increase in the incidence of self-reported 
ambulatory stumbling and unsteadiness over 18 months of follow up. Perhaps of greater 
concern in that particular study, was the lack of change in self-perceived health status over 
time, suggesting a lack of awareness of their deterioration thus rendering patients more 
susceptible to potential instability and falls (Gardner et al. 2004). At baseline the falls 
history data was collected retrospectively and thus it is not possible to predict future falls 
from this data, but instead offer comment on the relationship between balance and our 
patients’ retrospective falls history. While improving a risk factor does not guarantee a 
reduction in falls or improved outcome, it can be argued that the identification of a risk 
factor by such means as objective balance assessment offers a useful tool in directing 
therapy towards those at potential risk.  
 
The TUG test was the other measure of falls risk examined in this study and there were no 
immediate differences between the 2 groups, although on further analysis angioplasty 
patients performed significantly worse than exercise patients in terms of age adjusted pass 
fail rates with 21 of 47 passing compared to 37 of 52 exercise patients passing. The 
explanation for this finding at baseline is likely to be similar to that of the walking 
measures of physical function, in that the TUG test requires patients to walk and therefore 
those that are better able to walk comfortably are the exercise patients.   
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4.4.1.5 Quality of life  
At baseline this cohort demonstrated, as expected, poor QOL in physical domains but also 
in measures of activities. Angioplasty patients reported poorer QOL and this may reflect the 
fact that they are due to undergo a procedure which is in part indicated for poor quality of 
life and the inability to perform activities important to their lives which require pain free 
walking.  
 
4.4.2 Post treatment comparison between angioplasty and exercise 
Pre exercise ABPI and treadmill ICD were used as measures of ischaemia in comparing the 
effects of both treatments at 3, 6 and 12 months. The significant differences highlighted at 
baseline were that the angioplasty group had better pre exercise ABPI but worse treadmill 
ICD compared to the SEP group. As expected the angioplasty group improved in terms of 
ABPI whereas the SEP group had stable ABPI and therefore the significant difference 
between the groups was maintained as the difference between the 2 groups increased 
further. The explanation for this difference after treatment is that angioplasty revascularised 
the limb allowing improved blood flow but exercise treatment enables better tolerance of 
ischaemic conditions without drastically affecting blood flow and hence blood pressure.  
 
Gains were made by both groups in terms of walking distance post treatment justifying 
both as acceptable treatments for claudication. Despite differences at baseline the 
improvements made by the angioplasty group made any difference between them non-
significant at 6 and 12 months as the angioplasty group were able to match the exercise 
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group in terms of walking distance. Angioplasty treatment gave rise to greater 
improvements in walking distance due to the success of initial revascularisation, however 
ABPI were not maintained at the later time points and therefore the continued 
improvements must be due to an exercise effect in this group. It may be that once able to 
walk they continued to walk and exercise enough to improve walking function further.  
 
The short performance physical battery (SPPB) score was used as a measure of physical 
function and at baseline the SEP group performed significantly better. However likely due 
to the improvements made in walking the difference between the two groups was 
eliminated at 3, 6 and 12 months.  
 
Balance and falls risk were not significantly different between the two treatment groups at 
baseline and this non-significant difference was maintained at each of the time points post 
treatment. However the patterns of improvements made by both groups were different as 
explored in the previous 2 sub sections.  
 
Quality of life was significantly better for the SEP group at baseline compared to the 
angioplasty group, although following treatment the significance was reversed as the 
angioplasty data improved alongside that of the SEP group. The better quality of life noted 
by the exercise group at baseline may reflect their improved walking function and this may 
then explain why the angioplasty group, as their walking function improved to the same 
level of that of SEP, also showed similar quality of life scores as the study progressed. The 
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MIMIC trial compared angioplasty with no angioplasty for patients who had already 
participated in a structured exercise programme and found that there was no improvement 
in SF36 quality of life scores for patients with femoropopliteal disease but a significant 
improvement in the physical score of SF36 for the angioplasty group in patients with 
aortoiliac disease (Greenhalgh et al. 2008). 
 
This study acknowledges that the comparisons made between the 2 treatment groups are 
primarily observational. The study was non-randomised and identified clear differences 
between the 2 groups at baseline therefore a strict comparison of treatment effects was not 
possible. It is, however, possible to comment on the progress of the 2 distinct groups, as has 
been done, and to reiterate that both treatments have their place. This study is not designed 
to recommend one treatment over another but to investigate potential concomitant 
improvements in physical function, balance and falls, as have been demonstrated, after 
treatment.  
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4.5 Delimitations and limitations 
 
There are several important delimitations and limitations to discuss with this study, all of 
which have been alluded to in the main discussion. These are as follows; 
• This study was non-randomised and therefore a direct comparison between exercise 
and angioplasty treatment effects cannot be used to imply the superiority of one treatment. 
This study was aimed at every day vascular practice and therefore patients were recruited 
after a clinical decision regarding best treatment had been made. Randomization of this 
cohort would have been unethical in that the some patients would have been better served 
by a particular treatment modality in the first instance.  
• The spread of disease severity within the study was not uniform. There were only 5 
mild claudicants recruited and 39 severe claudicants. This is, however, representative of 
treatment patterns in daily vascular practice.  
• The pattern of arterial disease was not recorded or followed up. There may have 
been useful differences found between aortoiliac and femoropopliteal disease in terms of 
outcomes.  
• Radiological success was not measured after angioplasty due to the risks of an 
unnecessary radiological procedure, however, Duplex imaging may have highlighted 
success rate to some degree. ABPI was used as a surrogate marker for radiological success. 
• The history of falls and stumbles reported by patients may have been improved by 
documentation aids given to the patients such as a diary or reminder cards.  
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• Smoking rates were not recorded at follow up visits, which may have identified a 
risk factor for restenosis/occlusion or disease progression and hence treatment failure.  
• Not all patients referred for exercise took up the structured exercise class (125 
invited and 51 were enrolled into the trial). Many patients declined to participate for a 
number of reasons including transport availability to the class. Once they had begun the 
SEP the drop-out rate from the classes was less than 10%.  
• There was a drop-out rate from both groups throughout the study, and at 12 months 
18 patients had dropped out of the angioplasty group and 28 from the exercise group 
(Appendix 18). 
• This work contains multiple statistical comparisons and therefore there is a violation 
of the familywise error rate. This will result in an increased likelihood that statistical 
significance will appear where there may be no clinical significance due to the large 
number of tests performed (i.e. a type I error). There are several methods to adjust for 
multiple testing, which include the Bonferroni and Holm methods (Aickin and Gensler 
1996) which reduce the type I error rate. There have been several cautions proposed to such 
adjustments, most notably that the reduced type I error rate leads to the converse occurring, 
i.e. that there is an increased type II error rate (Perenger 1998). In this particular study, no 
adjustment was used partially owing to the massive type II error rate inflation that would 
occur from the large number of variables analysed. In addition, this study was powered for 
the primary hypotheses to compare baseline to 3 months; combining these two time points 
with the other two time points (i.e. 6 and 12 months) would require greater sample sizes. As 
this comparison was not powered for in this study, it is likely to be underpowered, 
particularly with the addition of the multiple testing corrections. As such, in all cases 
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significant and non-significant findings are also interpreted for clinical meaning and 
significant differences of no or uncertain clinical relevance have been discussed and 
discarded appropriately.   
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4.6 Future directions 
 
Specific randomised controlled trials (RCT) to consider would include the randomisation of 
patients with the same morphology of disease to each treatment arm. As previously 
discussed, in this study there were patients who were more suitable for angioplasty as a first 
line treatment and therefore randomisation was not appropriate for this cohort. However it 
would be possible to design a study specifically for patients who would be suitable for 
either treatment to then be randomised to determine treatment effect. Furthermore, an 
alternative RCT would be for patients having undergone angioplasty to then be randomised 
to SEP or no SEP to identify any cumulative benefit of both treatments, or an additional 
benefit of SEP.   
 
A future study investigating the impact of standard treatment on clinical indicators of lower 
limb ischaemia, physical function, balance, falls risk and quality of life in patients with 
critical limb ischaemia would be of interest and may demonstrate even further gains in 
terms of function. The most suitable RCT for this cohort may be to randomise patients after 
angioplasty to SEP or no SEP and assess function accordingly. 
 
Furthermore, modifications to the standard supervised exercise programme for claudicants 
could be made aimed at improving the gains in balance and physical function seen with the 
current programme. This might involve more targeted balance stations and more work to 
improve lower limb functional strength. This study proposed that one explanation for 
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improved function despite no improvement in ABPI from baseline among both angioplasty 
and exercise patients may result from improved levels of physical activity. Correlation with 
daily physical activity, either subjectively by asking patients directly or objectively, by 
measuring activity through accelerometers, pedometers and other devices, may confirm or 
refute this hypothesis. 
 
Other key areas of interest for the future work centre on the possible explanations for 
treatment effects. Histological examination of muscle biopsies pre and post treatment may 
identify changes brought on by exercise and angioplasty, and indeed differences between 
the 2 treatments. This would not be a straight forward study as muscle biopsies can be 
painful and patients may be reluctant to participate in that aspect of the study. Specifically 
to examine the reasons for improvement in balance with exercise treatment, central causes 
of balance function should be researched including concomitant cerebrovascular disease.  
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4.7 Conclusion  
 
This study highlights the impairments in physical function and balance among claudicants 
and recognises the link between balance abnormalities and falls risk. The relevance of 
balance and falls risk assessment specifically to vascular surgery has been clearly 
demonstrated by this study and this should act as a basis for on-going research to improve 
the functional outcome of vascular patients as well as purely improving their walking 
distance. The impact of research to improve functional outcome has the potential to be huge 
given our increasingly elderly population and improved survival into older age.  
 
This study alone does not offer a definitive answer to improving function. However it was 
found that treatment, either through angioplasty or a structured exercise programme, led to 
improvements in many of the measures of clinical indicators of lower limb ischaemia, 
physical function, balance, falls risk and quality of life in patients with lower limb 
ischaemia. Interestingly there were differences between the two treatment groups, in that 
angioplasty led to significant improvements in clinical indicators of lower limb ischaemia, 
markers of physical function that include an element of walking, history of falling or 
stumbling, fear of falling and quality of life, but improvements in balance were minimal. 
Balance was only slightly improved by angioplasty at 3 months following treatment. 
Exercise, however, led to marked improvements in balance throughout the year from 
baseline, with also significant improvements in walking distances, physical function and a 
history of stumbles. Quality of life improvements were seen at 3 and 6 months but not at 12 
months from baseline in the exercise group. 
 
190 
 
As has been discussed, the study was not randomised and therefore direct comparisons 
between the two treatment arms are limited. Future work, including randomising patients 
with similar disease morphology will improve the evidence for or against angioplasty and 
exercise in improving functional outcome. As some variables in this study did not improve 
with treatment, this work could be extended to study patients with critical limb ischaemia in 
whom additional functional gains might be expected given a poorer functional starting 
point.   
 
Falls risk and declining physical function will be an ever concerning issue with our ageing 
population. Therefore recognising patients at risk in all medical specialities and allied 
health disciplines will hopefully allow improvements in prevention, targeted treatment and 
consequent improvements in quality of life for those at risk.  
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Appendices 
Appendix 1. Patient letter and information sheet 
 
21
st
 January 2010 
 
Mr xx 
 
 
Dear Mr xx, 
 
I am writing to you to invite you to take part in a research study that we are undertaking in 
the Academic Vascular Unit at Hull Royal Infirmary. You are invited to take part in the 
trial because you have reduced circulation to your legs that causes pain when you walk and 
you are going to undergo treatment to try and improve the circulation. There is no 
compulsion for you to take part. I enclose an information sheet that tells you all about the 
trial. If you require any information then do not hesitate to contact me on 01482675523 or 
07736275213. If you wish to take part in the study then please complete the tear off slip at 
the bottom of this letter and return it in the stamped address envelope.  
 
Kind regards, 
 
 
 
Miss Katherine Mockford 
Clinical Research Fellow in Vascular Surgery 
 
 
Name:  
 
I wish / do not wish (please delete) to take part in the “The role of treatment on balance and 
stability in patients with intermittent claudication.” study. 
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PATIENT/SUBJECT INFORMATION LEAFLET 
 
The role of treatment on balance and stability in patients with intermittent 
claudication: A pilot study. 
 
You are invited to take part in a research study. Before you decide it is important for you to 
understand why the research is being done and what it will involve. Please take time to read 
the following information carefully and discuss it with friends, relatives and your GP if you 
wish. Ask us if there is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part.  
 
What is the purpose of this study? 
Patients with pains in their legs on walking caused by problems with their circulation 
(known as intermittent claudication) are more likely to experience a fall due to poor 
balance. Falls are associated with reduced mobility and a lower quality of life. No one 
knows what causes patients with intermittent claudication to fall and whether standard 
treatments aimed at improving the circulation and subsequently distances that you can walk 
also improve the balance of patients with poor circulation. Therefore, the goal of this study 
is to assess whether standard forms of treatment in patients with poor circulation to their 
legs improve balance and stability. 
 
Why have I been invited? 
You have been invited to participate in this study because you suffer from poor circulation 
to your legs (intermittent claudication) and the consultant in charge of your care in 
discussion with you has arranged for you to undergo either exercise treatment, or stretching 
of your arteries with a balloon (also known as angioplasty) or surgery to try and improve 
the distances that you can walk. The exercise programme consists of three sessions per 
week over a three months period and each session lasts for no more than one hour.  
 
What will happen if I decide to take part? 
If you decide to take part in this study, you will be invited to the Vascular Laboratory at 
Hull Royal Infirmary and the Human Performance Laboratory in the Department of Sport, 
Health and Exercise Science at the University of Hull, Cottingham. If you do not have your 
own transportation, it will be arranged for you by the Vascular Laboratory.  
 
When you arrive at the Vascular Laboratory, you will be asked to complete some 
questionnaires. These questionnaires are used to rate your perceived fear of falling, balance 
confidence and quality of life. You will also be asked to perform a number of walking tests 
performed at your own speed well as a test of your ability to stand up from a chair. One of 
the walking test is a treadmill test. This forms part of the normal assessment that you would 
undertake even if you were not in this study. You will also be asked to walk on the 
treadmill for a maximum of 5 minutes at a slow pace. The tests will be undertaken at the 
same time as your routine visit to the vascular laboratory for the assessment of your 
circulation. 
 
The second part of the assessment will take place at the University of Hull. You will 
complete a number of short tests on a platform that measures your balance control. For your 
own safety, you will be fitted with a security harness around your torso and waist. By 
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wearing a harness, the performance environment in which you will undertake the testing 
protocol is much safer. We will need to place some stickers on your legs to assess nerve 
and muscle function. They are small (about the size of a large postage stamp) but require a 
hair free area for best function. This means that if you are male you may need to shave a 
very small patch of hair from your lower leg so that the sticker will stick. You will be asked 
to bring a pair of shorts, comfortable shoes (no high heels!) and t-shirt. Shorts will be 
provided if you do not have a pair. If you do not have your own transportation, it will be 
arranged for you by the University. You will be reimbursed for the cost of travel to and 
from the University of Hull if you use your own transport. 
 
Only if you have been recommended to undergo an exercise training programme, this will 
involve three visits per week to the physiotherapy gym at Hull Royal Infirmary over a three 
months period with each session lasting no more than one hour. The session is run by a 
physiotherapist with a doctor present and the exercises are started lightly initially and 
increased as time goes on. The exercise training is not standard treatment in the NHS but 
results from studies already performed in Hull have found encouraging results with regard 
to improving walking distances and quality of life.  
 
What do I have to do? 
To take part in this study, you will need to visit the both the Vascular Laboratory at Hull 
Royal Infirmary as part of your normal vascular assessment which will take approximately 
one hour and the Human Performance Laboratory at the University of Hull for 
approximately 30 minutes.  
These assessments will be undertaken prior to your treatment and then at 3, 6 and 12 
months after your treatment. This results in a total of four visits to both sites over a year 
long period.  
 
Do I have to take part? 
Participation in this study is entirely voluntary. 
You may refuse to participate or withdraw from the study at any time. You do not need to 
tell the researchers why you do not want to take part. If you decide to take part you are still 
free to withdraw at any time without giving a reason. This will not affect the standard of 
care you receive. If you choose to withdraw or not to participate, your decision will in no 
way affect your future treatment. It may be that the investigator or sponsor of the study 
consider that it is in your interests to withdraw you or stop the study altogether.  
 
Are there any risks involved? 
Appropriate safety measures will be taken at all times. Very occasionally, you may get a 
feeling that you are going to fall when performing the balance tests at the Human 
Performance Laboratory but the safety harness will hold you up.  
 
Are there any costs involved? 
No 
 
What if new information becomes available? 
Sometimes during the course of a research project, new information becomes available 
about the treatment that is being studied. If this happens your research doctor will tell you 
about it and discuss with you whether you want to continue in the study. If you decide to 
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withdraw your research doctor will make arrangements for your care to continue. If you 
decide to continue in the study you will be asked to sign an updated consent form. 
Also on receiving new information your research doctor might consider it to be in your best 
interests to withdraw you from the study. He/she will explain the reasons and arrange for 
your care to continue. 
 
What happens when the research study stops? 
When the study is complete, you will if required be referred back to your original vascular 
surgeon for continued management. 
 
What if something goes wrong? 
In the unlikely event that you suffer from injury or illness as a result of participation in this 
study, indemnity will be provided by the Hull and East Yorkshire hospitals NHS Trust. 
Compensation will be by the usual NHS procedures. 
 
Will my taking part in the study be kept confidential? 
All information which is collected about you during the course of the research will be kept 
strictly confidential. Any information about you which leaves the hospital will have your 
name and address removed so that you cannot be recognised from it. If you consent to 
participate in the trial we will inform your GP unless this is against your wishes.  
 
What will happen to the results of the research study? 
The overall results will be published in leading scientific and medical journals in 
approximately 3 years. Your confidentiality will be preserved in all published articles.  
We would be happy to supply you with a copy of the results on request. 
 
Who is organising and funding the study? 
This study is funded by the academic vascular unit, hull royal infirmary. 
 
Who has reviewed this study?  
The ethics behind this study have been reviewed and supported by the South Humber Local 
Research Ethics Committee. 
 
Thank you for taking the time to read this information sheet and consenting to participate in 
the study. You will be given a copy of this information sheet and a copy of your consent to 
participate form. If you have any further queries or questions please don't hesitate to contact 
Miss Katherine Mockford (Clinical Research Fellow in Vascular Surgery; telephone 
number 01482675523 / 07736275213).  
 
Thank you. 
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Appendix 2. Data collection proforma, consent form and letters 
 
Initial Assessment  
 
Date of assessment:      
 
Study Patient ID:    
Surname:  Forename:  
DOB:  Age:  
Unit Number:    
    
Intervention: Single Visit PTA SEP Surgery 
    
Risk factors: Specify Hx Medication 
IHD / MI    
Hypertension     
    
Hypercholesterolaemia    
Cerebrovascular 
disease 
   
Diabetes mellitus    
Smoking    
OA    
Neurological disease    
Other medical history    
    
    
    
Other medication    
    
Allergies    
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Clinical Examination  
Initial Assessment 
Date of assessment:      
 
Study Patient ID:  
Pulse:  Visual Acuity Rt  
Systolic BP  Visual Acuity Lt  
Diastolic BP    
    
 Right Left  
Femoral    
Popliteal    
Dorsalis Pedis    
Posterior Tibial    
Ankle Pressure    
ABPI pre exercise    
Ankle pressure post    
ABPI post exercise    
Treadmill ICD    
Treadmill MWD    
PRWD    
Height    
Weight    
BMI   
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Neurological Assessment 
 
Light Touch (abnormalities) 
 
 
Pin prick (abnormalities) 
 
 
 
Power Right Left 
Hip Flexors   
Hip 
Extensors 
  
Knee Flexors   
Knee 
Extensors 
  
Ankle 
Dorsiflexion  
  
Ankle 
Plantarflexion 
  
 
 
Reflex Right Left 
Knee   
Ankle   
Plantar   
 
Other neurological deficiencies 
 
 
 
 
 
Hand grip 
strength 
Right Left 
1   
2   
3   
Mean   
 
Skin Thickness Measurement 
 
 1 2 3 mean 
Triceps     
Biceps     
Suprailiac     
 
Mid-calf circumference (cm) 
 
Right 
 
Left  
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Table 1— Toronto Clinical 
Neuropathy Score  
Symptom 
scores 
Reflex 
scores 
Sensory test 
scores 
 
Foot pain Knee 
reflexes 
Pinprick 
Numbness Ankle 
reflexes 
Temperature 
Tingling  Light touch 
Weakness  Vibration 
Ataxia  Position 
sense 
Upper 
limb 
symptoms 
  
 
Symptom scores: present = 1, 
absent = 0; reflex scores: absent = 
2, reduced = 1, normal = 0; sensory 
test scores: abnormal = 1, normal = 
0; total scores range from normal = 
0 to maximum of 19.  
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Outcome Measures  
Initial Assessment 
Date of assessment:      
 
Quality of life scores Functional Assessments 
SF 36  
PF  Chair stand test 
(time - s) 
 
RP   
BP  Semi tandem  
GH  Full tandem  
V  
RE  
MH  
SF  
PS  
MS  
  
VascuQol  
Activity  Other  
Symptoms  Overall  
Pain    
Emotional    
 
Chair Stand Test 
Using a standard chair with arms and with a seat height of approximately 17 inches for all assessments, 
regardless of the height of the subject. Place the back of the chair against a wall to prevent movement 
during the test. The patient is instructed to sit as far back as possible in the chair seat. They are then asked 
to stand up one time and sit down, returning completely to the correct starting position. The time taken to 
perform 5 repetitions is recorded. Two trials are performed separated by three minutes. 
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Outcome Measures  
Initial Assessment 
Date of assessment:      
 
Activities-specific Balance Confidence 
(ABC-UK) Scale 
  
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
11    
12    
13    
14    
15    
16    
Overall %    
    
Fall in last year Yes No  
Stumble in last year Yes No  
 
 
Fall: Unintentionally coming to rest in the ground or at some other level not as a result 
of an overwhelming hazard that would result in a fall by most young healthy people. 
 
Stumble: Loss of balance that was restored before a fall occurred. 
Unsteadiness: Routine or regular sense of difficulty with balance while walking. 
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Data collected from Uni of Hull Site 
 
1. Equitest 
2. TUG test 
3. 4 metre walk velocity 
4. Walking distance (6 minute walk) 
 
 
TUG test Time (s) 
1  
2  
3  
Best  
  
ICD 
Time  
Distance  
MWD 
Time  
Distance  
Four metre walk velocity test 
Usual speed  
Fastest speed  
 
Timed, Up, and Go Test (TUG) 
 
The timed "Up & Go" test measures, in seconds, the time taken by an individual 
to stand up from a standard arm chair (approximate seat height of 46 cm, arm 
height 65 cm), walk a distance of 3 meters (approximately 10 feet), turn, walk 
back to the chair, and sit down again. The subject wears his/her regular footwear. No 
physical assistance is given. 
 
The 4 Meter Walking Velocity Test 
 
Walking velocity is measured with a 4-meter walk performed
 
at usual pace and at fastest 
pace. Each walk is performed twice. The
 
faster walk in each pair is used in analyses.  
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Patient ID number; 
 
Consent Form 
Title of project;  
The role of treatment on balance and stability in patients with intermittent 
claudication. 
 
Names of researchers;  
Prof. PT McCollum MCh, FRCS. Professor of Vascular Surgery. Hull and East 
Yorkshire NHS Trust 
Mr IC Chetter MBChB FRCS. Senior Lecturer in Vascular Surgery. Hull and East 
Yorkshire NHS Trust 
Mr Patrick Coughlin MRCS. SpR in Vascular Surgery, Vascular Surgery, Hull and East 
Yorkshire NHS Trust. 
Miss K Mockford, MRCS Research Fellow in Vascular Surgery, Vascular Surgery, Hull 
and East Yorkshire NHS Trust. 
 
Contact Address:     Telephone No: 01482 674643 
Academic Vascular Unit    Fax No: 01482 675665  
Ward 100, Hull Royal Infirmary     
Anlaby Road, Hull HU3 2JZ 
 
Treatment arm (please circle): Exercise  Angioplasty  Surgery 
 
         Please initial box 
1 I confirm that I have read and understand the information sheet dated for the 
above study and have had the opportunity to ask questions. 
 
2 I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights 
being affected.         
 
 
3 I agree to take part in the above study.     
  
 
____________________________  _____ _________________________ 
Name of Subject (BLOCK CAPITALS) Date  Signature 
 
 
 
______________________________ _____ _________________________ 
Name of Person taking consent  Date  Signature 
    
 
 
 
______________________________ _____ __________________________ 
Researcher/witness    Date  Signature 
 
1 for patient, 1 for researcher, 1 to be kept with hospital notes  
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LETTER TO PATIENT’S GP 
 
Date 29/07/2013 
 
Dear Dr xxxxxx 
 
Re: <Patient Name and Address>. 
 ……………………………………. 
 ……………………………………. 
 
The role of treatment on balance and stability in patients with intermittent claudication. 
 
I am writing to inform you that your patient has been enrolled into the above research study. 
The consultant in charge of their case has following discussion advised your patient to undergo 
exercise training, angioplasty, surgery (delete as required) to help improve the symptoms that 
they have in their legs. Patients with intermittent claudication are known to have poor balance 
and stability that predispose to falls. Falls are associated with decreased independence and 
mobility and a lower quality of life. Virtually no studies have investigated the effect of 
intervention in claudicants upon balance and stability. Therefore, the goal of this project is to 
determine the role of intervention upon balance and stability in claudicants. There will be no 
deviation from standard treatment and patients will be recruited following a decision to treat has 
been made. 
The study will collect data on walking distance (both patient reported and treadmill) as well as 
assessing balance using a well validated questionnaire. Quality of life indicators specific to this 
group of individuals will also be considered using validated questionnaires. Performance data 
will be collected when the participant visits the Human Performance Laboratory in the 
Department of Sport, Health and Exercise Science at the University of Hull. The study length is 
one year with visits prior to and at 3, 6 and 12 months after intervention. If you have any 
questions regarding any of the above, please feel free to contact me on 01482 466212. 
 
Yours sincerely, 
 
 
 
Miss Katherine Mockford 
Clinical Research Fellow Vascular Surgery 
Academic Vascular Unit 
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Mr.  
Consultant Vascular Surgeon 
Hull Royal Infirmary 
Hull 
 
29 July 2013 
 
Dear Mr.  
 
Re: DOB: Unit Number: 
 
 
The above patient who is due to undergo an angioplasty underwent an assessment prior 
to angioplasty in the “The role of treatment on balance and stability in patients with 
intermittent claudication.” study. The following measurements were obtained. 
 
Treadmill ICD   metres 
Treadmill MWD   metres  
Pre ABPI: Right    Left   
Post ABPI:  Right    Left  
This patient will be seen again in three months after the PTA as part of this study. Many 
thanks for allowing this patient to take part. Please find enclosed a copy of the consent 
form for the hospital notes. 
 
Kind Regards 
 
 
 
 
Miss Katherine Mockford 
Clinical Research Fellow Vascular Surgery 
Academic Vascular Unit 
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Appendix 3. Activities-specific Balance Confidence (ABC-UK) 
Scale 
 
 
Instructions 
As you read each statement, remember there is no right or wrong answer. Just think 
about how confident you are to execute each activity. Do this by making a mark through 
the line anywhere along the line from ‘no-confidence’ to ‘complete confidence’. 
 
(1) Walk around the house 
 
 no        complete 
 confidence       confidence 
 
 
 
(2) Go up and down stairs 
 
 no        complete 
 confidence       confidence 
 
 
 
(3) Pick up a slipper from the floor 
 
 no        complete 
 confidence       confidence 
 
 
 
 
(4) Reach at eye level 
 
 no        complete 
 confidence       confidence 
 
 
 
 
(5) Reach on tiptoes 
 
 no        complete 
 confidence       confidence 
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(6) Stand on a chair to reach 
 
 no        complete 
 confidence       confidence 
 
 
 
 
(7) Sweep the floor 
 
 no        complete 
 confidence       confidence 
 
 
 
 
(8) Walk outside to a nearby car 
 
 no        complete 
 confidence       confidence 
 
 
 
 
(9) Get in/out of a car 
 
 no        complete 
 confidence       confidence 
 
 
 
 
(10) Walk across a car park to the shops 
 
 no        complete 
 confidence       confidence 
 
 
 
 
(11) Walk up and down ramp 
 
 no        complete 
 confidence       confidence 
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(12) Walk in a crowded shopping centre 
 
 no        complete 
 confidence       confidence 
 
 
 
 
(13) Walk in a crowd/ be bumped 
 
 no        complete 
 confidence       confidence 
 
 
 
 
(14) Travel on an escalator holding the rail  
 
 no        complete 
 confidence       confidence 
 
 
 
 
(15) Travel on an escalator not holding a rail 
 
 no        complete 
 confidence       confidence 
 
 
 
 
(16) Walk on an icy pavement 
 
 no        complete 
 confidence       confidence 
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Appendix 4. Patient demographics at baseline 
 All patients Angioplasty Exercise P 
N 98 47 51  
Age (years) 
- Median (IQR) 
 
69 (64-75) 
 
69 (63-76) 
 
70 (64-74) 
 
0.817 
NS 
Age group (years) 
- 20-59 
- 60-69 
- 70-79 
-  80 
 
12 
40 
34 
12 
 
6 
21 
13 
7 
 
6 
19 
21 
5 
0.683 
NS 
Gender 
- M 
- F 
 
67 
31 
 
33 
14 
 
34 
17 
0.708 
NS 
IHD 
- None 
- MI 
- Angina 
- Other 
- unknown 
 
55 
18 
10 
14 
1 
 
27 
6 
7 
7 
0 
 
28 
12 
3 
7 
1 
0.647 
NS 
Hypertension 
- No 
- Yes 
- unknown 
 
26 
70 
1 
 
15 
32 
0 
 
11 
38 
2 
0.273 
NS 
Cholesterol management 
- on statin 
- no statin 
- unknown 
 
79 
18 
1 
 
35 
12 
0 
 
44 
6 
1 
0.088 
NS 
CVA 
- none 
- TIA 
- CVA 
- unknown 
 
79 
8 
10 
1 
 
37 
5 
5 
0 
 
42 
3 
5 
1 
0.654 
NS 
Diabetes 
- none 
- diet controlled 
- tablet controlled 
- insulin controlled 
- unknown 
 
73 
4 
16 
4 
1 
 
38 
2 
7 
0 
0 
 
35 
2 
9 
4 
1 
0.195 
NS 
Smoking 
- never smoked 
- ex-smoker 
- current smoker 
- unknown 
 
14 
56 
27 
1 
 
6 
29 
12 
0 
 
8 
27 
15 
1 
0.475 
NS 
Osteoarthritis 
- none 
- back 
- lower limb 
- upper limb 
- unknown 
 
42 
16 
34 
5 
1 
 
17 
8 
20 
2 
0 
 
25 
8 
14 
3 
1 
0.188 
NS 
Hip or knee replacement 
- none 
- yes 
- unknown 
 
92 
5 
1 
 
45 
2 
0 
 
47 
3 
1 
0.699 
NS 
Previous vascular Interventions 
- none 
- same leg angioplasty 
- other leg angioplasty 
- other leg surgery 
 
56 
18 
8 
3 
 
26 
8 
6 
1 
 
30 
10 
2 
2 
0.550 
NS 
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- same leg surgery 
- unknown 
2 
11 
0 
6 
2 
5 
Visual acuity 
- 6/9 or 6/6 
- 6/12 
- Worse 
- missing 
 
53 
13 
14 
18 
 
33 
4 
4 
6 
 
20 
9 
10 
12 
0.070 
NS 
Height 
- Median 
- (IQR) 
 
167 
(161-173) 
 
169 
(159-173.3) 
 
167 
(162-173) 
0.887 
NS 
Weight 
- Median 
- (IQR) 
 
78.25 
(69-90.75) 
 
80 
(69-92.5) 
 
77 
(68-86) 
0.700 
NS 
BMI 
- Median 
- (IQR) 
 
28.21 
(25.54-30.61) 
 
28.41 
(25.35-31.1) 
 
27.7 
(25.63-30.4) 
0.665 
NS 
 
Values are expressed as median (IQR, interquartile range) or as numbers (N). M (male), F (female), BMI 
(body mass index). * 1 subject did not declare their medical history and therefore there is one set of 
missing data throughout the medical history section. Yes / No. (Y/N). Cerebrovascular accident (CVA), 
transient ischaemic attack (TIA). Osteoarthritis (OA). Visual acuity fractions; 6/6 is normal vision, 6/9 
indicated that at 6 metres the smallest row of letters the tested eye can discern would be what a normal 
eye can read at 9 metres, this applies to 6/12 but represents what a normal eye can read at 12 metres. 
Exercise and angioplasty groups were compared using Mann Whitney U test and P values are given. If P 
> 0.05 non significance is also expressed as NS.  
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Appendix 5. Clinical indicators of lower limb ischaemia for 
angioplasty patients 
 Baseline 
N=47 
3 months 
 
6 months 
 
12 months 
 
P 
Pre exercise ABPI median (IQR) 
- Right leg 
- Left leg 
- Symptomatic leg 
 
0.87 (0.72-1.00) 
0.86 (0.69-0.95) 
0.78 (0.61-0.92) 
 
0.96 (0.87-1.07) 
0.93 (0.86-1.03) 
0.90 (0.77-0.99) 
 
 
0.96 (0.70-1.13) 
0.85 (0.68-1.07) 
0.81 (0.60-0.99) 
 
0.89 (0.83-1.00) 
0.87 (0.77-0.99) 
0.85 (0.76-0.90) 
 
a0.001  
b0.091  
c0.311  
d0.306 
e0.026  
f0.856 
Post exercise ABPI 
- Right leg 
- Left leg 
- Symptomatic leg 
 
0.52 (0.31-0.84) 
0.67 (0.39-0.89) 
0.38 (0.25-0.63) 
 
0.78 (0.54-1.03) 
0.78 (0.56-0.92) 
0.63 (0.43-0.82) 
 
0.66 (0.44-1.00) 
0.63 (0.48-1.00) 
0.47 (0.40-0.73)  
 
0.84 (0.51-0.94) 
0.70 (0.50-0.86) 
0.60 (0.40-0.86)  
a0.002  
b0.078 
c0.035  
d0.192 
e0.162 
f0.841 
Post exercise ankle pressure 
(mmHg) 
66 (42-108) 98 (70-129) 80 (61-113)  80 (54-128)  a0.015  
b0.157 
c0.139  
d0.148  
e0.036  
f0.575 
Rutherford categories N 
- No claudication 
- Mild claudication 
- Moderate claudication 
- Severe claudication 
- Missing 
 
0 
4 
28 
13 
2 
 
17 
5 
14 
5 
6 
 
4 
5 
13 
2 
23 
 
7 
3 
15 
3 
19 
 
Treadmill completion N 
- Claudication felt during 
test 
- No claudication felt 
- Test stopped prematurely 
- Claudication stopped test 
- Test completed  
 
41 
 
1 
2 
37 
5 (4 with pain) 
 
18 
 
15 
6 
18 
15 
 
17 
 
4 
3 
13 
7 
 
19 
 
7 
2 
15 
9 
 
Treadmill ICD (m) median (IQR) 32.6 (19.13-
53.95) 
36 (26.5-45.25) 47 (37.5-140.5)  46 (34-78)  a0.015  
b0.002  
c0.052 
d0.041  
e0.012  
f0.575 
Treadmill MWD (m) 62.9 (39.48-
123.75) 
112 (64-215) 85 (59.25-215)  104.5 (68.25-
215)  
a0.001  
b0.003  
c0.007  
d0.102 
e0.089 
f0.198 
PRWD (m) 136 (90-370) 888 (247.5-888) 650 (210-888)  450 (90-888)  a<0.001  
b0.001  
c0.030 
d0.859 
e0.859  
f0.635 
 
Values are expressed as median (IQR, interquartile range) or as numbers (N). ABPI (ankle brachial 
pressure index, ICD (intermittent claudication distance), MWD (maximum walking distance), PRWD 
(patient reported walking distance). Each time point was compared to another using the Wilcoxon signed 
ranks test and P values are given. Significant P values of < 0.05 are highlighted in bold. Time points 
compared are as follows: 
a
baseline compared to 3 months, 
b
baseline compared to 6 months, 
c
baseline 
compared to 12 months, 
d
3 months compared to 6 months, 
e
3 months compared to 12 months and 
f
6 
months compared to 12 months.  
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Appendix 6. Physical function for angioplasty patients  
 Baseline  3 months 6 months 12 months P 
Short performance physical 
battery  
(Median, IQR) 
- 0-6 (N) 
- 7-9 
- 10-12 
- missing 
 
 
9 (8-11) 
5 
21 
19 
2 
 
 
10 (9-12) 
3 
9 
30 
5 
 
 
10.5 (8.75-11) 
1 
8 
13 
25 
 
 
10 (9-11) 
1 
12 
16 
18 
a0.011 
b0.001 
c0.002 
d0.438 
e0.882 
f0.593 
4 metre walk at usual pace 
(m/s) 
 - Median, IQR 
1.00 (0.74-1.15) 1.05 (0.83-1.19) 1.02 (0.83-1.15) 1.03 (0.81-1.19) a0.133 
b0.002 
c <0.001 
d0.139 
e0.004 
f0.149 
4 metre walk at fastest pace 
(m/s) 
 - Median, IQR 
1.31 (0.93-1.53) 1.36 (1.03-1.56) 1.33 (0.96-1.48) 1.27 (1.00-1.60) a0.026 
b0.003 
c0.002 
d0.020 
e0.003 
f0.602 
Chair stand test (s) 
 - Median, IQR 
17.02 (12.31-
20.55) 
13.53 (9.82-16.2) 13.5 (11.16-
16.54) 
13.27 (11.91-
22.08) 
a0.004 
b0.002 
c0.315 
d0.394 
e0.107 
f 0.016 
Semi tandem stance (N) 
- < 10 s 
- 10-29 s 
- 30 s 
- missing 
(Median, IQR) (s) 
 
6 
8 
33 
0 
30 (19.4-30) 
 
5 
2 
37 
3 
30 (30-30) 
 
2 
3 
20 
22 
30 (30-30) 
 
3 
2 
24 
18 
30 (30-30) 
a0.118 
b0.314 
c0.041 
d0.600 
e0.917 
f0.600 
Full tandem stance (N) 
- < 10 s 
- 10-29 s 
- 30 s 
- missing 
(Median, IQR) (s) 
 
12 
12 
23 
0 
29 (8.9-30) 
 
10 
5 
29 
3 
30 (11.66-30) 
 
6 
5 
14 
22 
30 (10.02-30) 
 
6 
5 
18 
18 
30 (11.1-30) 
a0.446 
b0.363 
c0.010 
d0.959 
e0.778 
f0.158 
 
Handgrip strength (kg) 
- Right hand 
(Median, IQR) 
 
26.24 (18.61-
40.4) 
 
 
31.8 (22.55-
40.44) 
 
 
26.9 (18.84-
37.32) 
 
 
28.64 (22.07-
36.73) 
 
a0.548 
b0.075 
c0.234 
d0.451 
e0.006 
f0.287 
Handgrip strength (kg) 
- Left hand 
(Median, IQR) 
 
29.05 (18.12-
37.63) 
 
30.47 (21.92-
38.58) 
 
26.97 (15.9-38.2) 
 
27.6 (20.92-
36.22) 
a0.130 
b0.249 
c0.010 
d0.551 
e0.054 
f0.862 
6 minute walk  
- ICD distance (m) 
 
85 (52.5-120) 
 
140 (45-190) 
 
200 (110-323) 
 
160 (100-210) 
 
a0.015  
b0.002 
c0.043 
d0.021 
e0.312 
f0.726 
- MWD distance (m) 
 
200 (120-380) 
 
360 (170-440) 
 
358 (200-440) 
 
335 (170-415) 
 
a0.001 
b0.001 
c0.211  
d0.008 
e0.365 
f0.814 
- ICD time (s) 
 
78.5 (56.25-
109.25) 
 
110 (57-164) 
 
210 (116-255) 
 
140 (105-196) 
 
a0.008 
b0.004 
c0.078 
d0.091 
e0.213 
f0.397 
- MWD time (s) 196 (111.5-330) 204 (300-360) 300 (224-360) 300 (188-360) a0.005 
b0.005 
c0.199 
d0.043 
212 
 
e0.479 
f0.933 
 
Values are expressed as median (IQR, interquartile range) or as numbers (N). ICD (intermittent 
claudication distance), MWD (maximum walking distance). Each time point was compared to another 
using the Wilcoxon signed ranks test and P values are given. Significant P values of < 0.05 are 
highlighted in bold. Time points compared are as follows: 
a
baseline compared to 3 months, 
b
baseline 
compared to 6 months, 
c
baseline compared to 12 months, 
d
3 months compared to 6 months, 
e
3 months 
compared to 12 months and 
f
6 months compared to 12 months.  
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Appendix 7a. Balance assessment for angioplasty patients 
 Baseline 3 months 6 months 12 months P 
Sensory organisation 
test 
- Pass 
- Fail 
- Missing 
 
 
29 
18 
0 
 
 
30 
12 
5 
 
 
15 
7 
25 
 
 
19 
10 
18 
a,b,c,d,e,fNS 
SOT composite score 
Median (IQR) 
70 (61-79) 73 (65-82) 
 
74 (62.5-77.75) 68 (32.5-76) a0.033 
b,c,d,e,fNS 
SOT mean trial score 
for each condition 
- Condition 1 
- Condition 2 
- Condition 3 
- Condition 4 
- Condition 5 
- Condition 6 
Median (IQR) 
 
 
95 (93-96) 
91.33 (85.67-93.33) 
89.66 (83.33-94.33) 
82 (66-85.67) 
56 (22.33-66) 
42 (17.66-63.37) 
 
 
95.33 (92.92-95.75) 
90.5 (88.25-93.42) 
89.67 (85.59-94.33) 
85.84 (81.25-88.08) 
57 (46.75-69) 
48.34 (19.50-64.42) 
 
 
94.5 (92.5-95.84) 
91.67 (85.59-93.42) 
88.5 (84.75-91.84) 
83.5 (77.17-88.08) 
54.67 (48.42-65.59) 
52.84 (20.08-69.67) 
 
 
95 (91.84-95.67) 
90.33 (87.5-93.67) 
88.33 (82.84-91) 
81.67 (75.33-86) 
51.67 (37.5-61.33) 
46 (23.5-58.5) 
 
 
a,b,c,d,e,fNS 
a,b,c,d,e,fNS 
a,b,c,d,e,fNS 
* (see below) 
b,c,d,e,f,gNS 
b,c,d,e,f,gNS 
 
* a0.009, 
b0.012,  
c0.038,d0.
039, 
e,fNS 
SOT Sensory analysis 
(N) 
- Somatosensory  
- Visual  
- Vestibular  
- Preferential  
Pass/fail 
 
 
39 / 8 
35 / 11 
28 / 18 
40 / 6 
 
 
40 / 2 
37 / 5 
30 / 12 
34 / 8 
 
 
20 / 2 
19 / 3 
15 / 7 
16 / 6 
 
 
25 / 4 
24 / 5 
17 / 12 
26 / 3 
 
 
a,b,c,d,e,fNS 
a,b,c,d,e,fNS 
a,b,c,d,e,fNS 
a,b,c,d,e,fNS 
SOT falls (N) 
- Any falls 
- Abnormal hip 
strategy 
- Abnormal ankle 
strategy 
No/Yes 
 
27 / 20 
33 / 14 
 
40 / 11 
 
22 / 20 
34 / 8 
 
24 / 18 
 
13 / 9 
19 / 3 
 
15 / 7 
 
 
17 / 12 
28 / 1 
 
17 / 12 
 
a,b,c,d,e,fNS 
a,b,d,e,fNS, 
c0.005 
a,b,c,d,e,fNS 
 
Motor control test – 
weight symmetry (N) 
- To backwards 
Translations 
- To forwards 
Translations 
Normal / abnormal 
 
 
44 / 2 (1 missing) 
 
44 / 2 (1 missing) 
 
 
38 / 3 (6 missing) 
 
39 / 2 
 
 
18 / 4 
 
20 / 2 
 
 
25 / 2 
 
24 / 3 
 
 
a,b,c,d,e,fNS 
 
a,b,c,d,e,fNS 
 
Motor control test – 
latency (N) 
- Normal / 
abnormal 
 
 
38 / 8 (1 missing) 
 
 
38 / 2 
 
 
18 / 4 
 
 
24 / 4 
 
 
a,b,c,d,e,fNS 
Motor control test – 
response strength (N) 
- To backwards 
Translations 
- To forwards 
Translations 
Normal / abnormal 
 
 
39 / 7 (1 missing) 
 
28 /18 (1 missing) 
 
 
34 / 7 
 
28 / 13 
 
 
21 / 2 
 
14 / 8 
 
 
26 / 1 
 
21 / 6 
 
 
a,b,c,d,e,fNS 
 
a,b,c,d,e,fNS 
 
 
MCT composite score 
Median (IQR) 
142 (134-151) 145 (135.5-149) 146.5 (135-151.25) 140.5 (136-148) a,b,c,dNS 
e0.004 
f0.043 
 
Values are expressed as median (IQR, interquartile range) or as numbers (N). Each time point was 
compared to another using the Wilcoxon signed ranks test (continuous data) Chi squared test (categorical 
data) and a P value of > 0.05 is expressed as NS (non-significant). P values of < 0.05 are given. Time 
points compared are as follows: 
a
baseline compared to 3 months, 
b
baseline compared to 6 months, 
c
baseline compared to 12 months, 
d
3 months compared to 6 months, 
e
3 months compared to 12 months 
and 
f
6 months compared to 12 months. 
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Appendix 7b. Balance assessment for angioplasty patients 
with specified P values 
 Baseline 3 months 6 months 12 months P 
Sensory organisation 
test 
- Pass 
- Fail 
- Missing 
 
 
29 
18 
0 
 
 
30 
12 
5 
 
 
15 
7 
25 
 
 
19 
10 
18 
a0.333 
b0.602 
c0.738 
d0.787 
e0.596 
f0.842 
SOT composite score 
Median (IQR) 
70 (61-79) 73 (65-82) 
 
74 (62.5-77.75) 68 (32.5-76) a0.033 
b0.154 
c0.965 
d0.678 
e0.615 
f0.463 
SOT mean trial score 
for each condition 
- Condition 1 
Median (IQR) 
 
 
95 (93-96) 
 
 
 
95.33 (92.92-95.75) 
 
 
 
94.5 (92.5-95.84) 
 
 
 
95 (91.84-95.67) 
 
a0.822 
b0.466 
c0.478 
d0.811 
e0.515 
f0.333 
SOT mean trial score 
for each condition 
- Condition 2 
Median (IQR) 
91.33 (85.67-93.33) 
 
90.5 (88.25-93.42) 
 
91.67 (85.59-93.42) 
 
90.33 (87.5-93.67) 
 
a0.521 
b0.088 
c0.767 
d0.601 
e0.753 
f0.962 
SOT mean trial score 
for each condition 
- Condition 3 
Median (IQR) 
89.66 (83.33-94.33) 
 
89.67 (85.59-94.33) 
 
88.5 (84.75-91.84) 
 
88.33 (82.84-91) 
 
a0.291 
b0.808 
c0.201 
d0.433 
e0.076 
f0.231 
SOT mean trial score 
for each condition 
- Condition 4 
Median (IQR) 
82 (66-85.67) 
 
85.84 (81.25-88.08) 
 
83.5 (77.17-88.08) 
 
81.67 (75.33-86) 
 
a0.009 
b0.012  
c0.038 
d0.039 
e0.124 
f0.831 
SOT mean trial score 
for each condition 
- Condition 5 
Median (IQR) 
56 (22.33-66) 
 
57 (46.75-69) 
 
54.67 (48.42-65.59) 
 
51.67 (37.5-61.33) 
 
a0.050 
b0.573 
c0.788 
d0.272 
e0.390 
f0.642 
SOT mean trial score 
for each condition 
- Condition 6 
Median (IQR) 
42 (17.66-63.37) 48.34 (19.50-64.42) 52.84 (20.08-69.67) 46 (23.5-58.5) a0.317 
b0.341 
c0.946 
d0.670 
e0.584 
f0.570 
SOT Sensory analysis 
(N) 
- Somatosensory  
Pass/fail 
 
 
39 / 8 
 
 
 
40 / 2 
 
 
 
20 / 2 
 
 
 
25 / 4 
 
a0.068 
b0.383 
c0.708 
d0.497 
e0.179 
f0.606 
SOT Sensory analysis 
(N) 
- Visual  
Pass/fail 
35 / 11 
 
37 / 5 
 
19 / 3 
 
24 / 5 
 
a0.145 
b0.327 
c0.492 
d0.842 
e0.525 
f0.726 
SOT Sensory analysis 
(N) 
- Vestibular  
Pass/fail 
28 / 18 
 
30 / 12 
 
15 / 7 
 
17 / 12 
 
a0.297 
b0.559 
c0.846 
d0.787 
e0.262 
f0.484 
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SOT Sensory analysis 
(N) 
- Preferential  
Pass/fail 
40 / 6 34 / 8 16 / 6 26 / 3 a0.442 
b0.150 
c0.726 
d0.450 
e0.319 
f0.116 
SOT falls (N) 
- Any falls 
No/Yes 
 
27 / 20 
 
 
 
22 / 20 
 
 
 
13 / 9 
 
 
 
17 / 12 
 
 
a0.632 
b0.897 
c0.919 
d0.609 
e0.603 
f0.973 
SOT falls (N) 
- Abnormal hip 
strategy 
No/Yes 
33 / 14 
 
34 / 8 
 
19 / 3 
 
28 / 1 
 
a0.241 
b0.147 
c0.005 
d0.586 
e0.052 
f0.484 
SOT falls (N) 
- Abnormal ankle 
strategy 
No/Yes 
24 / 23 24 / 18 15 / 7 
 
17 / 12 a0.566 
b0.181 
c0.521 
d0.389 
e0.901 
f0.484 
Motor control test – 
weight symmetry (N) 
- To backwards 
Translations 
Normal / abnormal 
 
 
44 / 2 (1 missing) 
 
 
 
 
38 / 3 (6 missing) 
 
 
 
 
18 / 4 
 
 
 
 
25 / 2 
 
 
a0.550 
b0.060 
c0.579 
d0.191 
e0.989 
f0.253 
Motor control test – 
weight symmetry (N) 
- To forwards 
Translations 
Normal / abnormal 
44 / 2 (1 missing) 39 / 2 20 / 2 24 / 3 a0.906 
b0.437 
c0.269 
d0.513 
e0.335 
f0.816 
Motor control test – 
latency (N) 
- Normal / 
abnormal 
 
 
38 / 8 (1 missing) 
 
 
38 / 2 
 
 
18 / 4 
 
 
24 / 4 
a0.074 
b0.936 
c0.725 
d0.093 
e0.184 
f0.709 
Motor control test – 
response strength (N) 
- To backwards 
Translations 
Normal / abnormal 
 
 
39 / 7 (1 missing) 
 
 
 
 
34 / 7 
 
 
 
 
21 / 2 
 
 
 
 
26 / 1 
 
 
a0.814 
b0.448 
c0.128 
d0.355 
e0.094 
f0.459 
Motor control test – 
response strength (N) 
- To forwards 
Translations 
Normal / abnormal 
28 /18 (1 missing) 28 / 13 14 / 8 21 / 6 a0.471 
b0.826 
c0.138 
d0.709 
e0.394 
f0.276 
MCT composite score 
Median (IQR) 
142 (134-151) 145 (135.5-149) 146.5 (135-151.25) 140.5 (136-148) a,0.678 
b0.862 
c0.149 
d0.794 
e0.004 
f0.043 
 
Values are expressed as median (IQR, interquartile range) or as numbers (N). Each time point was 
compared to another using the Wilcoxon signed ranks test (continuous data) or Chi squared test 
(categorical data) and P values are given. Significant P values of < 0.05 are highlighted in bold. Time 
points compared are as follows: 
a
baseline compared to 3 months, 
b
baseline compared to 6 months, 
c
baseline compared to 12 months, 
d
3 months compared to 6 months, 
e
3 months compared to 12 months 
and 
f
6 months compared to 12 months. 
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Appendix 8. Falls assessment for angioplasty patients 
 Baseline 3 months 6 months 12 months P 
History of falls 
(no/yes) (N) 
33 / 12 (2 missing) 36 / 3 (8 missing) 16 / 4 (missing 27) 19 / 6 (missing 22) a0.024 
b0.565 
c0.807 
d0.166 
e0.067 
f0.748 
History of 
stumbles 
(no/yes) (N) 
18 / 12 (17 missing) 32 / 7 (8 missing) 16 / 3 (missing 28) 16 / 8 (missing 23) a0.042 
b0.073 
c0.614 
d0.838 
e0.164 
f0.190 
ABC-UK score 
Median (IQR) 
79.56 (53.92-90.72) 87.60 (73.84-97.26) 78 (58.63-94.80) 81.07 (61.84-96.92) a<0.001 
b0.073 
c0.387 
d0.100 
e0.191 
f0.587 
Timed Up and 
Go test score 
Median (IQR) 
10.13 (7.5-12.5) 8.7 (7.04-10.97) 9.25 (7.565-10.575) 8.29 (7.2-11.43) a<0.001 
b<0.001 
c<0.001 
d0.005 
e0.061 
f0.089 
Timed Up and 
Go test age 
adjusted 
pass/fail (N) 
21 / 26 27 / 14 (6 missing) 14 / 8 (25 missing) 20 / 9 (18 missing) a0.047 
b0.142 
c0.039 
d0.860 
e0.785 
f0.689 
 
Values are expressed as median (IQR, interquartile range) or as numbers (N). Each time point was 
compared to another using the Wilcoxon signed ranks test (continuous data) or Chi squared test 
(categorical data) and P values are given. Significant P values of < 0.05 are highlighted in bold.  Time 
points compared are as follows: 
a
baseline compared to 3 months, 
b
baseline compared to 6 months, 
c
baseline compared to 12 months, 
d
3 months compared to 6 months, 
e
3 months compared to 12 months 
and 
f
6 months compared to 12 months. 
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Appendix 9. Clinical indicators of lower limb ischaemia for 
exercise patients 
 Baseline 
N=51 
3 months 
 
6 months 
 
12 months 
 
P 
Pre exercise ABPI median 
(IQR) 
- Right leg 
- Left leg 
- Symptomatic leg 
 
 
0.74 (0.61-0.89) 
0.64 (0.51-0.89) 
0.60 (0.49-0.83) 
 
 
0.69 (0.54-0.89) 
0.68 (0.54-0.88) 
0.58 (0.48-0.77) 
 
 
0.77 (0.53-0.89) 
0.63 (0.44-0.83) 
0.57 (0.44-0.77) 
 
 
0.74 (0.63-0.96) 
0.64 (0.45-0.95) 
0.61 (0.45-0.75) 
a0.463 
b0.502 
c0.085 
d0.939 
e0.273 
f0.601 
Post exercise ABPI 
- Right leg 
- Left leg 
- Symptomatic leg 
 
0.43 (0.26-0.69) 
0.38 (0.20-0.67) 
0.29 (0.19-0.47) 
 
0.38 (0.27-0.57) 
0.32 (0.20-0.64) 
0.30 (0.20-0.40) 
 
0.40 (0.26-0.70) 
0.33 (0.11-0.59) 
0.28 (0.11-0.42) 
 
0.57 (0.43-0.87) 
0.36 (0.18-0.80) 
0.32 (0.18-0.56) 
a0.203 
b0.108 
c0.616 
d0.657 
e0.537 
f0.080 
Post exercise ankle pressure 
(mmHg) 
47 (32-72) 45 (31-67) 40 (20-67) 43 (33-90) a0.313 
b0.199 
c0.809 
d0.764 
e0.776 
f0.764 
Rutherford categories N 
- No claudication 
- Mild claudication 
- Moderate claudication 
- Severe claudication 
- Missing 
 
0 
1 
24 
26 
0 
 
0 
2 
24 
23 
2 
 
1 
0 
14 
20 
16 
 
1 
1 
10 
10 
29 
 
Treadmill completion N 
- Claudication felt 
during test 
- No claudication felt 
- Test stopped 
prematurely 
- Claudication stopped 
test 
- Test completed  
 
48 
 
0 
2 
 
44 
 
4 
 
42 
 
2 
1 
 
42 
 
2 
 
32 
 
0 
2 
 
23 
 
5 
 
 
20 
 
0 
1 
 
13 
 
5 
 
Treadmill ICD (m) median 
(IQR) 
46.5 (27-68.03) 60 (42-85.75) 59 (38-95.5) 55 (39-93) a<0.001 
b0.005 
c0.070 
d0.866 
e0.271 
f0.130 
Treadmill MWD (m) 91.55 (52.75-
129.25) 
111 (61-178) 105 (52-163)  105 (65-203) a0.004 
b0.137 
c0.467 
d0.784 
e0.227 
f0.162 
PRWD (m) 
 
 
100 (90-182.5) 190.5 (67.25-
400) 
230.5 (136-400) 180 (60-866) a0.002 
b0.001 
c0.026 
d0.239 
e0.959 
f0.484 
 
Values are expressed as median (IQR, interquartile range) or as numbers (N). ABPI (ankle brachial 
pressure index, ICD (intermittent claudication distance), MWD (maximum walking distance), PRWD 
(patient reported walking distance). Each time point was compared to another using the Wilcoxon signed 
ranks test and P values are given. Significant P values of < 0.05 are highlighted in bold.  Time points 
compared are as follows: 
a
baseline compared to 3 months, 
b
baseline compared to 6 months, 
c
baseline 
compared to 12 months, 
d
3 months compared to 6 months, 
e
3 months compared to 12 months and 
f
6 
months compared to 12 months.  
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Appendix 10. Physical Function for exercise patients 
 Baseline 3 months 6 months 12 months P 
Short performance 
physical battery  
(median, IQR) 
- 0-6 (N) 
- 7-9 
- 10-12 
- missing 
 
 
10 (9-11.25) 
1 
13 
36 
1 
 
 
11 (10-12) 
1 
8 
40 
1 
 
 
11 (10-11) 
1 
6 
28 
16 
 
 
10 (9.5-12) 
0 
5 
16 
30 
a0.005 
b0.137 
c0.266 
d1.000 
e0.803 
f0.527 
4 metre walk at 
usual pace (m/s) 
Median, IQR 
1.03 (0.92-1.16) 1.11 (1.04-1.27) 1.15 (1.00-1.31) 1.16 (0.98-1.37) a<0.001 
b<0.001 
c0.001 
d0.085 
e0.455 
f0.313 
4 metre walk at 
fastest pace (m/s) 
Median, IQR 
1.39 (1.14-1.60) 1.43 (1.26-1.64) 1.45 (1.20-1.75) 1.52 (1.12-1.81) a0.048 
b0.021 
c0.050 
d0.116 
e0.717 
f0.313 
Chair stand test (s) 
Median, IQR 
13.81 (10.94-16.92) 12.57 (10.36-
16.35) 
12.99 (11.35-15.98) 14.05 (10.21-16.14) a0.196 
b0.108 
c0.355 
d0.101 
e0.985 
f0.709 
Semi tandem stance 
(N) 
- < 10 s 
- 10-29 s 
- 30 s 
- missing 
Median, IQR 
 
 
0 
4 
46 
1 
30 (30-30) 
 
 
0 
1 
49 
1 
30 (30-30) 
 
 
0 
1 
34 
16 
30 (30-30) 
 
 
0 
3 
19 
29 
30 (30-30) 
a0.343 
b0.465 
c0.893 
d0.317 
e0.715 
f0.715 
Full tandem stance 
(N) 
- < 10 s 
- 10-29 s 
- 30 s 
- missing 
Median, IQR 
 
 
4 
14 
32 
1 
30 (15.62-30) 
 
 
4 
9 
37 
1 
30 (28.89-30) 
 
 
1 
7 
27 
16 
30 (30-30) 
 
 
4 
5 
13 
29 
30 (16.25-30) 
a0.403 
b0.078 
c0.169 
d0.266 
e0.043 
f0.021 
Handgrip strength 
(kg) 
- Right 
hand 
(Median, IQR) 
 
31.64 (20.70-39.22) 
 
30.79 (21.13-
36.98) 
 
33.87 (26.10-39.47) 
 
33.67 (21.00-37.88) 
a0.004 
b0.443 
c0.532 
d0.155 
e0.865 
f0.191 
Handgrip strength 
(kg) 
- Left 
hand 
(Median, IQR) 
 
30.83 (19.54-36.79) 
 
28.34 (17.50-
35.38) 
 
28.77 (22.73-35.50) 
 
31.67 (17.83-35.44) 
a<0.001 
b0.003 
c0.118 
d0.986 
e0.865 
f0.887 
6 minute walk  
- ICD distance 
(m) 
 
120 (80-195) 
 
 
160 (100-225) 
 
160 (120-240) 
 
137 (93.5-162) 
a0.003 
b0.039 
c0.959 
d0.483 
e0.274 
f0.177 
- MWD 
distance (m) 
 
280 (160-400) 
 
370 (180-430) 360 (270-460) 351 (247.5-360) a0.003 
b0.003 
c0.972 
d0.945 
e0.017 
f0.077 
- ICD time (s) 
 
111 (60.75-157) 
 
113 (88.5-186.5) 125 (99.5-196) 165 (120-200) a0.034 
b0.113 
c0.456 
d0.259 
e0.256 
f0.569 
- MWD time 
(s) 
244 (146-360) 314 (162-360) 311 (237-360) 340 (270-430) a0.071 
b0.128 
c0.756 
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d0.926 
e0.198 
f0.363 
 
Values are expressed as median (IQR, interquartile range) or as numbers (N). ICD (intermittent 
claudication distance), MWD (maximum walking distance). Each time point was compared to another 
using the Wilcoxon signed ranks test and P values are given. Significant P values of < 0.05 are 
highlighted in bold. Time points compared are as follows: 
a
baseline compared to 3 months, 
b
baseline 
compared to 6 months, 
c
baseline compared to 12 months, 
d
3 months compared to 6 months, 
e
3 months 
compared to 12 months and 
f
6 months compared to 12 months.  
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Appendix 11a. Balance assessment for exercise patients 
 Baseline 3 months 6 months 12 months P 
Sensory organisation 
test 
- Pass 
- Fail 
- Missing 
 
 
23 
28 
0 
 
 
33 
16 
2 
 
 
26 
9 
16 
 
 
20 
3 
28 
a0.025 
b0.007 
c<0.001 
d,e,fNS 
SOT composite score 
Median (IQR) 
 
65 (54-75) 
 
69 (60.5-
77.5) 
 
73 (66-78) 
 
74 (68-77) 
 
a0.018 
b0.013 
c0.007 
d,e,fNS 
SOT mean trial score 
for each condition 
- Condition 1 
 
- Condition 2 
 
- Condition 3 
- Condition 4 
 
- Condition 5 
 
- Condition 6 
 
Median (IQR) 
 
 
94.67 (92.67-
95.33) 
89.67 (87-92) 
 
87.33 (83-91) 
81 (73-85.67) 
 
39.66 (22.33-
58) 
39.66 (12-55) 
 
 
94.33 (92.15-
95.33) 
89.33 (86.84-
92) 
89 (83-91.67) 
84.66 (78.5-
87.67) 
51 (39.17-
62.83) 
43.33 (24-
64.67) 
 
 
94.33 (93-94.67) 
 
90.33 (88.33-
92.33) 
90.33 (86.33-92) 
84 (79.33-87.67) 
 
59.67 (40.67-69) 
 
44.33 (29.33-63) 
 
 
 
94 (93-95) 
 
90.33 (88.33-92) 
 
89 (84.67-90.67) 
83 (78.67-87) 
 
55.33 (48-63.67) 
 
53 (40.33-66.67) 
 
 
 
a,bNS, c0.032, d,e,fNS 
 
a-fNS 
 
a-fNS 
a0.002, b0.035, c,d,e,fNS 
 
* (see below) 
 
** (see below)  
 
* a0.005, b0.009,c0.003, 
dNS 
e0.044, fNS 
** a0.014, b0.023, 
c0.004, d,eNS, f0.009 
SOT Sensory analysis 
- Somatosensory  
- Visual 
- Vestibular 
 
- Preferential  
Pass/Fail 
 
47 / 4 
39 / 12 
18 / 33 
 
42 / 9 
 
46 / 3 
44 / 5 
28 / 21 
 
40 / 9 
 
35 / 0 
28 / 7 
24 / 11 
 
31 / 4 
 
23 / 0 
20 / 3 
17 / 6 
 
21 / 2 
 
a-fNS 
a-fNS 
a0.028, b0.002, 
c0.002,d,e,fNS 
a-fNS 
SOT falls 
- Any falls no/yes 
- Abnormal hip 
strategy no/yes 
- Abnormal ankle 
strategy no/yes 
 
16 / 35 
40 / 11 
 
20 / 31 
 
22 / 26 
39 / 8 
 
25 / 22 
 
17 / 18 
28 / 7 
 
19 / 16 
 
12 / 11 
19 / 4 
 
12 / 11 
 
a-fNS  
a-fNS 
 
a-fNS 
Motor control test – 
weight symmetry 
- To backwards 
Translations 
- To forwards 
Translations 
Normal / abnormal 
 
 
44 / 6 (1 
missing) 
 
45 / 5 (1 
missing) 
 
 
42 / 5 (4 
missing) 
 
44 / 3 (4 
missing) 
 
 
31 / 3 (17 
missing) 
 
31 / 3 (17 
missing) 
 
 
21 / 1 (29 
missing) 
21 / 1 (29 
missing) 
 
 
a-fNS  
 
a-fNS  
Motor control test – 
latency 
- Normal / 
abnormal 
 
44 / 6 (1 
missing) 
 
42 / 5 (4 
missing) 
 
32 / 2 (17 
missing) 
 
21 / 1 (29 
missing) 
 
a-fNS  
Motor control test – 
response strength 
- To backwards 
Translations 
- To forwards 
Translations 
Normal / abnormal 
 
 
39 / 11 (1 
missing) 
43 / 7 (1 
missing) 
 
 
38 / 8 
 
38 / 8 
 
 
28 / 6 
 
29 / 5 
 
 
20 / 2 
 
18 / 4 
 
 
a-fNS 
 
a-fNS 
 
MCT composite score 
Median (IQR) 
141 (133.5-
149.25) 
140 (131-
147) 
141.5 (135.75-
149) 
144.5 (134.75-
150.5) 
a-fNS 
 
 
Values are expressed as median (IQR, interquartile range) or as numbers (N). Each time point was 
compared to another using the Wilcoxon signed ranks test (continuous data) Chi squared test (categorical 
data) and a P value of > 0.05 is expressed as NS (non-significant). P values of < 0.05 are given. Time 
points compared are as follows: 
a
baseline compared to 3 months, 
b
baseline compared to 6 months, 
c
baseline compared to 12 months, 
d
3 months compared to 6 months, 
e
3 months compared to 12 months 
and 
f
6 months compared to 12 months. 
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Appendix 11b. Balance assessment for exercise patients with 
specified P values 
 Baseline 3 months 6 months 12 months P 
Sensory organisation 
test 
- Pass 
- Fail 
- Missing 
 
 
23 
28 
0 
 
 
33 
16 
2 
 
 
26 
9 
16 
 
 
20 
3 
28 
a0.025 
b0.007 
c<0.001 
d0.493 
e0.078 
f0.244 
SOT composite score 
Median (IQR) 
 
65 (54-75) 
 
69 (60.5-77.5) 
 
73 (66-78) 
 
74 (68-77) 
a0.018 
b0.013 
c0.007 
d0.314 
e0.112 
f0.076 
SOT mean trial score 
for each condition 
- Condition 1 
Median (IQR) 
 
 
94.67 (92.67-95.33) 
 
 
 
94.33 (92.15-95.33) 
 
 
 
94.33 (93-94.67) 
 
 
 
 
94 (93-95) 
 
 
a0.682 
b0.587 
c0.032 
d0.194 
e0.413 
f0.354 
SOT mean trial score 
for each condition 
- Condition 2 
Median (IQR) 
 
89.67 (87-92) 
 
 
 
89.33 (86.84-92) 
 
 
90.33 (88.33-92.33) 
 
 
90.33 (88.33-92) 
 
a0.575 
b0.200 
c0.915 
d0.893 
e0.614 
f0.513 
SOT mean trial score 
for each condition 
- Condition 3 
Median (IQR) 
 
87.33 (83-91) 
 
 
89 (83-91.67) 
 
 
90.33 (86.33-92) 
 
 
89 (84.67-90.67) 
 
a0.246 
b0.108 
c0.770 
d0.141 
e0.588 
f0.821 
SOT mean trial score 
for each condition 
- Condition 4 
Median (IQR) 
 
81 (73-85.67) 
 
 
 
84.66 (78.5-87.67) 
 
 
84 (79.33-87.67) 
 
 
 
83 (78.67-87) 
 
a0.002 
b0.035  
c0.068 
d0.943 
e0.972 
f0.219 
SOT mean trial score 
for each condition 
- Condition 5 
Median (IQR) 
 
39.66 (22.33-58) 
 
 
51 (39.17-62.83) 
 
 
59.67 (40.67-69) 
 
 
 
55.33 (48-63.67) 
 
 
a0.005 
b0.009 
c0.003 
d0.221 
e0.044 
f0.370 
SOT mean trial score 
for each condition 
- Condition 6 
Median (IQR) 
 
39.66 (12-55) 
 
43.33 (24-64.67) 
 
44.33 (29.33-63) 
 
 
53 (40.33-66.67) 
 
a0.014 
b0.023 
c0.004 
 d0.660 
e0.191 
f0.009 
SOT Sensory analysis 
(N) 
- Somatosensory  
Pass/fail 
 
47 / 4 
 
 
46 / 3 
 
 
35 / 0 
 
 
23 / 0 
 
a0.736 
b0.090 
c0.167 
d0.136 
e0.225 
f0.999 
SOT Sensory analysis 
(N) 
- Visual  
Pass/fail 
 
39 / 12 
 
 
44 / 5 
 
 
28 / 7 
 
 
20 / 3 
 
a0.076 
b0.698 
c0.299 
d0.206 
e0.721 
f0.493 
SOT Sensory analysis 
(N) 
- Vestibular  
Pass/fail 
 
18 / 33 
 
28 / 21 
 
24 / 11 
 
17 / 6 
a0.028 
b0.002 
c0.002 
d0.288 
e0.171 
f0.662 
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SOT Sensory analysis 
(N) 
- Preferential  
Pass/fail 
 
42 / 9 
 
40 / 9 
 
31 / 4 
 
21 / 2 
a0.925 
b0.429 
c0.316 
d0.386 
e0.288 
f0.738 
SOT falls (N) 
- Any falls 
No/Yes 
 
16 / 35 
 
 
22 / 26 
 
 
17 / 18 
 
 
12 / 11 
 
a0.139 
b0.107 
c0.088 
d0.805 
e0.617 
f0.789 
SOT falls (N) 
- Abnormal hip 
strategy 
No/Yes 
 
40 / 11 
 
 
39 / 8 
 
 
28 / 7 
 
 
19 / 4 
 
a0.569 
b0.861 
c0.679 
d0.730 
e0.969 
f0.804 
SOT falls (N) 
- Abnormal ankle 
strategy 
No/Yes 
 
20 / 31 
 
25 / 22 
 
19 / 16 
 
12 / 11 
a0.165 
b0.168 
c0.298 
d0.921 
e0.936 
f0.875 
Motor control test – 
weight symmetry (N) 
- To backwards 
Translations 
Normal / abnormal 
 
 
44 / 6 (1 missing) 
 
 
42 / 5 (4 missing) 
 
 
 
31 / 3 (17 missing) 
 
 
 
21 / 1 (29 
missing) 
 
a0.833 
b0.644 
c0.325 
d0.787 
e0.403 
f0.544 
Motor control test – 
weight symmetry (N) 
- To forwards 
Translations 
Normal / abnormal 
 
 
45 / 5 (1 missing) 
 
 
44 / 3 (4 missing) 
 
 
31 / 3 (17 missing) 
 
 
21 / 1 (29 
missing) 
a0.518 
b0.857 
c0.440 
d0.679 
e0.761 
f0.544 
Motor control test – 
latency (N) 
- Normal / 
abnormal 
 
44 / 6 (1 missing) 
 
42 / 5 (4 missing) 
 
32 / 2 (17 missing) 
 
21 / 1 (29 
missing) 
a0.833 
b0.358 
c0.325 
d0.452 
e0.403 
f0.828 
Motor control test – 
response strength (N) 
- To backwards 
Translations 
Normal / abnormal 
 
 
39 / 11 (1 missing) 
 
 
 
38 / 8 
 
 
 
28 / 6 
 
 
 
20 / 2 
 
a0.571 
b0.626 
c0.190 
d0.976 
e0.366 
f0.372 
Motor control test – 
response strength (N) 
- To forwards 
Translations 
Normal / abnormal 
 
 
43 / 7 (1 missing) 
 
 
38 / 8 
 
 
29 / 5 
 
 
18 / 4 
a0.648 
b0.928 
c0.650 
d0.748 
e0.936 
f0.729 
MCT composite score 
Median (IQR) 
141 (133.5-149.25) 140 (131-147) 141.5 (135.75-149) 144.5 (134.75-
150.5) 
a,0.975 
b0.364 
c0.931 
d0.243 
e0.981 
f0.304 
 
Values are expressed as median (IQR, interquartile range) or as numbers (N). Each time point was 
compared to another using the Wilcoxon signed ranks test (continuous data) or Chi squared test 
(categorical data) and P values are given. Significant P values of < 0.05 are highlighted in bold. Time 
points compared are as follows: 
a
baseline compared to 3 months, 
b
baseline compared to 6 months, 
c
baseline compared to 12 months, 
d
3 months compared to 6 months, 
e
3 months compared to 12 months 
and 
f
6 months compared to 12 months. 
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Appendix 12. Falls assessment for exercise patients 
 Baseline 3 months 6 months 12 months P 
History of falls 
(no/yes) 
42 / 8 (1 missing) 44 / 6 (1 missing) 31 / 4 (16 missing) 19 / 4 (28 missing) a0.564 
b0.551 
c0.882 
d0.936 
e0.533 
f0.519 
History of 
stumbles (no/yes) 
32 / 18 (1 missing) 42 / 7 (2 missing) 25 / 8 (18 missing) 16 / 6 (29 missing) a0.013 
b0.258 
c0.469 
d0.253 
e0.191 
f0.800 
ABC-UK score 
Median (IQR) 
82.47 (69.21 – 94.09) 84.19 (63.63-
93.25) 
83.25 (68.28-
94.64) 
84.19 (58.76-
92.60) 
a0.368 
b0.514 
c0.414 
d0.348 
e0.848 
f0.446 
Timed Up and Go 
test score (s) 
Median (IQR) 
8.65 (7.44-10.19) 7.48 (6.8-9.6) 8.03 (6.69-9.75) 8.06 (5.87-10.47) a0.001 
b0.011 
c0.023 
d0.059 
e0.092 
f0.862 
Timed Up and Go 
test age adjusted 
pass/fail 
37 / 14 42 / 8 28 / 7 20 / 6 a0.163 
b0.429 
c0.679 
d0.634 
e0.450 
f0.772 
 
Values are expressed as median (IQR, interquartile range) or as numbers (N). Each time point was 
compared to another using the Wilcoxon signed ranks test (continuous data) or Chi squared test 
(categorical data) and P values are given. Significant P values of < 0.05 are highlighted in bold.   Time 
points compared are as follows: 
a
baseline compared to 3 months, 
b
baseline compared to 6 months, 
c
baseline compared to 12 months, 
d
3 months compared to 6 months, 
e
3 months compared to 12 months 
and 
f
6 months compared to 12 months. 
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Appendix 13. Clinical indicators of lower limb ischaemia at 
baseline 
 All Angioplasty Exercise P 
Pre exercise ABPI 
- Right leg 
- Left leg 
- Symptomatic leg 
 
0.79 (0.64-0.94) 
0.79 (0.58-0.93) 
0.69 (0.55-0.86) 
 
0.87 (0.72-1.00) 
0.86 (0.69-0.95) 
0.78 (0.61-0.92) 
 
0.74 (0.61-0.89) 
0.64 (0.51-0.89) 
0.60 (0.49-0.83) 
 
0.009 
0.008 
0.001 
Post exercise ABPI 
- Right leg 
- Left leg 
- Symptomatic leg 
 
0.46 (0.28-0.75) 
0.53 (0.24-0.84) 
0.32 (0.22-0.52) 
 
0.52 (0.31-0.84) 
0.67 (0.39-0.89) 
0.38 (0.25-0.63) 
 
0.43 (0.26-0.69) 
0.38 (0.20-0.67) 
0.29 (0.19-0.47) 
  
0.107 
0.003 
0.022 
Treadmill ICD (m) 39.5 (24.75-60.38) 32.6 (19.13-53.95) 46.5 (27-68.03) 0.046 
Treadmill MWD (m) 74.7 (47.43-129) 62.9 (39.48-123.75) 91.55 (52.75-
129.25) 
0.225 
PRWD (m) 135 (90-274) 136 (90-370) 100 (90-182.5) 0.348 
 
Values are expressed as median (IQR, interquartile range). Exercise and angioplasty groups were 
compared using Mann Whitney U test and P values are given. Significant P values of < 0.05are 
highlighted in bold. 
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Appendix 14. Physical Function at baseline 
 All Angioplasty Exercise P 
Short performance 
physical battery  
(median, IQR) 
- 0-6 (N) 
- 7-9 
- 10-12 
- missing 
 
 
10 (9-11) 
6 
34 
55 
3 
 
 
9 (8-11) 
5 
21 
19 
2 
 
 
10 (9-11.25) 
1 
13 
36 
1 
 
 
0.007 
4 metre walk at usual 
pace (m/s) 
Median, IQR 
1.01 (0.84-1.15) 1.00 (0.74-1.15) 1.03 (0.92-1.16) 0.169 
4 metre walk at fastest 
pace (m/s) 
Median, IQR 
1.07 (1.33-1.54) 1.31 (0.93-1.53) 1.39 (1.14-1.60) 0.112 
Chair stand test (s) 
Median, IQR 
14.86 (11.73-19.07) 17.02 (12.31-20.55) 13.81 (10.94-
16.92) 
0.044 
Semi tandem stance (N) 
- < 10 s 
- 10-29 s 
- 30 s 
- missing 
Median, IQR 
 
6 
12 
79 
1 
30 (30-30) 
 
6 
8 
33 
0 
30 (19.4-30) 
 
0 
4 
46 
1 
30 (30-30) 
 
 
 
 
 
0.004 
Full tandem stance (N) 
- < 10 s 
- 10-29 s 
- 30 s 
- missing 
Median, IQR 
 
16 
26 
55 
1 
30 (12.99-30) 
 
12 
12 
23 
0 
29 (8.9-30) 
 
4 
14 
32 
1 
30 (15.62-30) 
 
 
 
 
 
0.055 
Handgrip strength (kg) 
- Right hand 
 
- Left hand 
Median, IQR 
 
30.9 (19.8-39.6) 
 
29.9 (19.1-36.8) 
 
26.24 (18.61-40.4) 
 
29.05 (18.12-37.63) 
 
31.64 (20.7-
39.22) 
30.83 (19.54-
36.79) 
 
0.467 
 
0.918 
6 minute walk  
- ICD distance (m) 
- MWD distance (m) 
- ICD time (s) 
- MWD time (s) 
Median, IQR 
 
100 (60-160) 
240 (160-400) 
58.5 (92.5-135.5) 
221 (132.5-360) 
 
85 (52.5-120) 
200 (120-380) 
78.5 (56.25-109.25) 
196 (111.5-330) 
 
120 (80-195) 
280 (160-400) 
111 (60.75-157) 
244 (146-360) 
 
0.025 
0.243 
0.018 
0.205 
 
Values are expressed as median (IQR, interquartile range) or as numbers (N). ICD (intermittent 
claudication distance), MWD (maximum walking distance). Exercise and angioplasty groups were 
compared using the Mann Whitney U test (continuous data) or Chi squared test (categorical data) and P 
values are given. Significant P values of < 0.05 are highlighted in bold.  
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Appendix 15. Balance at baseline  
 All Angioplasty Exercise P 
Sensory organisation test 
- Pass 
- Fail 
- Missing 
 
52 
46 
0 
 
29 
18 
0 
 
23 
28 
0 
0.100 
SOT composite score 
Median (IQR) 
 
68 (57.5-76) 
 
70 (61-79) 
 
65 (54-75) 
 
0.063 
SOT mean trial score for each 
condition 
- Condition 1 
- Condition 2 
- Condition 3 
- Condition 4 
- Condition 5 
- Condition 6 
Median (IQR) 
 
94.67 (93-95.66) 
90.33 (86.92-92.75) 
88.67 (83.25-92.33) 
81.17 (70.33-85.67) 
47.33 (22.33-61.42) 
41.34 (14.34-60.58) 
 
 
95 (93-96) 
91.33 (85.67-93.33) 
89.66 (83.33-94.33) 
82 (66-85.67) 
56 (22.33-66) 
42 (17.66-63.37) 
 
94.67 (92.67-95.33) 
89.67 (87-92) 
87.33 (83-91) 
81 (73-85.67) 
39.66 (22.33-58) 
39.66 (12-55) 
 
0.448 
0.123 
0.042 
0.963 
0.070 
0.254 
SOT Sensory analysis 
- Somatosensory pass/fail 
- Visual pass/fail 
- Vestibular pass/fail 
- Preferential pass/fail 
 
86 / 12 
74 / 23 (1 missing) 
46 / 51 (1 missing) 
82 / 15 (1 missing) 
 
39 / 8 
35 / 11 
28 / 18 
40 / 6 
 
47 / 4 
39 / 12 
18 / 33 
42 / 9 
 
0.168 
0.965 
0.012 
0.533 
SOT falls 
- Any falls no/yes 
- Abnormal hip strategy 
no/yes 
- Abnormal ankle strategy 
no/yes 
 
43 / 55 
73 / 25 
44 / 54 
 
 
27 / 20 
33 / 14 
40 / 11 
 
16 / 35 
40 / 11 
20 / 31 
 
0.009 
0.354 
<0.001 
 
Motor control test – weight symmetry 
- To backwards Translations 
- To forwards Translations 
Normal / abnormal 
 
88 / 8 (2 missing) 
89 / 7 (2 missing) 
 
44 / 2 (1 missing) 
44 / 2 (1 missing) 
 
44 / 6 (1 missing) 
45 / 5 (1 missing) 
 
0.178 
0.290 
 
Motor control test – latency 
- Normal / abnormal 
 
82 / 14 (2 missing) 
 
38 / 8 (1 missing) 
 
44 / 6 (1 missing) 
 
0.457 
Motor control test – response strength 
- To backwards Translations 
- To forwards Translations 
Normal / abnormal 
 
78 / 18 (2 missing) 
71 / 25 (2 missing) 
 
39 / 7 (1 missing) 
28 /18 (1 missing) 
 
39 / 11 (1 missing) 
43 / 7 (1 missing) 
 
0.311 
0.005 
MCT composite score 
Median (IQR) 
141 (134-150) 142 (134-151) 141 (133.5-149.25) 0.828 
 
Values are expressed as median (IQR, interquartile range) or as numbers (N). ICD (intermittent 
claudication distance), MWD (maximum walking distance). Exercise and angioplasty groups were 
compared using the Mann Whitney U test (continuous data) or Chi squared test (categorical data) and P 
values are given. Significant P values of < 0.05 are highlighted in bold. SOT (sensory organisation test). 
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Appendix 16. Falls assessment at baseline 
 All Angioplasty Exercise P 
History of falls (no/yes) 75 / 20 (3 missing) 33 / 12 (2 missing) 42 / 8 (1 missing) 0.203 
History of stumbles (no/yes) 50 / 30 (18 missing) 18 / 12 (17 missing) 32 / 18 (1 missing) 0.720 
ABC-UK score 
Median (IQR) 
80.6 (64.6-92.75) 79.56 (53.92-90.72) 82.47 (69.21 – 94.09) 0.110 
Timed Up and Go test score (s) 
Median (IQR) 
9.16 (7.49-11.18) 10.13 (7.5-12.5) 8.65 (7.44-10.19) 0.059 
Timed Up and Go test age adjusted 
pass/fail 
58 / 40 21 / 26 37 / 14 0.005 
 
Values are expressed as median (IQR, interquartile range) or as numbers (N). ICD (intermittent 
claudication distance), MWD (maximum walking distance). Exercise and angioplasty groups were 
compared using the Mann Whitney U test (continuous data) or Chi squared test (categorical data) and P 
values are given. Significant P values of < 0.05 are highlighted in bold.   
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Appendix 17. Quality of life at baseline 
 All Angioplasty Exercise P 
SF36 
- Physical function 
- Role physical 
- Bodily pain 
- General health 
- Vitality 
- Role emotional 
- Mental health 
- Social function 
- Physical summary 
- Mental summary 
 
40 (30-50) 
0 (0-50) 
41 (31-51.75) 
52 (40-67.75) 
50 (40-65) 
66.7 (37.5-100) 
76 (33.35-100) 
76 (60-88) 
31.3 (25.3-36.25) 
52.9 (44.78-61.38) 
 
35 (28.75-50) 
0 (0-50) 
36.5 (31-51) 
47 (35-69.5) 
50 (30-65) 
50 (33.3-87.5) 
67.35 (48-100) 
73.5 (50-87.63) 
30.1 (25.2-33.9) 
51.2 (40.3-60.9) 
 
45 (33.75-55) 
0 (0-56.25) 
42 (41-64) 
55 (41-68.5) 
55 (40-65) 
75 (50-100) 
100 (33.3-100) 
78 (71-92) 
31.9 (25.55-37.3) 
56.7 (46.45-62.1) 
 
0.04 
0.897 
0.03 
0.435 
0.192 
0.018 
0.223 
0.043 
0.228 
0.209 
VascuQol 
- Pain 
- Social 
- Activities 
- Symptoms 
- Emotional 
- Total 
 
4.25 (3.25-4.75) 
4.5 (3.5-6) 
3.88 (3.25-4.63) 
5.25 (4.25-6.00) 
5.0 (4.14-5.71) 
4.6 (3.64-5.12) 
 
4.0 (2.75-4.63) 
4.0 (3.5-5.5) 
3.63 (3.19-4.32) 
4.75 (4-5.75) 
4.57 (3.57-5.5) 
4.32 (3.22-5.02) 
 
4.25 (3.5-5.25) 
5.5 (4-6.5) 
4.13 (3.47-5) 
5.5 (4.94-6.06) 
5.14 (4.68-5.86) 
4.84 (4.13-5.35) 
 
0.106 
0.008 
0.009 
0.009 
0.030 
0.007 
SF8 
- Physical function 
- Role physical 
- Bodily pain 
- General health 
- Vitality 
- Role emotional 
- Mental health 
- Social function 
- Physical summary 
- Mental summary 
 
40.1 (30.3-40.1) 
38.7 (28.3-46.9) 
40.1 (40.1-47.7) 
42.4 (38.4-46.4) 
45.2 (45.2-55.6) 
45.7 (38.1-52.4) 
49.6 (41.5-56.8) 
40.4 (40.4-49.5) 
36.8 (30.03-42.63) 
51.25 (40.33-58.53) 
 
30.3 (30.3-40.1) 
38.7 (28.3-46.9) 
40.1 (31.5-40.1) 
38.4 (38.4-46.4) 
45.2 (45.2-55.6) 
45.7 (32.85-52.4) 
49.6 (36.55-56.80) 
40.4 (29.5-49.5) 
34.65 (29.18-40.38) 
46.3 (38.58-57.38) 
 
40.1 (30.3-42.15) 
38.7 (38.7-46.9) 
40.1 (40.1-47.7) 
46.4 (38.4-46.4) 
45.2 (45.2-55.6) 
52.4 (38.1-52.4) 
49.6 (41.5-56.8) 
49.5 (40.4-55.3) 
39.25 (30.7-44.2) 
53.4 (42.48-59) 
 
0.125 
0.060 
0.085 
0.050 
0.503 
0.013 
0.049 
0.023 
0.043 
0.037 
 
Values are expressed as median (IQR, interquartile range) or as numbers (N). ICD (intermittent 
claudication distance), MWD (maximum walking distance). Exercise and angioplasty groups were 
compared using the Mann Whitney U test (continuous data) or Chi squared test (categorical data) and P 
values are given. Significant P values of < 0.05 are highlighted in bold.  
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Appendix 18. Number of patients at each visit 
 Angioplasty Exercise 
Baseline (N) 47 51 
3 months (N) 42 49 
6 months (N) 22 35 
12 months (N) 29 23 
 
(N) Number of patients who attended for follow up in each group at the 4 study time points. 
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